Emergency Diagnosis and Treatment of Acute - emcreg

Loading...
EMERGENCY DIAGNOSIS AND TREATMENT OF ACUTE DECOMPENSATED HEART FAILURE (ADHF) - MARCH 2005

Produced by

© 2005 EMCREG-International www.emcreg.org

EMERGENCY DIAGNOSIS AND TREATMENT OF ACUTE DECOMPENSATED HEART FAILURE (ADHF) IN THIS ISSUE

CME Monograph from the ACEP 2005 Spring Congress Satellite Symposium Orlando, Florida March 4, 2005

EMCREG-International

This educational monograph was supported in part by an unrestricted educational grant from Scios.

Printed in t h e U S A

Produced by

%-%2'%.#9 $)!'./3)3!.$ 42%!4-%.4/&!#54% $%#/-0%.3!4%$ (%!24&!),52%!$(&

 Êœ˜œ}À>«… vÀœ“Ê̅iÊ

*ÊÓääx -«Àˆ˜}Ê œ˜}ÀiÃÃÊÊ ->ÌiˆÌiÊ-ޓ«œÃˆÕ“ "À>˜`œ]ʏœÀˆ`> >ÀV…Ê{]ÊÓääx

%DITEDBY !NDRA,"LOMKALNS -$ !SSISTANT0ROFESSOR 2ESIDENCY$IRECTOR $EPARTMENTOF%MERGENCY-EDICINE 5NIVERSITYOF#INCINNATI #INCINNATI /( 53! $IRECTOR #-%AND%NDURING-ATERIALS %-#2%' )NTERNATIONAL

*Àœ`ÕVi`ÊLÞÊ

 , ‡˜ÌiÀ˜>̈œ˜>Ê Q “iÀ}i˜VÞÊi`ˆVˆ˜iÊ >À`ˆ>VÊ,iÃi>ÀV…Ê >˜`Ê `ÕV>̈œ˜ÊÀœÕ«R

7"RIAN'IBLER -$ )NTERNATIONAL W W W  E M C R E G  O R G

0ROFESSOR#HAIRMAN $EPARTMENTOF%MERGENCY-EDICINE 5NIVERSITYOF#INCINNATI #INCINNATI /( 53! 0RESIDENT %-#2%' )NTERNATIONAL

)NTERNATIONAL >ÞÊÓääx i>ÀÊ œi>}ÕiÃ\

>V…ÊÞi>À]ʘi>ÀÞʜ˜iʓˆˆœ˜Ê«>̈i˜ÌÃʈ˜Ê̅iÊ1˜ˆÌi`Ê-Ì>ÌiÃÊ>ÀiʅœÃ«ˆÌ>ˆâi`Ê܈̅Ê>VÕÌiÊ`iVœ“«i˜Ã>Ìi`ʅi>ÀÌÊv>ˆÕÀiÊ­ ®°Ê˜Ê̅iÊ «>ÃÌ]Ê̅iÀiʅ>ÛiÊLii˜Êˆ“ˆÌi`Ê«À>V̈ViÊ}Ո`iˆ˜iÃÊvœÀÊ̅iÊi“iÀ}i˜VÞʓ>˜>}i“i˜ÌʜvÊ̅ˆÃÊVœ˜`ˆÌˆœ˜°Ê >Ì>ÊvÀœ“Ê̅iÊ  , ʭ̅iÊ VÕÌiÊ iVœ“«i˜Ã>Ìi`Êi>ÀÌÊ>ˆÕÀiÊ >̈œ˜>Ê,i}ˆÃÌÀÞ®]ʈ˜`ˆV>ÌiÊ̅>ÌÊ Ê«>̈i˜ÌÃÊ>ÀiÊÀi«i>Ìi`ÞʅœÃ«ˆÌ>ˆâi`]Ê>˜`ʜ̅iÀ܈Ãiʅ>ÛiÊ >ÊÛiÀÞʅˆ}…ÊÀ>ÌiʜvʓœÀLˆ`ˆÌÞÊ>˜`ʓœÀÌ>ˆÌÞ°Ê/…iʓ>˜>}i“i˜ÌÊ>˜`ÊV>ÀiʜvÊ̅ˆÃÊ«>̈i˜ÌÊ}ÀœÕ«ÊÀi“>ˆ˜ÃÊÃÕLœ«Ìˆ“>°Ê/…ˆÃÊVœ“«Ài…i˜ÃˆÛiÊ >˜`Ê«Àœ}ÀiÃÈÛiʓœ˜œ}À>«…Ê܈ÊÀiۈiÜÊ̅iʏ>ÌiÃÌÊ`ˆ>}˜œÃ̈VÊ>˜`Ê̅iÀ>«iṎVʓœ`>ˆÌˆiÃÊvœÀÊ Ê>˜`ÊÃÕ}}iÃÌʓi̅œ`ÃÊ̜ʈ“«ÀœÛiÊ Ì…iÊV>ÀiÊvœÀÊ̅iÃiÊ«>̈i˜ÌÃÊ>ÌÊޜÕÀʈ˜Ã̈ÌṎœ˜°Ê˜Ãˆ}…ÌÃÊ>˜`ʏiÃܘÃÊvÀœ“Ê  , Ê܈Ê>ÃœÊLiÊÀiۈiÜi`Ê>˜`Ê`ˆÃVÕÃÃi`° /…iÊ “iÀ}i˜VÞÊi`ˆVˆ˜iÊ >À`ˆ>VÊ,iÃi>ÀV…Ê>˜`Ê `ÕV>̈œ˜ÊÀœÕ«‡˜ÌiÀ˜>̈œ˜>Ê­  , ®ÊˆÃÊ«i>Ãi`Ê̜ʫÀiÃi˜ÌÊ̅ˆÃÊi`ÕV>̈œ˜>Ê “œ˜œ}À>«…Ê ÃՓ“>Àˆâˆ˜}Ê œÕÀÊ ÓääxÊ  , Ê -ޓ«œÃˆÕ“Ê œ˜Ê ̅iÊ “iÀ}i˜VÞÊ i«>À̓i˜ÌÊ ˆ>}˜œÃˆÃÊ >˜`Ê /Ài>̓i˜ÌÊ œvÊ  Ê …i`Ê ˆ˜Ê "À>˜`œ]Ê œÀˆ`>°Ê Ê /…ˆÃÊ «Àœ}À>“Ê ˆÃÊ >ÃœÊ >Û>ˆ>LiÊ >ÃÊ >˜Ê œ˜‡`i“>˜`Ê ÜiLÊ V>ÃÌÊ œ˜Ê ̅iÊ ˆ˜VÕ`i`Ê ‡,"Ê >˜`Ê >ÌÊÊ …ÌÌ«\ÉÉ>`…v°`ˆ}ˆÃVÀˆ«Ì°Vœ“ÊLi}ˆ˜˜ˆ˜}Ê՘iÊÓääx°ÊÌʈÃʜÕÀʅœ«iÊ̅>ÌÊ̅ˆÃʓ>ÌiÀˆ>Ê܈Ê«ÀœÛˆ`iÊi“iÀ}i˜VÞÊ«…ÞÈVˆ>˜ÃÊ܈̅ʈ˜vœÀ“>̈œ˜Ê ˜iViÃÃ>ÀÞÊ̜ʈ“«ÀœÛiÊ>˜`Êv>VˆˆÌ>ÌiÊV>ÀiÊvœÀÊ̅ˆÃÊ՘ˆµÕiÊ«>̈i˜ÌÊ«œ«Õ>̈œ˜°

 , Ê `ÕV>̈œ˜>ÊˆÃȜ˜ /…iÊ “ˆÃȜ˜Ê œvÊ  , ‡˜ÌiÀ˜>̈œ˜>Ê ˆÃÊ ÌœÊ «ÀœÛˆ`iÊ Õ«‡Ìœ‡`>Ìi]Ê iۈ`i˜ViÊ L>Ãi`]Ê >˜`Ê Vˆ˜ˆV>ÞÊ ÕÃivÕÊ i`ÕV>̈œ˜>Ê “>ÌiÀˆ>ÃÊ ÌœÊ …i>Ì…V>ÀiÊ«ÀœÛˆ`iÀÃʈ˜ÛœÛi`ʈ˜Ê̅iÊV>ÀiʜvÊi“iÀ}i˜VÞÊVœ˜`ˆÌˆœ˜Ã°Ê7iÊÌ>ŽiÊ}Ài>ÌÊ«Àˆ`iÊ>˜`ÊivvœÀÌÊ̜ʫÀœÛˆ`iÊ̅iÃiʓ>ÌiÀˆ>ÃÊvÀiiÊ œvÊVœ““iÀVˆ>ÊLˆ>ðÊ7…ˆiÊ̅iÃiÊi`ÕV>̈œ˜>Êi˜`i>ۜÀÃÊ>ÀiÊ뜘ÜÀi`ʈ˜Ê«>ÀÌÊLÞʈ˜`ÕÃÌÀÞ]Êëi>ŽiÀʜÀÊVœ˜ÌÀˆLÕ̜Àʈ˜yÕi˜ViʜÀÊ Lˆ>ÃʈÃÊV>ÀivՏÞÊÀiۈiÜi`Ê>˜`ÊÃÌÀˆV̏ÞÊ«Àœ…ˆLˆÌi`°ÊÊ œ““i˜ÌÃÊÀi}>À`ˆ˜}Ê>˜ÞʜvʜÕÀÊi`ÕV>̈œ˜>Ê“>ÌiÀˆ>ÃÊV>˜ÊLiÊÀiviÀÀi`Ê`ˆÀiV̏ÞÊ ÌœÊ˜`À>Ê°Ê œ“Ž>˜Ã]Ê ]Ê ˆÀiV̜ÀʜvÊ  Ê>˜`Ê ˜`ÕÀˆ˜}Ê>ÌiÀˆ>ÃÊ>ÌÊÃÕ««œÀÌJi“VÀi}°œÀ}° -ˆ˜ViÀiÞ]

Ê Ê Ê Ê Ê Ê Ê

˜`À>Ê°Ê œ“Ž>˜Ã]Ê Ê ÃÈÃÌ>˜ÌÊ*ÀœviÃÜÀ]Ê,iÈ`i˜VÞÊ ˆÀiV̜ÀÊ i«>À̓i˜ÌʜvÊ “iÀ}i˜VÞÊi`ˆVˆ˜iÊ 1˜ˆÛiÀÈÌÞʜvÊ ˆ˜Vˆ˜˜>̈ÊÊ

ˆ˜Vˆ˜˜>̈]Ê"Ê ˆÀiV̜À]Ê  Ê>˜`Ê ˜`ÕÀˆ˜}Ê>ÌiÀˆ>ÃÊ

 , ‡˜ÌiÀ˜>̈œ˜>

7°Ê Àˆ>˜ÊˆLiÀ]Ê Ê Ê *ÀœviÃÜÀÊ>˜`Ê …>ˆÀ“>˜Ê Ê i«>À̓i˜ÌʜvÊ “iÀ}i˜VÞÊi`ˆVˆ˜i 1˜ˆÛiÀÈÌÞʜvÊ ˆ˜Vˆ˜˜>̈Ê

ˆ˜Vˆ˜˜>̈]Ê" *ÀiÈ`i˜Ì]Ê  , ‡˜ÌiÀ˜>̈œ˜>Ê

Ê

VVÀi`ˆÌ>̈œ˜\Ê/…iÊ1˜ˆÛiÀÈÌÞʜvÊ ˆ˜Vˆ˜˜>ÌˆÊ œi}iʜvÊi`ˆVˆ˜iÊ`iÈ}˜>ÌiÃÊ̅ˆÃÊi`ÕV>̈œ˜>Ê>V̈ۈÌÞÊvœÀÊ>ʓ>݈“Õ“ÊœvÊÓʅœÕÀÃʜvÊ >Ìi}œÀÞÊ£ÊVÀi`ˆÌÊ ÌœÜ>À`ÃÊ̅iÊÊ*…ÞÈVˆ>˜½ÃÊ,iVœ}˜ˆÌˆœ˜ÊÜ>À`°Ê >V…Ê«…ÞÈVˆ>˜ÊŜՏ`ÊV>ˆ“Êœ˜ÞÊ̅œÃiʅœÕÀÃÊ̅>ÌʅiÉÅiÊ>VÌÕ>ÞÊëi˜Ìʜ˜Ê̅iÊi`ÕV>̈œ˜>Ê>V̈ۈÌÞ°Ê /…iÊ1˜ˆÛiÀÈÌÞʜvÊ ˆ˜Vˆ˜˜>̈ʈÃÊ>VVÀi`ˆÌi`ÊLÞÊ̅iÊVVÀi`ˆÌ>̈œ˜Ê œÕ˜VˆÊvœÀÊ œ˜Ìˆ˜Õˆ˜}Êi`ˆV>Ê `ÕV>̈œ˜Ê­

 ®Ê̜ÊÃÕ««œÀÌÊVœ˜Ìˆ˜Õˆ˜}ʓi`ˆV>Ê i`ÕV>̈œ˜ÊvœÀÊ«…ÞÈVˆ>˜Ã°Ê /…ˆÃÊi`ÕV>̈œ˜>Ê“œ˜œ}À>«…ÊÜ>ÃÊÃÕ««œÀÌi`ʈ˜Ê«>ÀÌÊLÞÊ>˜Ê՘ÀiÃÌÀˆVÌi`Êi`ÕV>̈œ˜>Ê}À>˜ÌÊvÀœ“Ê-VˆœÃ° /…ˆÃÊ`œVՓi˜ÌʈÃÊ̜ÊLiÊÕÃi`Ê>ÃÊ>ÊÃՓ“>ÀÞÊ>˜`ÊVˆ˜ˆV>ÊÀiviÀi˜ViÊ̜œÊ>˜`Ê "/Ê>ÃÊ>ÊÃÕLÃ̈ÌÕÌiÊvœÀÊÀi>`ˆ˜}Ê̅iÊÛ>Õ>LiÊ>˜`ʜÀˆ}ˆ˜>ÊÜÕÀViÊ`œVՓi˜ÌðÊÊ

 , Ê܈Ê˜œÌÊLiʏˆ>LiÊ̜ÊޜÕʜÀÊ>˜Þœ˜iÊiÃiÊvœÀÊ>˜ÞÊ`iVˆÃˆœ˜Ê“>`iʜÀÊ>V̈œ˜ÊÌ>Ži˜Ê­œÀʘœÌÊÌ>Ži˜®ÊLÞÊޜÕʈ˜ÊÀiˆ>˜Viʜ˜Ê̅iÃiʓ>ÌiÀˆ>Ã°ÊÊ/…ˆÃÊ `œVՓi˜ÌÊ`œiÃʘœÌÊÀi«>Viʈ˜`ˆÛˆ`Õ>Ê«…ÞÈVˆ>˜ÊVˆ˜ˆV>ÊÕ`}“i˜Ì°

ˆ˜ˆV>ÊÕ`}“i˜ÌʓÕÃÌÊ}Ո`iÊi>V…Ê«ÀœviÃȜ˜>Êˆ˜ÊÜiˆ}…ˆ˜}Ê̅iÊLi˜iwÌÃʜvÊÌÀi>̓i˜ÌÊ>}>ˆ˜ÃÌÊ̅iÊÀˆÃŽÊœvÊ̜݈VˆÌÞ°ÊÊ œÃiÃ]ʈ˜`ˆV>̈œ˜ÃÊ>˜`ʓi̅œ`ÃʜvÊ ÕÃiÊvœÀÊ«Àœ`ÕVÌÃÊÀiviÀÀi`Ê̜ʈ˜Ê̅ˆÃÊ«Àœ}À>“Ê>ÀiʘœÌʘiViÃÃ>ÀˆÞÊ̅iÊÃ>“iÊ>Ãʈ˜`ˆV>Ìi`ʈ˜Ê̅iÊ«>VŽ>}iʈ˜ÃiÀÌÊ>˜`ʓ>ÞÊLiÊ`iÀˆÛi`ÊvÀœ“Ê̅iÊ«ÀœviÃȜ˜>Ê ˆÌiÀ>ÌÕÀiʜÀʜ̅iÀÊVˆ˜ˆV>ÊVœÕÀÃiðÊÊ œ˜ÃՏÌÊVœ“«iÌiÊ«ÀiÃVÀˆLˆ˜}ʈ˜vœÀ“>̈œ˜ÊLivœÀiÊ>`“ˆ˜ˆÃÌiÀˆ˜}°Ê

I

ÊÊ/>LiʜvÊ œ˜Ìi˜Ìà ˆ>}˜œÃˆÃʜvÊVÕÌiÊ iVœ“«i˜Ã>Ìi`Êi>ÀÌÊ>ˆÕÀiʈ˜Ê̅iÊ Ê°°°°°°°°°°°°°°°°°°°°°°°°°°°°° £ Õ``Ê °Êœ>˜`iÀ]Ê *ÀœviÃÜÀ i«>À̓i˜ÌʜvÊ “iÀ}i˜VÞÊi`ˆVˆ˜i 1˜ˆÛiÀÈÌÞʜvÊ*i˜˜ÃޏÛ>˜ˆ>]Ê*…ˆ>`i«…ˆ>]Ê*

/Ài>̓i˜ÌʜvÊVÕÌiÊ iVœ“«i˜Ã>Ìi`Êi>ÀÌÊ>ˆÕÀiʈ˜Ê̅iÊ Ê°°°°°°°°°°°°°°°°°°°°°°°°°°°° x œÕ}>ÃÊ°Ê …>À]Ê ÃÈÃÌ>˜ÌÊ*ÀœviÃÜÀ ˆÛˆÃˆœ˜ÊœvÊ “iÀ}i˜VÞÊi`ˆVˆ˜i 7>ň˜}̜˜Ê1˜ˆÛiÀÈÌÞ]Ê-̰ʜՈÃ]Ê"

/…iÊ ÛœÛˆ˜}Ê,œiʜvÊ *ʈ˜Ê̅iÊ ˆ>}˜œÃˆÃÊ>˜`Ê/Ài>̓i˜ÌʜvÊ \ÊÊ Ê-Փ“>ÀÞʜvÊ̅iÊ *Ê œ˜Ãi˜ÃÕÃÊ*>˜iÊ,i«œÀÌÊ°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°° £Ç 7°ÊÀ>˜ŽÊ*i>VœVŽ]Ê *ÀœviÃÜÀ 6ˆVi‡ …>ˆÀ]Ê,iÃi>ÀV…]Ê i«>À̓i˜ÌʜvÊ “iÀ}i˜VÞÊi`ˆVˆ˜i /…iÊ iÛi>˜`Ê ˆ˜ˆV]Ê iÛi>˜`]Ê"

>VŽ}ÀœÕ˜`Ê>˜`ʈ˜`ˆ˜}ÃÊÀœ“Ê̅iÊ  , Ê /" Ê, -/,9Ê°°°°°°°°°°°°°°°°°° ÓÇ 7ˆˆ>“Ê/°ÊLÀ>…>“]Ê *ÀœviÃÜÀ

…ˆiv]Ê ˆÛˆÃˆœ˜ÊœvÊ >À`ˆœÛ>ÃVՏ>ÀÊi`ˆVˆ˜i /…iÊ"…ˆœÊ-Ì>ÌiÊ1˜ˆÛiÀÈÌÞ]Ê œÕ“LÕÃ]Ê"

ˆÃi>ÃiÊ>˜>}i“i˜ÌʜvÊVÕÌiÊ iVœ“«i˜Ã>Ìi`Êi>ÀÌÊ>ˆÕÀi\Ê/…iÊ  , Ê

“iÀ}i˜VÞÊi`ˆVˆ˜iÊœ`ՏiÊÊ°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°° ÎÎ ,ˆV…>À`Ê°Ê-Փ“iÀÃ]Ê *ÀœviÃÜÀ i«>À̓i˜ÌʜvÊ “iÀ}i˜VÞÊi`ˆVˆ˜i 1˜ˆÛiÀÈÌÞʜvʈÃÈÃÈ««ˆÊi`ˆV>Ê i˜ÌiÀ]Ê>VŽÃœ˜]Ê-

VÕÌiÊ iVœ“«i˜Ã>Ìi`Êi>ÀÌÊ>ˆÕÀiÊ ˆÃi>ÃiÊ>˜>}i“i˜ÌÊ/œœÃÊ°°°°°°°°°°°°°°°°°°° Ι -i>˜Ê*°Ê œˆ˜Ã]Ê ÃÈÃÌ>˜ÌÊ*ÀœviÃÜÀ i«>À̓i˜ÌʜvÊ “iÀ}i˜VÞÊi`ˆVˆ˜i 1˜ˆÛiÀÈÌÞʜvÊ ˆ˜Vˆ˜˜>̈]Ê ˆ˜Vˆ˜˜>̈]Ê"

œ˜Ìˆ˜Õˆ˜}Êi`ˆV>Ê `ÕV>̈œ˜Ê+ÕiÃ̈œ˜ÃÊ°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°° {Ç

II

œ˜ÌÀˆLṎ˜}ÊÕ̅œÀà 7ˆˆ>“Ê/°ÊLÀ>…>“]Ê *ÀœviÃÜÀ

…ˆiv]Ê ˆÛˆÃˆœ˜ÊœvÊ >À`ˆœÛ>ÃVՏ>ÀÊi`ˆVˆ˜i /…iÊ"…ˆœÊ-Ì>ÌiÊ1˜ˆÛiÀÈÌÞ

œÕ“LÕÃ]Ê"…ˆœÊ œÕ}>ÃÊ°Ê …>À]Ê ÃÈÃÌ>˜ÌÊ*ÀœviÃÜÀ 7>ň˜}̜˜Ê1˜ˆÛiÀÈÌÞ -̰ʜՈÃ]ʈÃÜÕÀˆÊ

ÃÈÃÌ>˜ÌÊ*ÀœviÃÜÀ 1˜ˆÛiÀÈÌÞʜvÊ ˆ˜Vˆ˜˜>̈

ˆ˜Vˆ˜˜>̈]Ê"…ˆœ

7°ÊÀ>˜ŽÊ*i>VœVŽ]Ê *ÀœviÃÜÀ /…iÊ iÛi>˜`Ê ˆ˜ˆVÊ

iÛi>˜`]Ê"…ˆœ

Õ``Ê °Êœ>˜`iÀ]Ê *ÀœviÃÜÀ 1˜ˆÛiÀÈÌÞʜvÊ*i˜˜ÃޏÛ>˜ˆ> *…ˆ>`i«…ˆ>]Ê*i˜˜ÃޏÛ>˜ˆ>

,ˆV…>À`Ê°Ê-Փ“iÀÃ]Ê *ÀœviÃÜÀ 1˜ˆÛiÀÈÌÞʜvʈÃÈÃÈ««ˆÊ >VŽÃœ˜]ʈÃÈÃÈ««ˆ

-i>˜Ê*°Ê œˆ˜Ã]Ê

 , Êi“LiÀà 7°Ê Àˆ>˜ÊˆLiÀ]Ê ]Ê*ÀiÈ`i˜Ì 1˜ˆÛiÀÈÌÞʜvÊ ˆ˜Vˆ˜˜>̈

ˆ˜Vˆ˜˜>̈]Ê"…ˆœ

iÀ“>˜Ê°Ê iœœâ]Ê 1˜ˆÛiÀÈÌÞʜëˆÌ>Ê>Ã̅ՈÃLiÀ} iÕÛi˜]Ê i}ˆÕ“

-…ˆ˜}œÊœÀˆ]Ê iˆœÊ1˜ˆÛiÀÈÌÞ /œŽÞœ]Ê>«>˜

À̅ÕÀÊ°Ê*>˜Vˆœˆ]Ê 1˜ˆÛiÀÈÌÞʜvÊ ˆ˜Vˆ˜˜>̈

ˆ˜Vˆ˜˜>̈]Ê"…ˆœ

6°Ê˜>˜Ì…>À>“>˜]Ê -ˆ˜}>«œÀiÊi˜iÀ>ÊœÃ«ˆÌ> -ˆ˜}>«œÀi

iLœÀ>…Ê-°Ê ˆiÀVŽÃ]Ê 1° °Ê >ۈÃÊi`ˆV>Ê i˜ÌiÀ ->VÀ>“i˜Ìœ]Ê >ˆvœÀ˜ˆ>

`Ü>À`Ê °Ê>ÕV…]Ê 1˜ˆÛiÀÈÌÞʜvÊ ˆ˜Vˆ˜˜>̈

ˆ˜Vˆ˜˜>̈]Ê"…ˆœ

7°ÊÀ>˜ŽÊ*i>VœVŽ]Ê /…iÊ iÛi>˜`Ê ˆ˜ˆVÊ

iÛi>˜`]Ê"…ˆœ

/œ“Ê*°ÊÕv`iÀ…iˆ`i]Ê i`ˆV>Ê œi}iʜvÊ7ˆÃVœ˜Ãˆ˜ ˆÜ>Վii]Ê7ˆÃVœ˜Ãˆ˜

Ài}œÀÞÊ°ÊiÀ“>˜˜]Ê 1˜ˆÛiÀÈÌÞʜvÊ ˆ˜Vˆ˜˜>̈

ˆ˜Vˆ˜˜>̈]Ê"…ˆœ

,>ޓœ˜`Ê °Ê>VŽÃœ˜]Ê 7ˆˆ>“Ê i>Փœ˜ÌʜëˆÌ> ,œÞ>Ê">Ž]ʈV…ˆ}>˜

…>ÀiÃÊ6°Ê*œ>VŽ]Ê 1˜ˆÛiÀÈÌÞʜvÊ*i˜˜ÃޏÛ>˜ˆ>ʜëˆÌ> *…ˆ>`i«…ˆ>]Ê*i˜˜ÃޏÛ>˜ˆ>

,œLiÀÌœÊ >ÃÃ>˜]Ê *Àœ‡ >À`ˆ>VœÊœÃ«ˆÌ> ,ˆœÊ`iÊ>˜iˆÀœ]Ê À>∏

À>˜VˆÃÊ°ÊiӈÀi]Ê

À>˜}iÀÊi`ˆV>Ê i˜ÌiÀ

…>ÌÌ>˜œœ}>]Ê/i˜˜iÃÃii

°Ê œÕ}>ÃʈÀŽ]Ê 1° °Ê >ۈÃÊi`ˆV>Ê i˜ÌiÀ ->VÀ>“i˜Ìœ]Ê >ˆvœÀ˜ˆ>

>ÀÀÞÊ-iÛiÀ>˜Vi]Ê ՎiÊ1˜ˆÛiÀÈÌÞÊi`ˆV>Ê i˜ÌiÀ ÕÀ…>“]Ê œÀÌ…Ê >Àœˆ˜>

˜`À>Ê°Ê œ“Ž>˜Ã]Ê 1˜ˆÛiÀÈÌÞʜvÊ ˆ˜Vˆ˜˜>̈

ˆ˜Vˆ˜˜>̈]Ê"…ˆœ

°ÊiiÊ>ÀÛiÞ]Ê

>Àœˆ˜>ÃÊi`ˆV>Ê i˜ÌiÀ

…>ÀœÌÌi]Ê œÀÌ…Ê >Àœˆ˜>

…ÀˆÃ̜«…iÀʰʈ˜`Ãi]Ê*… 1˜ˆÛiÀÈÌÞʜvÊ ˆ˜Vˆ˜˜>̈

ˆ˜Vˆ˜˜>̈]Ê"…ˆœ

7>ÌiÀÊ°Ê-V…À>`ˆ˜}]Ê 9œÀŽÊœÃ«ˆÌ> 9œÀŽ]Ê*i˜˜ÃޏÛ>˜ˆ>

iÀ>`Ê8°Ê Àœ}>˜]Ê œÀ̅Ê-…œÀiÊ1˜ˆÛiÀÈÌÞʜëˆÌ> *>ˆ˜ÛˆiÜ]Ê iÜÊ9œÀŽ

>ÀÞÊ °ÊÀii˜]Ê œ…˜ÃÊœ«Žˆ˜ÃÊi`ˆV>Ê ˜Ã̈ÌṎœ˜Ã >Ìˆ“œÀi]Ê>Àޏ>˜`

Û>˜`ÀœÊiõՈÌ>]Ê *Àœ‡ >À`ˆ>VœÊœÃ«ˆÌ> ,ˆœÊ`iÊ>˜iˆÀœ]Ê À>∏

œÀiÞÊ°Ê-œÛˆÃ]Ê 6>˜`iÀLˆÌÊ1˜ˆÛiÀÈÌÞ >Åۈi]Ê/i˜˜iÃÃii

,ˆV…>À`Ê°Ê œÜ>Ž]Ê i˜ÀÞÊœÀ`ʜëˆÌ> iÌÀœˆÌ]ʈV…ˆ}>˜

,ˆV…>À`Ê°Ê-Փ“iÀÃ]Ê 1˜ˆÛiÀÈÌÞʜvʈÃÈÃÈ««ˆÊÊ >VŽÃœ˜]ʈÃÈÃÈ««ˆ

>Ã>̜ňÊ"L>]Ê ÕÀՎ>Ü>Ê ˆÌÞʜëˆÌ> >«>˜

Àˆ>˜Ê,°Ê/ˆvv>˜Þ]Ê >ÀˆVœ«>Êi`ˆV>Ê i˜ÌiÀ *…œi˜ˆÝ]ÊÀˆâœ˜>

Àˆ>˜Ê°Ê"½ iˆ]Ê ->ˆ˜ÌÊœ…˜ÃʜëˆÌ> iÌÀœˆÌ]ʈV…ˆ}>˜

>“iÃÊ °Ê7iLiÀ]Ê 1˜ˆÛiÀÈÌÞʜvʈV…ˆ}>˜ ˆ˜Ì]ʈV…ˆ}>˜

œÃi«…Ê*°Ê"À˜>̜]Ê i`ˆV>Ê œi}iʜvÊ6ˆÀ}ˆ˜ˆ> ,ˆV…“œ˜`]Ê6ˆÀ}ˆ˜ˆ>

,œLiÀÌÊ°Ê<>i˜ÃŽˆ]Ê 7>ޘiÊ-Ì>ÌiÊ1˜ˆÛiÀÈÌÞ iÌÀœˆÌ]ʈV…ˆ}>˜

>ۈ`Ê°Ê°Ê ÀœÜ˜]Ê >ÃÃ>V…ÕÃiÌÌÃÊi˜iÀ>ÊœÃ«ˆÌ> œÃ̜˜]Ê>ÃÃ>V…ÕÃiÌÌÃ

III

ˆ˜Ê°Ê>˜]Ê 1˜ˆÛiÀÈÌÞʜvÊ ˆ˜Vˆ˜˜>̈

ˆ˜Vˆ˜˜>̈]Ê"…ˆœ

œÕ}>ÃÊ°Ê …>À]Ê 7>ň˜}̜˜Ê1˜ˆÛiÀÈÌÞÊ-V…œœÊœvÊ i`ˆVˆ˜i -̰ʜՈÃ]ʈÃÜÕÀˆÊ

>“iÃÊ7°ÊœiŽÃÌÀ>]Ê 7>ŽiÊœÀiÃÌÊ1˜ˆÛiÀÈÌÞ 7ˆ˜Ã̜˜Ê->i“]Ê œÀÌ…Ê >Àœˆ˜>

>“iÃÊ°Ê …ÀˆÃÌi˜Ãœ˜]Ê -Ì°Ê*>Տ½ÃʜëˆÌ> 6>˜VœÕÛiÀ]Ê ÀˆÌˆÃ…Ê œÕ“Lˆ>

Õ``Ê °Êœ>˜`iÀ]Ê 1˜ˆÛiÀÈÌÞʜvÊ*i˜˜ÃޏÛ>˜ˆ> *…ˆ>`i«…ˆ>]Ê*i˜˜ÃޏÛ>˜ˆ>

-i>˜Ê*°Ê œˆ˜Ã]Ê 1˜ˆÛiÀÈÌÞʜvÊ ˆ˜Vˆ˜˜>̈

ˆ˜Vˆ˜˜>̈]Ê"…ˆœ

Àˆ>˜Ê,°ÊœÀœÞ`]Ê 1˜ˆÛiÀÈÌÞʜvʏLiÀÌ>ʜëˆÌ>Ã

`“œ˜Ìœ˜]ʏLiÀÌ>]Ê >˜>`>

 "--Ê"Ê 1/ Ê "* -/ Ê  ,/Ê1, Ê Ê/ Ê *UDD%(OLLANDER -$ $EPARTMENTOF%MERGENCY-EDICINE 5NIVERSITYOF0ENNSYLVANIA 0HILADELPHIA 0!

"  /6 -\ £°Ê iw˜iÊ̅iÊÕÃiʜvÊ *Ê̜Ê`ˆÃ̈˜}ՈÅʅi>ÀÌÊv>ˆÕÀiÊvÀœ“ʜ̅iÀÊœ}ˆiÃʜvÊŜÀ̘iÃÃʜvÊ LÀi>̅ Ó°Ê iˆ˜i>ÌiÊ̅iÊÀœiʜvÊ *ÊvœÀÊÀˆÃŽÊÃÌÀ>̈vވ˜}Ê«>̈i˜ÌÃÊ܈̅ʅi>ÀÌÊv>ˆÕÀi

 /," 1 /" !SWEHAVEIMPROVEDTHECAREOFPATIENTSWITHACUTECORONARYSYNDROMES!#3 PA TIENTSWITHCARDIOVASCULARDISEASEARELIVINGLONGERTHANEVER%FFECTIVEINTERVENTIONSTO DECREASEMORTALITYOFPATIENTSWITH!#3HAVEINCREASEDTHEINCIDENCEOFHEARTFAILURE 4HECOSTOFHEARTFAILURENOWEXCEEDSBILLIONAYEAR MOSTOFWHICHISDUETOHOS PITALIZATION5NFORTUNATELY HEARTFAILUREISACHRONICCONDITIONANDNEARLYHALFOFPA TIENTSADMITTEDTOTHEHOSPITALAREREADMITTEDWITHINSIXMONTHS4ODETERMINEOPTIMAL THERAPYFORPATIENTSWITHACUTEDECOMPENSATEDHEARTFAILURE!$(& THEEMERGENCY PHYSICIANMUSTBEABLETOCONlDENTLYDIAGNOSEPATIENTSWITHHEARTFAILURE4HISREQUIRES KNOWLEDGEOFTHEDIAGNOSTICMETHODSUSEDTOIDENTIFYPATIENTSWITHHEARTFAILUREASWELL ASKNOWLEDGEOFTHEDIFFERENTETIOLOGIESOFHEARTFAILURE 3ORTING/UTTHE%TIOLOGYOF(EART &AILURE 4HE POTENTIAL ETIOLOGIES OF ACUTE HEART FAILURE ARE MULTIFACTORIAL AND SHOULD BE BROADLY DIVIDED INTO TWO CATEGORIES  THE UNDERLYING ETIOLOGY OF THE HEART FAILURE AND THEETIOLOGYOFTHEACUTE PRECIPITANTTHATRESULTSINWORSENINGFROM THECHRONICCOMPENSATEDSTATE&ORSOME PATIENTS PARTICULARLYTHOSEPRESENTINGFOR THElRSTTIME THESETWOCOMPONENTSMAY BE IDENTICAL 4HE MOST COMMON ETIOLO GIES OF HEART FAILURE ARE CORONARY ARTERY DISEASE AND LONG STANDING HYPERTENSION /THER POTENTIAL ETIOLOGIES INCLUDE DI LATED HYPERTROPHIC AND RESTRICTIVE CAR DIOMYOPATHIES MYOCARDITIS PERICARDIAL TAMPONADE VALVULAR HEART DISEASE AND SECONDARYEFFECTSOFPULMONARYDISEASES ORMETABOLICDISORDERS

!LTHOUGHINVESTIGATIONOFTHEUNDERLYING ETIOLOGY IS IMPORTANT TO HELP DETERMINE WHETHERTHEREISAREVERSIBLECOMPONENT OFTHEDISEASE THISISUSUALLYBEYONDTHE SCOPEOFTHEEMERGENCYPHYSICIAN4HERE ARE HOWEVER SEVERALETIOLOGIESFORHEART FAILURE THAT THE EMERGENCY PHYSICIAN SHOULDBEAWAREOF ASTHEYMAYREQUIRE MODIlCATIONOFINITIALTHERAPY4HESEARE SEVERE AORTIC STENOSIS IDIOPATHIC HYPER TROPHICSUBAORTICSTENOSISORHYPERTROPHIC OBSTRUCTIVECARDIOMYOPATHY ANDPULMO NARY HYPERTENSION )DENTIlCATION OF PA TIENTSWITHTHESECONDITIONSISIMPORTANT BECAUSEAGGRESSIVEPRELOADANDAFTERLOAD REDUCTIONCANLEADTOCARDIOVASCULARCOL LAPSESINCETHESEPATIENTSCANNOTINCREASE THEIR FORWARD BLOOD mOW THROUGH THE lXEDMECHANICALLESIONSUCHASAmOW RESTRICTEDAORTICVALVE 

/…iÊ«œÌi˜Ìˆ>Êœ}ˆiÃÊ œvÊ>VÕÌiʅi>ÀÌÊv>ˆÕÀiÊ >ÀiʓՏ̈v>V̜Àˆ>Ê>˜`Ê Ã…œÕ`ÊLiÊLÀœ>`ÞÊ `ˆÛˆ`i`ʈ˜ÌœÊÌÜœÊ V>Ìi}œÀˆiÃ\Ê­£®Ê̅iÊ Õ˜`iÀÞˆ˜}Êœ}ÞʜvÊ Ì…iʅi>ÀÌÊv>ˆÕÀi]Ê>˜`Ê ­Ó®Ê̅iÊœ}ÞʜvÊ̅iÊ >VÕÌiÊ«ÀiVˆ«ˆÌ>˜ÌÊ̅>ÌÊ ÀiÃՏÌÃʈ˜ÊܜÀÃi˜ˆ˜}Ê vÀœ“Ê̅iÊV…Àœ˜ˆVÊ Vœ“«i˜Ã>Ìi`ÊÃÌ>Ìi°Ê



%MERGENCY$IAGNOSISAND4REATMENTOF !CUTE$ECOMPENSATED(EART&AILURE!$(&

3EPARATEANDDISTINCTFROMTHEINITIALETI OLOGY IS THE CAUSE OF THE ACUTE PRECIPI TANT#ONGESTIVEHEARTFAILURECANBEEX ACERBATEDBYWORSENINGOFTHEUNDERLYING CONDITION BYMEDICATIONORDIETARYNON COMPLIANCE OR BY DEVELOPMENT OF NEW ORCOMPLICATINGMEDICALCONDITIONSEG ISCHEMIA DYSRHYTHMIAS PULMONARYEM BOLUS ORINFECTION !PPROXIMATELY OF PATIENTS PRESENTING TO THE EMERGENCY DEPARTMENT%$ WITHHEARTFAILUREHAVE APRIORDIAGNOSISOFHEARTFAILURE ,iˆ>˜ViÊÕ«œ˜ÊVˆ˜ˆV>Ê ˆ“«ÀiÃȜ˜Ê>œ˜iÊ i>`ÃÊ̜Ê`ˆ>}˜œÃ̈VÊ Õ˜ViÀÌ>ˆ˜ÌÞÊLiV>ÕÃiÊ̅iÊ Ãˆ}˜ÃÊ>˜`ÊÃޓ«Ìœ“ÃÊ œvʅi>ÀÌÊv>ˆÕÀiÊ>ÀiÊ Ài>̈ÛiÞʘœ˜Ã«iVˆwV°

qqqqqqq

/…iÊ Ài>̅ˆ˜}Ê œÌÊ*Àœ«iÀÞÊ/Àˆ>Ê `i“œ˜ÃÌÀ>Ìi`Ê̅>ÌÊÊ *ʈÃÊÕÃivՏÊvœÀÊÊ Ì…iÊ`ˆ>}˜œÃˆÃʜvÊ ÊÊ ˆ˜Ê̅iÊ °Ê



0ROGRESSINTHE$IAGNOSISOF(EART&AILURE 4HE DIAGNOSIS OF HEART FAILURE HAS TRADI TIONALLYBEENCHALLENGING2ELIANCEUPON CLINICAL IMPRESSION ALONE LEADS TO DIAG NOSTIC UNCERTAINTY BECAUSE THE SIGNS AND SYMPTOMS OF HEART FAILURE ARE RELATIVELY NONSPECIlC+EYSYMPTOMSSUCHASSHORT NESSOFBREATHARENONSPECIlCINPATIENTS WITH COMORBIDITIES SUCH AS REACTIVE AIR WAYDISEASE,IKEWISE ROUTINELABORATORY TESTS ELECTROCARDIOGRAMS ANDRADIOGRAPHS CANNOTBERELIEDUPONTOALWAYSGUIDEAN ACCURATEANDAPPROPRIATEDIAGNOSIS $ESPITE THESE CHALLENGES DIAGNOSTIC CA PABILITIESINHEARTFAILUREHAVEIMPROVED IN RECENT YEARS WITH RECOGNITION OF THE ROLETHAT" TYPENATRIURETICPEPTIDE".0 PLAYSINTHEDISEASE)NADDITIONTOBEING APUMP THEHEARTISANENDOCRINEORGAN THATFUNCTIONSTOGETHERWITHOTHERPHYSI OLOGICALSYSTEMSTOCONTROLmUIDVOLUME 4HE MYOCARDIUM PRODUCES NATRIURETIC PEPTIDES ONEOFWHICHIS".0 AHORMONE WITH DIURETIC NATRIURETIC AND VASCULAR SMOOTHMUSCLERELAXINGACTIONS".0IS A NATURAL ANTAGONIST FOR THE SYMPATHETIC NERVOUS SYSTEM AND THE RENIN ANGIOTEN SIN ALDOSTERONEAXIS".0ISSECRETEDIN

RESPONSE TO WALL STRETCH VENTRICULAR DI LATIONANDORINCREASEDlLLINGPRESSURES -EASUREMENTOFENDOGENOUS".0ISTHUS ACLINICALLYSENSIBLEWAYTOASSESSWHETH ERAPARTICULARPATIENTHASHEARTFAILURE 4HE "REATHING .OT 0ROPERLY STUDY OF  PATIENTSWHOPRESENTEDTO%$SWITH SHORTNESSOFBREATHSHOWEDTHAT".0LEV ELS ALONE WERE MORE ACCURATE PREDICTORS OFTHEPRESENCEORABSENCEOFHEARTFAILURE THANANYHISTORICALFACTORS PHYSICALlND INGS OR LABORATORY VALUES  ".0 LEVELS WEREMUCHHIGHERINPATIENTSWHOWERE SUBSEQUENTLY DIAGNOSED WITH HEART FAIL URETHANINTHOSEDIAGNOSEDWITHNONCAR DIACDYSPNEAPGD,VSPGD,  ! ".0 CUTOFF VALUE OF  PGM, HAD ASENSITIVITYOFANDASPECIlCITYOF FORDIFFERENTIATINGHEARTFAILUREFROM OTHERCAUSESOFDYSPNEA ANDACUTOFFOF PGM,HADANEGATIVEPREDICTIVEVAL UE OF 7ITHOUT KNOWLEDGE OF ".0 LEVELS EMERGENCYPHYSICIANSHADA INDECISIONRATEINTRYINGTOMAKEADIAG NOSIS".0LEVELSADDEDSIGNIlCANTLYTO THE CLINICAL IMPRESSION AS IT WAS FOUND THATCLINICALDECISION MAKINGINCONJUNC TIONWITH".0LEVELSCOULDHAVEREDUCED THEDIAGNOSTICINDECISIONRATETO)N MULTIVARIATEANALYSES ".0LEVELSALWAYS CONTRIBUTED TO THE DIAGNOSIS EVEN AFTER TAKING INTO ACCOUNT lNDINGS FROM THE HISTORY AND PHYSICALEXAMINATION4HUS THE"REATHING.OT0ROPERLYTRIALDEMON STRATED THAT ".0 LEVELS HAVE SIGNIlCANT CLINICAL UTILITY FOR BOTH THE DIAGNOSIS AND RISK STRATIlCATION OF HEART FAILURE PATIENTS IN THE %$  "OTH DIASTOLIC AND SYSTOLIC DYSFUNCTION ARE ASSOCIATED WITH HIGH".0LEVELSOFMOREORLESSTHESAME DEGREE

 "--Ê"Ê 1/ Ê "* -/ Ê  ,/Ê1, Ê Ê/ Ê

".0MUSTBEUSEDWITHCAUTIONINCERTAIN POPULATIONS!LTHOUGH".0CANHELPDIF FERENTIATEPULMONARYFROMCARDIACETIOLO GIESOFDYSPNEA SOMETYPESOFLUNGDIS EASE SUCH AS COR PULMONALE AND PULMO NARYEMBOLISMHAVEELEVATED".0LEVELS HOWEVER".0ISNOTUSUALLYELEVATEDASTO ASHIGHALEVELASITISINPATIENTSWITHHEART FAILURE )N A SUBGROUP OF PATIENTS WITH A HISTORY OF REACTIVE AIRWAY DISEASE IN THE "REATHING.OT0ROPERLYTRIAL OFSUB JECTSWITHAHISTORYOFASTHMAORCHRONIC OBSTRUCTIVE PULMONARY DISEASE WITHOUT A HISTORYOF#(& WEREFOUNDTOHAVE NEWLY DISCOVERED #(& /NLY  WERE IDENTIlED IN THE %$ WHILE A ".0  PGM,IDENTIlED!DDITIONALLY ".0 LEVELS  PGM, PROVIDED DIAGNOSTIC INFORMATIONBEYONDTHATOBTAINEDFROMIN DIVIDUALCHESTRADIOGRAPHICINDICATORS 4HERE IS A SIGNIlCANT INVERSE RELATIONSHIP BETWEEN BODY WEIGHT BODY MASS INDEX AND ".0 LEVELS4HIN PATIENTS WITH HEART FAILUREAREMORELIKELYTOHAVEELEVATED".0 VALUESINTHEABSENCEOFHEARTFAILURE#ON VERSELY OBESE PATIENTS ARE MORE LIKELY TO HAVELOWERLEVELSOF".0FORANYGIVENSE VERITYOFHEARTFAILURE!SARESULT ".0LEV ELSSHOULDBEUSEDWITHCAUTIONINPATIENTS WITHOBESITY UNLESSOFCOURSEBASELINE".0 VALUES ARE KNOWN 4HEN THE OBESE PATIENT CANBEFOLLOWEDFORDECOMPENSATION 4HE "REATHING .OT 0ROPERLY 4RIAL DEM ONSTRATEDTHAT".0ISUSEFULFORTHEDIAG NOSIS OF #(& IN THE %$ 4HE 2%$(/4 3TUDY SUGGESTS THAT ".0 MIGHT ALSO BE USEFULTOIMPROVETRIAGEANDDISPOSITIONOF PATIENTSWHOPRESENTTOTHE%$WITHHEART FAILURE4HISTRIALDEMONSTRATEDAhDISCON NECTvBETWEENTHEPHYSICIANPERCEPTIONOF THESEVERITYOFHEARTFAILUREANDTHEACTUAL ".0VALUE)NTHElRSTPHASE PATIENTS

VISITING %$S WITH COMPLAINTS OF BREATH ING DIFlCULTY HAD ".0 MEASUREMENTS TAKENONARRIVAL0HYSICIANSWEREBLINDED TO".0RESULTSHOWEVERINCLUSIONINTHE TRIALREQUIREDA".0PGML0ATIENTS DISCHARGEDFROMTHE%$HADHIGHER".0 LEVELSTHANTHOSEADMITTEDTOTHEHOSPITAL PGMLVSPGML 7ITHRESPECTTO THEADMITTEDPATIENTS HAD".0LEV ELSPGML WHICHISINDICATIVEOFLESS SEVERE#(&-OSTOFTHESEPATIENTSWERE PERCEIVEDTOHAVECLASS)))OR)6HEARTFAIL URE-ORTALITYFORTHESEPATIENTSWASAT DAYSANDONLYATDAYS SUGGESTING THATPATIENTSWITHHEARTFAILUREANDLOWLEV ELSOF".0MIGHTHAVEACTUALLYBEENSAFE FORDISCHARGE7ITHRESPECTTOPATIENTSTHAT WERE ACTUALLY DISCHARGED  HAD ".0 LEVELSPGM,!TDAYS MORTALITY WAS4HEREWASNOMORTALITYOFTHOSE DISCHARGEDWITH".0LEVELSPGM, 4HISSUGGESTSTHATUSEOF".0INTHE%$ MIGHTALSOHELPDETERMINEWHICHWELLAP PEARINGPATIENTSAREHIGHRISKFORABADOUT COMEOVERTHESHORTTERMDAYS 

iÛ>̈œ˜ÃʜvÊ *Ê>ÀiÊ ÕÃivՏÊvœÀÊ>ÃÃiÃȘ}Ê ÀˆÃŽÊÃÌÀ>̈wV>̈œ˜Ê>˜`Ê «Àœ}˜œÃˆÃʈ˜Ê«>̈i˜ÌÃÊ ÜˆÌ…Ê…i>ÀÌÊv>ˆÕÀi°

%LEVATED ".0 LEVELS ARE USEFUL FOR AS SESSING RISK STRATIlCATION AND PROGNOSIS INPATIENTSWITHHEARTFAILURE".0LEVELS ARE RELATED TO CHANGES IN LIMITATIONS OF PHYSICAL ACTIVITIES AND FUNCTIONAL STATUS (ARRISONETALFOLLOWEDPATIENTSFOR MONTHSAFTERANINDEXVISITTOTHE%$FOR DYSPNEA (IGHER ".0 LEVELS WERE ASSO CIATED WITH A PROGRESSIVELY WORSE PROG NOSIS 4HE RELATIVE RISK OF  MONTH #(& ADMISSIONORDEATHINPATIENTSWITH".0 LEVELSPGM,WASTIMESTHERISK OFPATIENTSWITHLEVELSLESSTHAN7HEN COMBINEDWITHTROPONIN) BOTHTROPONIN) AND".0ALONEANDINCOMBINATIONPRE DICTSURVIVALIN#(&"OTHTOGETHERHAVE ADDITIVEPROGNOSTICRISK 

%MERGENCY$IAGNOSISAND4REATMENTOF !CUTE$ECOMPENSATED(EART&AILURE!$(&

4HE UTILITY OF ".0 TO DIAGNOSIS #(& IS WELL ESTAB LISHEDHOWEVER ITSABILITYTODRIVETREATMENTISSTILL UNDERSTUDY2%$(/4))ISARANDOMIZEDCONTROLLED TRIAL COMPARING TREATMENT AND OUTCOMES OF PATIENTS WHERETHERAPYISGUIDEDBYSERIAL".0MEASUREMENTS IN THE EXPERIMENTAL GROUP 4HIS STUDY SHOULD SHED SOMELIGHTONTHEUTILITYOF".0TODRIVETREATMENT $UETOTHEVOLUMINOUSDATAONTHECLINICALUTILITYOF ".0 CONSENSUSPANELGUIDELINESWERERECENTLYPUB LISHED4HESERECOMMENDATIONSSTATE % -ANYPATIENTSPRESENTINGTOEMERGENCYSERVICES WITH DYSPNEA A HISTORY PHYSICAL EXAMINATION ANDACHESTX RAYAND%#'SHOULDBEUNDERTAKEN TOGETHER WITH LABORATORY MEASUREMENTS THAT INCLUDE".0 % !S".0LEVELSRISEWITHAGEANDAREAFFECTEDBY GENDER COMORBIDITY ANDDRUGTHERAPY THEPLASMA ".0MEASUREMENTSHOULDNOTBEUSEDINISOLATION FROMTHECLINICALCONTEXT % )F THE ".0 IS  PGM, THEN HEART FAILURE IS HIGHLYUNLIKELYNEGATIVEPREDICTIVEVALUE   % )F THE ".0 LEVEL IS  PGM, THEN #(& IS HIGHLYLIKELYPOSITIVEPREDICTIVEVALUE  % &OR".0LEVELSOFn ONESHOULDCONSIDER THE FOLLOWING CONDITIONS IN THE DIFFERENTIAL DIAGNOSIS A "ASELINE".0VALUEDUETOSTABLEUNDERLYING DYSFUNCTION B 2IGHTVENTRICULARFAILUREFROMCOR

PULMONALE C !CUTEPULMONARYEMBOLISM D 2ENALFAILURE s 0ATIENTSMAYPRESENTWITH#(&WITHNORMAL ".0 LEVELS OR WITH LEVELS BELOW WHAT MIGHTONEEXPECTCANOCCURINTHEFOLLOWING SITUATIONS A &LASHPULMONARYEDEMAnHOURS B (EART FAILURE UP STREAM FROM THE LEFT VENTRICLE IE ACUTE MITRAL REGURGITATION FROMPAPILLARYMUSCLERUPTURE C /BESE PATIENTS BODY MASS INDEX  KGM

,  ,



-AISEL!3 +RISHNASWAMY0 .OWAK2- ETAL2APID MEASUREMENTOF" TYPENATRIURETICPEPTIDEINTHEEMERGENCY DIAGNOSISOFHEARTFAILURE.%NGL*-ED 



-C#ULLOUGH0! .OWAK2- -C#ORD* ETAL" TYPENATRIURETIC PEPTIDEANDCLINICALJUDGMENTINEMERGENCYDIAGNOSISOFHEART FAILUREANALYSISFROM"REATHING.OT0ROPERLY".0 -ULTINATIONAL 3TUDY#IRCULATION 



-AISEL!3 -C#ORD* .OWAK2- (OLLANDER*% 7U!(" $UC0 /MLAND4 3TORROW!" +RISHNASWAMY0 !BRAHAM74 #LOPTON0 3TEG0' !UMONT-# 7ESTHEIM! +NUDSEN#7 0EREZ! +AMIN2 +AZANEGRA2 (ERRMANN(# -C#ULLOUGH0! FORTHE".0-ULTINATIONAL3TUDY)NVESTIGATORS"EDSIDE" TYPE NATRIURETICPEPTIDEINTHEEMERGENCYDIAGNOSISOFHEARTFAILUREWITH REDUCEDORPRESERVEDEJECTIONFRACTION2ESULTSFROMTHE"REATHING .OT0ROPERLY".0 -ULTINATIONAL3TUDY*!M#OLL#ARDIOL  



-C#ULLOUGH0! (OLLANDER*% .OWAK2- ETAL5NCOVERING HEARTFAILUREINPATIENTSWITHAHISTORYOFPULMONARYDISEASE RATIONALEFORTHEEARLYUSEOF" TYPENATRIURETICPEPTIDEINTHE EMERGENCYDEPARTMENT!CAD%MERG-ED  



+NUDSEN#7 /MLAND4 #LOPTON0 7ESTHEIM! !BRAHAM 74 3TORROW!" -C#ORD* .OWAK2- !UMONT-# $UC0 (OLLANDER*% 7U!(" -C#ULLOUGH0! -AISEL!3$IAGNOSTIC VALUEOF" TYPENATRIURETICPEPTIDEANDCHESTRADIOGRAPHIClNDINGS INPATIENTSWITHACUTEDYSPNEA!M*-ED  



-C#ORD* -UNDY"* (UDSON-0 -AISEL!3 (OLLANDER*% !BRAHAM74 3TEG0' /MLAND4 +NUDSEN#7 3ANDBERG+2 -C#ULLOUGH0! FORTHE"REATHING.OT0ROPERLY-ULTINATIONAL 3TUDY)NVESTIGATORS2ELATIONSHIPBETWEENOBESITYANDB TYPE NATRIURETICPEPTIDELEVELS!RCH)NTERN-ED 



-AISEL! (OLLANDER*% 'USS$ ETAL0RIMARYRESULTSOFTHERAPID EMERGENCYDEPARTMENTHEARTFAILUREOUTPATIENTTRIAL2%$(/4 A MULTICENTERSTUDYOFB TYPENATRIURETICPEPTIDELEVELS EMERGENCY DEPARTMENTDECISIONMAKING ANDOUTCOMESINPATIENTSPRESENTING WITHSHORTNESSOFBREATH*!MER#OLL#ARDIOL  



(ARRISON! -ORRISON,+ +RISHNASWAMY0 ETAL" TYPE NATRIURETICPEPTIDE".0 PREDICTSFUTURECARDIACEVENTSINPATIENTS PRESENTINGTOTHEEMERGENCYDEPARTMENTWITHDYSPNEA!NN%MERG -EDn



(ORWICH4" 0ATEL* -AC,ELLAN27 ETAL#ARDIACTROPONIN )ISASSOCIATEDWITHIMPAIREDHEMODYNAMICS PROGRESSIVELEFT VENTRICULARDYSFUNCTIONANDINCREASEDMORTALITYINADVANCEDHEART FAILURE#IRCULATION 

 3ILVER-! -AISEL! 9ANCY#7 -C#ULLOUGH0! "URNETT*# &RANCIS'3 -EHRA-2 0EACOCK7& &ONAROW' 'IBLER7" -ORROW$! (OLLANDER*".0#ONSENSUS0ANEL!CLINICAL APPROACHFORTHEDIAGNOSTIC PROGNOSTIC SCREENING TREATMENT MONITORINGANDTHERAPEUTICROLESOFNATRIURETICPEPTIDESIN CARDIOVASCULARDISEASES#ONG(EART&AILURE SUPPL  

#OPYRIGHT%-#2%' )NTERNATIONAL 



/, / /Ê"Ê 1/ Ê "* -/ Ê ,/Ê 1, Ê Ê/ Ê  , 9Ê *,/ / $OUGLAS-#HAR -$ $IVISIONOF%MERGENCY-EDICINE 7ASHINGTON5NIVERSITY 3T,OUIS -/

"  /6 -\ £°Ê iÃVÀˆLiÊ>Êȓ«iÊÌܜÊÃÌi«Ê>««Àœ>V…Ê̜Ê>ÃÃiÃȘ}Ê̅iÊVˆ˜ˆV>ÊÃÌ>ÌÕÃʜvÊ Ê«>̈i˜ÌÃÊÜˆÌ…Ê   Ó°Ê iw˜iÊ̅iÊÀœiʜvÊÛ>Ü`ˆ>̜ÀÃÊ>ÃÊ̅iʓ>ˆ˜ÃÌ>ÞʜvÊ̅iÀ>«ÞÊvœÀÊ 

 /," 1 /" !CUTELYDECOMPENSATEDHEARTFAILURE!$(& ISACOMMONREASONFORPATIENTSSEEKING EMERGENCYDEPARTMENT%$ CAREANDTHELEADING-EDICAREDIAGNOSISFORHOSPITALIZED PATIENTS OVER THE AGE OF  (OSPITAL READMISSION FOR HEART FAILURE IS COMMON AP PROXIMATELYOFPATIENTSAREREADMITTEDWITHINDAYSANDWITHINMONTHS 2ECENTADVANCESINTHEUNDERSTANDINGOFTHECOMPLEXPATHOPHYSIOLOGICPROCESSTHAT EXACERBATEHEARTFAILUREHASLEDTOIMPROVEDDIAGNOSESANDEFFECTIVE%$TREATMENTOF THISCLINICALENTITY 0ATHOPHYSIOLOGYAND(EMODYNAMIC !SSESSMENT )N THE PAST DECOMPENSATED HEART FAILURE WAS FELT TO BE DUE TO VOLUME OVERLOAD AND IMPAIRED FORWARD mOW 4REATMENT WASFOCUSEDONMAXIMIZINGCARDIACOUT PUT)THASNOWBECOMEAPPARENTTHATIN MOST !$(&PULMONARY EDEMA THERE IS INCREASED SYSTEMIC VASCULAR RESISTANCE SUPERIMPOSEDONREDUCEDMYOCARDIALRE SERVEBOTHSYSTOLICANDDIASTOLIC -ANY VARIABLESPLAYAROLEIN!$(&THATEXAC ERBATE LEFT VENTRICULAR ,6 DYSFUNCTION AND LEAD TO DETERIORATION ,OW CARDIAC OUTPUTRESULTSINDECREASEDRENALmOWAND STIMULATESNEUROHORMONALACTIVATION IN CLUDINGTHERELEASEOFANGIOTENSIN))$E CREASEDCARDIACOUTPUTCAUSESPROGRESSIVE BLOODVOLUMEEXPANSIONFURTHERINCREAS ING ,6 lLLING PRESSURES AND MYOCARDIAL OXYGENCONSUMPTION(YPOTENSIONPRO MOTES BARORECEPTOR ACTIVATION LEADING

TOINCREASEDSYMPATHETICTONEANDVASO CONSTRICTIONWHICHFURTHERINCREASESSYS TEMIC VASCULAR RESISTANCE COMPROMISING SYSTOLIC PERFORMANCE 4HERE IS MARKED UP REGULATIONOFVASOCONSTRICTORS INCLUD ING NOREPINEPHRINE ANGIOTENSIN )) AND ENDOTHELIN ALDOSTERONEANDARGININEVA SOPRESSINRISECONTRIBUTINGTOTHESALTAND WATERRETENTION  4OCOUNTER BALANCETHEEFFECTSOFNEURO HORMONES RELEASED BY THE SYMPATHETIC NERVOUS SYSTEM AND THE RENIN ANGIOTEN SIN ALDOSTERONE SYSTEM 2!!3 AND TO MAINTAIN CIRCULATORY HOMEOSTASIS THE BODY PRODUCES A FAMILY OF VASODILATOR ANTIPROLIFERATIVENATRIURETICPEPTIDESTHAT PLAY AN IMPORTANT ROLE IN HEART FAILURE !TRIAL AND " TYPE NATRIURETIC PEPTIDES ARERELEASEDFROMTHEMYOCARDIUMINRE SPONSETOINCREASEDATRIALNATRIURETICPEP TIDE AND VENTRICULAR " TYPE NATRIURETIC

/…iÊÀii>ÃiÊ>˜`Ê «Àœ`ÕV̈œ˜ÊœvÊÃ̜Ài`Ê ˜>ÌÀˆÕÀïVÊ«i«Ìˆ`iÃÊ>ÀiÊ ˆ˜ÃÕvwVˆi˜ÌÊ̜ÊL>>˜ViÊ Ì…iÊyՈ`ÊÀiÌi˜Ìˆœ˜ÊÊ œvÊ̅iÊ,-°



%MERGENCY$IAGNOSISAND4REATMENTOF !CUTE$ECOMPENSATED(EART&AILURE!$(& ˆ}ÕÀiÊ£°Ê

(YLGHQFHIRU/RZ3HUIXVLRQ 1DUURZ3XOVH3UHVVXUH 3XOVXV$OWHUDWLRQV &RRO)RUHDUPVDQG/HJV 0D\EH6OHHS\2EWXQGHG $&6,QKLELWRU5HODWHG 6\PSWRPDWLF+\SRWHQVLRQ 'HFOLQLQJ6HUXP6RGLXP/HYHO :RUVHQLQJ5HQDO)XQFWLRQ

/RZ3HUIXVLRQDW5HVW"

$IAGRAMINDICATINGXTABLEOFHEMODYNAMICPROlLESFORPATIENTS PRESENTING WITH HEART FAILURE -OST PATIENTS CAN BE CLASSIlED IN A  MINUTEBEDSIDEASSESSMENTACCORDINGTOTHESIGNSANDSYMPTOMS SHOWNALTHOUGHINPRACTICESOMEPATIENTSMAYBEONTHEBORDERBE TWEENTHEWARM AND WETANDCOLD AND WETPROlLES4HISCLASSIlCATION HELPSGUIDEINITIALTHERAPYANDPROGNOSISFORPATIENTSPRESENTINGWITH ADVANCEDHEARTFAILURE!LTHOUGHMOSTPATIENTSPRESENTINGWITHHYPO PERFUSIONALSOHAVEELEVATEDlLLINGPRESSURESCOLDANDWETPROlLE MANYPATIENTSPRESENTWITHELEVATEDlLLINGPRESSURESWITHOUTMAJOR REDUCTION IN PERFUSION WARM AND WET PROlLE  0ATIENTS PRESENTING WITHSYMPTOMSOFHEARTFAILUREATRESTORMINIMALEXERTIONWITHOUT CLINICALEVIDENCEOFELEVATEDlLLINGPRESSURESORHYPOPERFUSIONWARM ANDDRYPROlLE SHOULDBECAREFULLYEVALUATEDTODETERMINEWHETHER THEIRSYMPTOMSRESULTFROMHEARTFAILURE

1R


PEPTIDE".0 STRESS4HEYINCREASEGLOMERULARlL TRATION RATE '&2 INHIBIT SODIUM REABSORPTION AND REDUCEVASCULARSMOOTHMUSCLETONE CAUSINGADIURE SIS NATRIURESISANDBALANCEDARTERIALANDVENOUSDILA TION!LLTHESEEFFECTSCONTRIBUTETOREDUCEDPLASMA VOLUME BLOODPRESSUREANDVENTRICULARPRELOAD".0 HASLUSITROPICRELAXING EFFECTSANDMAYBEANTIlBROT IC AND ANTIPROLIFERATIVE )N!$(& THE RELEASE AND PRODUCTION OF STORED NATRIURETIC PEPTIDES ARE INSUFl CIENTTOBALANCETHEmUIDRETENTIONOFTHE2!!3 2APID BEDSIDE ASSESSMENT OF!$(& CAN BE SIMPLI lEDBYPLACINGTHEPATIENTINTOONEOFFOURHEMODY NAMICPROlLESQˆ}ÕÀiÊ £R4WOKEYHEMODYNAMIC PARAMETERS ARE THE PRESENCE OR ABSENCE OF ELEVATED lLLINGPRESSURESWETORDRY ANDADEQUACYOFPERFU SIONWARMORCOLD #ONGESTIONCORRESPONDSTOEL EVATEDPULMONARYCAPILLARYWEDGEPRESSURE0#70



/ܜ‡ˆ˜ÕÌiÊÃÃiÃÓi˜ÌʜvÊi“œ`ޘ>“ˆVÊ *Àœwi°Ê,i«Àœ`ÕVi`Ê>˜`ÊÀi«Àˆ˜Ìi`ÊÜˆÌ…Ê «iÀ“ˆÃȜ˜ÊvÀœ“Ê œ…Àˆ>Ê]Êi܈ÃÊ ]Ê -ÌiÛi˜Ãœ˜Ê7°ÊÊÓääÓÆÓnÇ\ÈÓn‡È{ä°

(YLGHQFHIRU&RQJHVWLRQ (OHYDWHG)LOOLQJ3UHVVXUH 2UWKRSQHD +LJK-XJXODU9HQRXV3UHVVXUH ,QFUHDVLQJ6 /RXG3 (GHPD $VFLWHV 5DOHV 8QFRPPRQ $EGRPLQRMXJXODU5HIOX[ 9DOVDOYD6TXDUH:DYH

&RQJHVWLRQDW5HVW" 1R


:DUPDQG'U\

:DUPDQG:HW

$

%

&ROGDQG'U\

&ROGDQG:HW

/

&

ANDIMPAIREDPERFUSIONISSUGGESTEDBYALOWCARDIAC INDEX'REATERTHANOFPATIENTSPRESENTINGWITH !$(&ARECONGESTEDWET 4HEYMAYHAVEADEQUATE ORREDUCEDPERFUSIONWITHTHEMAJORITYEXPERIENCING ELEVATED SYSTEMIC VASCULAR RESISTANCE #ONGESTION ELEVATED lLLING PRESSURE IN !$(& IS REPRESENTED BY DYSPNEA AND ORTHOPNEA AND ELEVATED JUGULAR VE NOUSPRESSURE2ALESWHILEAHELPFULSIGNAREABSENT IN  OF PATIENTS WITH CHRONICALLY ELEVATED lLLING PRESSURESDUETOPULMONARYLYMPHATICCOMPENSATION 0ERIPHERALEDEMAISRELATIVELYINSENSITIVETOELEVATED lLLINGPRESSURES ANDASSOCIATEDWITHMANYNONCARDI ACCAUSES4HETHIRDHEARTSOUND3 WHILEASENSITIVE MARKER ISRARELYAPPRECIATED4HEMOSTREADILYAVAIL ABLEINDICATOROFPERFUSIONISBLOODPRESSUREANDPULSE PRESSURE4HISRAPIDASSESSMENTSYSTEMALLOWSFORAP PROPRIATETARGETINGOFTHERAPYIN!$(&PATIENTS

/, / /Ê"Ê 1/ Ê "* -/ Ê ,/Ê 1, Ê Ê/ Ê  , 9Ê *,/ /

$ETERMININGTHE%TIOLOGYOF!CUTE $ECOMPENSATIONAND3ETTING 4REATMENT'OALS 4HEETIOLOGIESOF!$(&AREMULTIFACTORI ALBUTCANBEDIVIDEDINTOTWOCATEGORIES  THE UNDERLYING THE HEART FAILURE AND  THEACUTEPRECIPITANTTHATRESULTSINDE TERIORATIONFROMTHECHRONICCOMPENSATED STATE)NPATIENTSPRESENTINGFORTHElRST TIME THE TWO COMPONENTS ARE IDENTICAL 4HE MOST COMMON CAUSES OF HEART FAIL UREARECORONARYARTERYDISEASEANDLONG STANDINGHYPERTENSION/THERETIOLOGIES INCLUDEDILATED HYPERTROPHICANDRESTRIC TIVECARDIOMYOPATHIES MYOCARDITIS PERI CARDIALTAMPONADE VALVULARHEARTDISEASE ANDSECONDARYEFFECTSOFPULMONARYAND METABOLICDISORDERS5NDERSTANDINGTHE UNDERLYINGETIOLOGYISIMPORTANTINHELP ING TO DETERMINE IF THERE IS A REVERSIBLE COMPONENTPRESENT4HEEMERGENCYPHY SICIANMUSTBEAWAREOFNUMBEROFSPE CIAL CAUSES OF HEART FAILURE THAT REQUIRE CONSIDERATION WHEN MAKING THERAPEUTIC DECISIONS )N SEVERE AORTIC STENOSIS ID IOPATHIC HYPERTROPHIC SUBAORTIC STENOSIS OR HYPERTROPHIC OBSTRUCTIVE CARDIOMY OPATHY ANDPULMONARYHYPERTENSION AG GRESSIVE AFTERLOAD REDUCTION CAN LEAD TO CARDIOVASCULARCOLLAPSEASTHESEPATIENTS CANNOTINCREASETHEIRFORWARDBLOODmOW INTHEFACEOFAlXEDMECHANICALLESION 'REATERTHANOFPATIENTSPRESENTING TOTHE%$WITH!$(&HAVEAPRIORDIAG NOSISOFHEARTFAILURE!NACUTEPRECIPI TANT CAN OFTEN BE IDENTIlED %XACERBA TIONORWORSENINGOFTHEUNDERLYINGCON DITIONCANBEDUETOMEDICATIONORDIETARY NON COMPLIANCE ORTHEDEVELOPMENTOFA NEW OR COMPLICATING MEDICAL CONDITION

SUCH AS ISCHEMIA DYSRHYTHMIA PULMO NARY EMBOLUS OR INFECTION  4REATMENT DEPENDSONTHESEVERITYOFTHESYMPTOMS ANDDECOMPENSATIONTIMECOURSE  4HERAPEUTICGOALSIN!$(&PATIENTSCAN BEDIVIDEDINTHREEPHASES4HEPRIMARY GOALINTHE%$ISRESTORATIONOFOXYGEN ATION ORGAN PERFUSION AND TOTAL BODY mUID BALANCE 4HIS IS ACCOMPLISHED BY REVERSINGACUTEHEMODYNAMICABNORMAL ITIESANDRELIEVINGSYMPTOMS)NTERMEDI ATE GOALS INCLUDE MINIMIZING END ORGAN DAMAGE REDUCING HOSPITALIZATION DURA TION AND INITIATION OF BENElCIAL MEDICAL THERAPIES AND SHOULD COMMENCE IN THE %$,ONG TERMGOALSFOCUSONREDUCING READMISSION AND IMPROVING LONG TERM SURVIVAL WITH TREATMENT THAT DECREASES DISEASEPROGRESSION4HISOCCURAFTERTHE PATIENT LEAVES THE %$ 7HILE NATIONAL GUIDELINES EXIST FOR MANY ACUTE CARDIO VASCULARCONDITIONSTHEREARENOCONSEN SUS GUIDELINES FOR THE MANAGEMENT OF !$(& 'IVEN THE LACK OF RANDOMIZED CONTROLLEDTRIALS CONSENSUSTHATINCORPO RATESEVIDENCE BASEDLITERATUREANDEXPERT OPINIONSHOULDBEUSEDASGUIDELINES

/ܜʎiÞʅi“œ`ޘ>“ˆVÊ «>À>“iÌiÀÃÊ>ÀiÊ̅iÊ «ÀiÃi˜ViʜÀÊ>LÃi˜ViÊÊ œvÊiiÛ>Ìi`Êwˆ˜}Ê «ÀiÃÃÕÀiÃÊ­ÜiÌʜÀÊ`ÀÞ®Ê >˜`Ê̅iÊ>`iµÕ>VÞÊÊ œvÊ«iÀvÕȜ˜ÊÊ ­Ü>À“ÊœÀÊVœ`®°

!PPROACHTO)NITIAL4REATMENT /URIMPROVEDUNDERSTANDINGOFTHEETIOL OGYOFHEARTFAILUREANDITSPROGRESSIONHAS IDENTIlEDTHE2!!3ANDNEUROHORMONAL PATHWAYSASTARGETSOFTHERAPY ANDMAY EXPLAIN THE BENElTS OF NEUROHORMONAL BLOCKERS SUCH AS ANGIO CONVERTING EN ZYME!#% INHIBITORS BETA BLOCKERS AL DOSTERONEBLOCKERSEG SPIRONOLACTONE ANDSUPRAPHYSIOLOGICDOSESOFNATRIURETIC PEPTIDESSUCHAS!.0AND".0 INTHE TREATMENTOFHEARTFAILURE



%MERGENCY$IAGNOSISAND4REATMENTOF !CUTE$ECOMPENSATED(EART&AILURE!$(&

)NITIALTHERAPYSHOULDBEGUIDEDBYTHEPATIENTS HEMODYNAMICPROlLEQˆ}ÕÀiÊÓR &ORPATIENTS WITHOUTEVIDENCEOFELEVATEDlLLINGPRESSURESOR HYPOPERFUSION DRY AND WARM NO IMMEDIATE INTERVENTION IS NEEDED #ARE SHOULD FOCUS ON MAINTAININGSTABLEVOLUMESTATUSANDPREVENTING DISEASEPROGRESSION4HESEPATIENTSRARELYPRES ENT TO THE %$ )N PATIENTS WITH ELEVATED lLLING PRESSURESBUTADEQUATEPERFUSIONWETANDWARM THERAPY AIMS TO DIURESE !SSUMING THEY ARE AL READYRECEIVING!#%INHIBITORS THEGOALISTOEN HANCETHEIRDIURETICREGIMEN)NMOREADVANCED CASES THE USE OF INTRAVENOUS LOOP DIURETICS AND VASODILATORS SUCH AS NITROGLYCERIN OR NESIRITIDE CAN ACCELERATE SYMPTOM RESOLUTION 4HE MAIN CHALLENGE IS AVOIDING HYPOTENSION )N THIS SITU ATION INOTROPIC THERAPY IS CONTRAINDICATED &OR CONGESTEDELEVATEDlLLINGPRESSURE PATIENTSWITH CLINICALHYPOPERFUSIONWETANDCOLD ITISUSUALLY NECESSARYTOhWARMUPINORDERTODRYOUTv&OR THESEPATIENTS INWHOMREmEXRESPONSESSUPPORT THEFAILINGCIRCULATION ` BLOCKERSAND!#%INHIB ITORSMAYNEEDTOBEWITHDRAWNUNTILSTABILIZATION ISACHIEVED,OWCARDIACOUTPUTISOFTENASSOCI ATEDWITHHIGHSYSTEMICVASCULARRESISTANCE AND

ˆ}ÕÀiÊÓ°Ê VÕÌiÊ`iVœ“«i˜Ã>Ìi`ʅi>ÀÌÊv>ˆÕÀiÊ­ ®ÊÌÀi>̓i˜ÌÊÊ >}œÀˆÌ…“°ÊÊ,i«Àˆ˜Ìi`Ê܈̅ʫiÀ“ˆÃȜ˜ÊvÀœ“Ê ˆ œ“i˜ˆ‡ VœÊiÌÊ>°Ê˜˜Ê*…>À“>VœÌ…iÀ°ÊÓää{ÆÎn\È{™‡ÈÈä

$IWHUGLDJQRVLVRI$'+)LQLWLDWHWKHUDS\EDVHGRQSUHVHQWLQJVLJQVDQGV\PSRPV

$ 6LJQVDQG6\PSRPVRI9ROXPH2YHUORDG 2UWKRSQHD31' ,QFUHDVHG-9' '2(62% 6RU6 3LWWLQJHGHPD 5DOHV &KHVW[UD\SXORQDU\ +-5$-5 FRQJHVWLRQ l%13 5HFHQWZHLJKWJDLQ

& 0LOG YROXPH RYHUORDG

% 6LJQVDQG6\PSRPVRI/RZ&DUGLDF2XWSXW 1DUURZSXOVHSUHVVXUH $OWHUHGPHQWDOVWDWXV 3UHUHQDOD]RWHPLD &RROH[WUHPLWLHV

* 0LOG0RGHUDWH

( 0RGHUDWH6HYHUH9ROXPH2YHUORDG ,QDGHTXDWHUHVSRQVHWR,9GLXUHWLFV 3UHUHQDOD]RWHPLD ,QFUHDVHGR[\JHQUHTXLUHPHQWV &3$3RU%L3$3UHTXLUHPHQWV )DWLJXH ,QSDWLHQWGLVSRVLWLRQXQFOHDU 2XWSDWLHQWIXURVHPLGHGRVH!PGGDLO\ 6%3!PP+*

' ,9'LXUHWLFV ,9IXURVHPLGH Ɣ2QSRIXURVHPLGHDWKRPH" *LYHWRWDOGRVHDV,9EROXV  PD[PJ Ɣ1RSRIXURVHPLGHDWKRPH" 6&UVWDUWZLWKPJ,9SXVK 6&U!VWDUWZLWKPJ,9SXVK

'HFUHDVHGXULQHRXWSXW ,QDGHTXDWHUHVSRQVHWR ,9GLXUHWLFV

6%3!PP+J

- 9HU\/RZ &DUGLDF2XWSXW

.O

9ES 2QDBEORFNHU FKURQLFDOO\"

9ES

3XOPRQDU\DUWHU\ FDWKHWHUSODFHG +LJK695 +LJK3&:3 /RZ&, 6%3!PP+J

&RQVLGHUYDVRGLODWRUV DIWHULQLWLDWLRQRI LQRWURSLFVXSSRUW

.O , 0LOULQRQH

, 'REXWDPLQH

‡MJNJPLQ LQIXVLRQ ‡$GMXVWGRVHUHQDOO\

‡MJNJPLQLQIXVLRQ ‡0D\DOVRUHTXLUH YDVRSUHVVRUVIRU%3 VXSSRUW

,QDGHTXDWH5HVSRQH P/ZLWKLQKRXUV ,QDGHTXDWH5HVSRQH &RQVLGHU0RGHUDWH6HYHUH 9ROXPH2YHUORDG ( RU /RZ&DUGLDF2XWSXW %

&RQVLGHU9HU\/RZ&DUGLDF2XWSXW -

) ,9'LXUHWLFV,99DVRGLODWRUV

!*2  ABDOMINAL JUGULAR REmEX "I0!0  BILEVEL POSITIVE AIRWAY PRESSURE ".0  B NATRIURETIC PEPTIDE #)  CARDIAC INDEX #0!0  CONTINUOUS POSITIVE AIRWAY PRESSURE $/%  DYSPNEA ON EXERTION(*2HEPATOJUGULARREmEX*6$JUGULARVENOUSDISTENTION 0#70  PULMONARY CAPILLARY WEDGE PRESSURE 0.$  PAROXYSMAL NOCTURNAL DYSPNEA 3"0  SYSTOLIC BLOOD PRESSURE 3#R  SERUM CREATININE 3/"  SHORTNESS OF BREATH 362  SYSTEMIC VASCULAR RESISTANCE

MAYIMPROVEWITHVASODILATORTHERAPYALONE4HERE REMAINSCONTROVERSYABOUTTHEROLEOFINOTROPIC VASO DILATORAGENTSSUCHASDOBUTAMINEANDMILRINONE DUE TOTHEINCREASEDRISKFORISCHEMICEVENTSANDTACHYAR RHYTHMIAS0ATIENTSWITHLOWCARDIACOUTPUTWITHOUT EVIDENCE OF ELEVATED lLLING PRESSURE COLD AND DRY



,9IXURVHPLGH ‡,IIXURVHPLGHJLYHQSUHYLRXVO\GRXEOHSUHYLRXV,9GRVH PD[PJ ‡,IQRIXURVHPLGHJLYHQSUHYLRXVO\DQGVLJQVV\PSWRPVRIYROXPHRYHUORDG JLYHPJ,9DVGHVFULEHGDERYH 3/86 1HVLULWLGHMJNJ,9SXVKWKHQMJNJYHLQLQIXVLRQ 25 1LWURJO\FHULQSJPLQLQIXVLRQ ‡WRDFKLHYHGHFUHDVHLQ3&:3GRVHRIMJPLQPD\EH QHFHVVDU\

MAY BE SURPRISINGLY STABLE AND DO NOT PRESENT WITH URGENTSYMPTOMS5NLESSTHEYHAVESUBNORMALlLLING PRESSURESVOLUMEDEPLETED OREXCESSIVEVASODILATION THEYOFTENDONOTIMPROVEACUTELY)NOTROPICINFUSION WHILEHELPINGTHESYMPTOMS MAYLEADTODEPENDENCY ANDTACHYPHYLAXIS

/, / /Ê"Ê 1/ Ê "* -/ Ê ,/Ê 1, Ê Ê/ Ê  , 9Ê *,/ /

0HARMACOLOGIC/PTIONS !NIDEALAGENTFOR!$(&WOULDBEONE THATRAPIDLYREDUCES0#7RELIEVINGSYMP TOMSANDHYPOXIA INDUCESBALANCEDARTE RIAL AND VENOUS DILATION LACKS POSITIVE INOTROPIC EFFECTS PROMOTES NATRIURESIS ANDDOESNTCAUSEREmEXNEUROENDOCRINE ACTIVATION $IURETICSARETRADITIONALLYUSEDTOREDUCE PRELOADTHEREBYIMPROVINGSYMPTOMSIN !$(& PATIENTS 4HEY DO NOT HAVE ANY DIRECTMYOCARDIALBENElTBUTACTIVATETHE NEUROHORMONALSYSTEMLEADINGTOALDOSTE RONEELEVATION$IURETICSHAVEBEENUSED FORDECADESANDMOSTPROVIDERSAREVERY COMFORTABLE WITH THEM DESPITE THE FACT THAT THEY LACK OF EVIDENCE OF IMPROVED MORTALITY)NTRAVENOUSFUROSEMIDECAUSES ADECREASEIN0#70ANDRIGHTATRIALPRES SUREASARESULTOFVENODILATIONANDDIURE SIS4HEREISACONCOMITANTDECREASEIN STROKEVOLUME INCREASEINSYSTEMICVAS CULARRESISTANCEANDPRONOUNCEDSPIKEIN NEUROHORMONAL ACTIVATION )NCREASES IN THE2!!3ANDSYMPATHETICNERVOUSSYS TEM ACTIVATION NOREPINEPHRINE LEVELS CANBESEENSHORTLYAFTERFUROSEMIDEIN FUSION )N ONE TRIAL OF HIGH DOSE LOOP DIURETICS COMPARED TO LOW DOSE DIURETICS COM BINED WITH INTRAVENOUS VASODILATORS PATIENTS TREATED WITH HIGH DOSE FUROSE MIDE DID SIGNIlCANTLY WORSE IN ALL OUT COME MEASURES ! RECENT ANALYSIS OF EIGHT SMALL TRIALS FOUND THAT THERE WAS GREATER DIURESIS AND A BETTER SAFETY PRO lLEIFDIURETICSWEREGIVENASACONTINU OUS INSTEAD OF BOLUS INFUSION 7HILE INTRAVENOUSDIURETICSPROMOTENATRIURESIS ANDDIURESIS THEYDOSOATTHEEXPENSEOF NEUROHORMONAL ACTIVATION AND SYSTEMIC

VASOCONSTRICTION THAT PREVENTS REDUCTION OF VENTRICULAR lLLING PRESSURES $IURETIC RESISTANCE IS A CLINICAL STATE IN WHICH DIURETIC RESPONSE IS DIMINISHED OR LOST 4HIS MAY BE CAUSED BY PRERENAL AZOTE MIA HYPONATREMIA SODIUM RETENTION OR ALTEREDDIURETICPHARMACOKINETICS4HERE ISACYCLEOFLOWCARDIACOUTPUTLEADINGTO DIMINISHEDRENALPERFUSIONWHICHINTURN PRODUCES VOLUME OVERLOAD AND WORSENS HEART FAILURE 4HESE DELETERIOUS EFFECTS ARE EVEN MORE PRONOUNCED IN PATIENTS WITH UNDERLYING RENAL INSUFlCIENCY $I URETICREQUIREMENTSINCREASEASTHEHEART FAILUREPROGRESSES !RGININEVASOPRESSINISANEUROHORMONE PRODUCEDBYTHECENTRALNERVOUSSYSTEMIN RESPONSETOCHANGESINSERUMOSMOLARITY SEVEREHYPOVOLEMIAORHYPOTENSION/NE APPROACH TO ANTAGONIZING VASOPRESSINS ACTIONISTOSELECTIVELYBLOCKITSRECEPTOR RESULTINGINAQUARESISWITHOUTELECTROLYTE IMBALANCES OR NEUROHORMONAL STIMULA TION 4HE NOVEL COMPOUND TOLVAPTAN IS ANANTAGONISTTHATCAUSESINCREASEDURINE OUTPUT AND DECREASES BODY WEIGHT AND EDEMA /NE STUDY LOOKED AT WEIGHT RE DUCTIONFOLLOWINGHOURSOFINFUSIONIN PATIENTS WITH IMPAIRED VENTRICULAR FUNC TION%& 4HEREWASNODIFFERENCE IN IN HOSPITAL MORTALITY OR WORSENING OF HEART FAILURE 4HIS NOVEL AGENT SHOWS PROMISEOFFACILITATINGmUIDLOSSWITHOUT ADVERSESEQUELAEINPATIENTSWITHREDUCED SYSTOLICFUNCTION

˜ˆÌˆ>Ê̅iÀ>«ÞÊŜՏ`ÊLiÊ }Ո`i`ÊLÞÊ̅iÊ«>̈i˜Ì½ÃÊ …i“œ`ޘ>“ˆVÊ«Àœwi°

qqqqqqq

ˆÕÀïVÃʅ>ÛiÊLii˜Ê ÕÃi`ÊvœÀÊ`iV>`iÃÊ>˜`Ê “œÃÌÊ«ÀœÛˆ`iÀÃÊ>ÀiÊÛiÀÞÊ Vœ“vœÀÌ>LiÊ܈̅Ê̅i“Ê `iëˆÌiÊ̅iÊv>VÌÊ̅>ÌÊ Ì…iÞʏ>VŽÊœvÊiۈ`i˜ViʜvÊ ˆ“«ÀœÛi`ʓœÀÌ>ˆÌÞ°

)NOTROPESHAVEBEENAMAINSTAYOFTHERA PYFOR!$(&BECAUSEOFTHEIRBENElCIAL EFFECTS ON HEMODYNAMIC PARAMETERS NAMELY INCREASING CARDIAC CONTRACTILITY WHICHIMPROVESCARDIACOUTPUT)NOTRO PESAREUSEDINFREQUENTLYINTHE%$DUE 

%MERGENCY$IAGNOSISAND4REATMENTOF !CUTE$ECOMPENSATED(EART&AILURE!$(&

PRIMARILYTOLOGISTICALCONCERNS2ECENTLARGESTUDIES DEMONSTRATED A LACK OF EFlCACY IN MANY!$(& PA TIENTSANDEXPOSEDSAFETYCONCERNS)NOTROPESINCREASE HEARTRATEANDMYOCARDIALOXYGENDEMAND AGGRAVATE ISCHEMIA PRECIPITATEARRHYTHMIASANDCANCAUSEHY POTENSION!TRIALCOMPARINGDOBUTAMINEVERSUSNE SIRITIDE DEMONSTRATEDTHATDOBUTAMINEINCREASESVEN TRICULAR ECTOPY AND VENTRICULAR TACHYCARDIA -ILRI NONEFAILEDTODEMONSTRATESIGNIlCANTIMPROVEMENTS INLENGTHOFHOSPITALIZATION SYMPTOMRELIEFORMORTAL ITY COMPAREDTOPLACEBO)TWASHOWEVERASSOCIATED WITHSUSTAINEDHYPOTENSIONANDTACHYARRHYTHMIASIN THE/04)-% #(&TRIAL$OBUTAMINEISPREFERRED IN PATIENTS WHO ARE HYPOTENSIVE SYSTOLIC "0  MM (G SINCE IT EXERTS ITS EFFECTS BY STIMULATING ` ADRENERGICRECEPTORS(IGHERDOSESAREOFTENREQUIRED IN PATIENTS ON CHRONIC ` BLOCKER THERAPY -ILRINONE ISAPHOSPHODIESTERASEINHIBITORANDITSACTIONISNOT IMPACTED BY CONCOMITANT ` BLOCKER USE -ILRINONE DOESNT INCREASE MYOCARDIAL OXYGEN CONSUMPTION OR EFFECT HEART RATE TO THE SAME DEGREE THAT DOBUTA MINEDOES)NGENERAL GIVENTHEIRINABILITYTOAFFECT OUTCOMEANDINCREASEDINCIDENCEOFADVERSEEFFECTS INOTROPICSUPPORTSHOULDBERESERVEDFORPATIENTSWITH VERYLOWCARDIACOUTPUT4HEYSHOULDONLYBEUSEDIN THE%$SETTINGONPATIENTSWITHSYMPTOMATICHYPOTEN SIONUNTILFURTHERTHERAPYINTRA AORTICBALLOONPUMP CANBEINSTITUTED #ALCIUM SENSITIZERS SUCH AS LEVOSIMENDAN PRODUCE INCREASED INOTROPY IN A CYCLIC !-0 INDEPENDENT FASHIONBYINCREASINGTHESENSITIVITYOFTROPONIN#TO INTRACELLULAR IONIZED CALCIUM AS WELL AS PERIPHERAL VASODILATION THROUGH THE VASCULAR + !40ASE CHAN NELS !N EFFECTIVE POSITIVE INOTROPE LEVOSIMENDAN INCREASESINSTROKEVOLUMEANDCARDIACINDEXANDDE CREASES 0#70 RIGHT ATRIAL PRESSURES PULMONARY AR TERIALPRESSURESANDMEANARTERIALPRESSURES)NTHIS STUDY THEHEMODYNAMICEFFECTSWEREMAINTAINEDDUR INGAHOURINFUSIONANDFORATLEASTHOURSAFTER DISCONTINUATION 7HEN LEVOSIMENDAN WAS ADDED TO DOBUTAMINEIN.EW9ORK(EART!SSOCIATIONCLASS)6



PATIENTS REFRACTORY TO DOBUTAMINE AND FUROSEMIDE OFPATIENTSGETTINGALLTHREEAGENTSCOMPAREDTO NONE IN THE STANDARD GROUP EXPERIENCED A  IN CREASEINCARDIACINDEX4HISEXCITINGAGENTISINTHE EARLYCLINICALTRIALS 6ASODILATORSREDUCEPRELOADANDAFTERLOAD ENHANCING VENTRICULARFUNCTIONANDCARDIACOUTPUTBYIMPROVING RESTING HEMODYNAMICS6ASODILATORS REDUCE VENTRIC ULAR lLING PRESSURES 0#70 AND PRELOAD AND OVER TIMEMYOCARDIALOXYGENCONSUMPTION6ASODILATORS ALSO DECREASE SYSTEMIC VASCULAR RESISTANCE 362 OR AFTERLOAD REDUCE VENTRICULAR WORKLOAD INCREASE STROKEVOLUMEANDIMPROVECARDIACOUTPUT .ITRATES IN PARTICULAR NITROGLYCERIN HAVE BEEN THE lRST LINEPREHOSPITALAND%$THERAPYFORPATIENTSWITH SEVERESYMPTOMS.ITRATESNITROGLYCERINANDNITRO PRUSSIDE ACT BY INCREASING CYCLIC GUANOSINE MONO PHOSPHATEINTHEVASCULARSMOOTHMUSCLELEADINGTO VASODILATION4HEY IMPROVE SYMPTOMS AND DECREASE 0#70RELATIVELYQUICKLY.ITROGLYCERINUSEISLIMITED BYFEAROFHYPOTENSION ANDNEEDFORTITRATIONSECOND ARY TACHYPHYLAXIS YET IT IS FREQUENTLY UNDERDOSED .ITROGLYCERINHASDIRECTAFFECTSONLARGECORONARYAR TERIESANDINCREASESCOLLATERALmOW MAKINGITAUSEFUL INPATIENTSWITHMYOCARDIALISCHEMIA(OWEVER THERE ARE NO TRIALS LOOKING AT ITS OUTCOME EFlCACY .ITRO PRUSSIDE WHILE EFlCACIOUS IS USED INFREQUENTLY DUE TOCONCERNSABOUTTHIOCYANATETOXICITYESPECIALLYIN THEFACEOFHEPATICORRENALHYPOPERFUSIONDYSFUNC TION  )T CAN ALSO PRECIPITATE PROFOUND HYPOTENSION EXACERBATEISCHEMIABYINDUCINGCORONARYSTEAL AND REQUIRES INVASIVE MONITORING "OTH OF THESE AGENTS CAUSEREmEXACTIVATIONOFTHE2!!3ANDSYMPATHETIC NERVOUSSYSTEMWHICHLIMITSTHEIRLONG TERMUSE !NGIOTENSIN CONVERTING ENZYME !#% INHIBITION BLOCKSCONVERSIONOFANGIOTENSIN)INTOANGIOTENSIN)) RESULTINGINDIMINISHEDSYSTEMICVASCULARRESISTANCE BLOODPRESSURE PRELOADANDAFTERLOAD!#%INHIBITORS ALSOBLOCKTHEDEGRADATIONOFBRADYKININS ANATURAL

/, / /Ê"Ê 1/ Ê "* -/ Ê ,/Ê 1, Ê Ê/ Ê  , 9Ê *,/ /

LY OCCURRING VASODILATOR !#% INHIBITOR THERAPYINCREASESRENALPERFUSIONANDDE CREASE RENAL VASCULAR RESISTANCE IMPROV INGGLOMERULARlLTRATIONRATEBYINDUCING VASODILATIONINBOTHAFFERENTANDEFFERENT ARTERIOLES4HEMAJORDRAWBACKTOTHEUSE OF INTRAVENOUS !#% INHIBITORS SUCH AS ENALAPRILATINTHEACUTESETTINGISITSPRO PENSITYTOINDUCEHYPOTENSION)NTHESTA BLEPATIENT THEAGENTSMAJOR LIMITATIONS ARE RENAL INSUFlCIENCY AND ANGIOEDEMA %NALAPRILAT HAS BEEN USED IN THE SETTING OF!$(&SECONDARYTOUNCONTROLLEDHY PERTENSION/RAL!#%INHIBITORSAREREC OMMENDED EARLY OUT FOR THOSE PATIENTS NOTALREADYRECEIVINGTHEM(OWEVER THE PATIENTMUSTBEHEMODYNAMICALLYSTABLE BEFORETHESEAGENTSAREINITIATED ANDTHIS LIMITSTHEIRAGGRESSIVEUPFRONTUSEINTHE %$!NGIOTENSIN RECEPTORBLOCKERCANBE SUBSTITUTEDINPATIENTSWHOCANTTOLERATE !#%INHIBITORS 2ECENTATTENTIONHASBEENFOCUSEDONTHE ACUTE BLOCKADE OF DELETERIOUS NEUROHOR MONES %NDOTHELIN %4 IS A VASOCON STRICTOR PEPTIDE RELEASED FROM VASCULAR ENDOTHELIUM AND SMOOTH MUSCLE OF THE RENALANDPULMONARYSYSTEMS4EZOSEN TAN IS A HIGHLY SPECIlC AND POTENT %4 RECEPTORANTAGONIST4HEREISADOSEDE PENDENTINCREASEINCARDIACINDEXDUETO VASODILATIONANDDECREASEIN0#70)N THE 2)4: PROJECT TEZOSENTAN IMPROVED HEMODYNAMICBUTNOTCLINICALOUTCOMEOF PATIENTSWITHACUTEHEARTFAILURE!RECENT TRIALEVALUATINGLOWERDOSES INHOSPITAL IZED!$(&PATIENTSWITHDYSPNEADESPITE INITIAL TREATMENT SHOWED INCREASED CAR DIAC INDEX AND DECREASED 0#70 WITHIN HOURSATTHEMGHOURANDMGHOUR TREATMENTGROUPS ANDBYHOURSINTHE

MGHOURCOHORT4HEEFFECTCONTINUED BEYOND TREATMENT DISCONTINUATION IN THE  MGHOUR GROUP %NDOTHELIUM LEVELS WEREINCREASEDINTHEHIGHERDOSEGROUPS SUGGESTING SYMPATHETIC NERVOUS SYSTEM ACTIVATION BUTNOTINTHEMGHOURSUB SET 4EZOSENTANS EFFECT WHILE CLINICALLY SIGNIlCANT IS NOT PRESENTLY APPROPRIATE FORTHE%$GIVENITSDELAYEDONSET 4HE NATRIURETIC PEPTIDE FAMILY CONSISTS OF FOUR DISTINCT PEPTIDES !TRIAL NATRIURETIC PEPTIDES!.0 AND" TYPENATRIURETICPEP TIDES".0 ARESTRUCTURALLYSIMILAR# TYPE NATRIURETICPEPTIDES#.0 AND$ TYPENA TRIURETICPEPTIDES$.0 ARELESSWELLCHAR ACTERIZED!TRIALAND" TYPENATRIURETICPEP TIDESHAVEIMPORTANTCENTRALANDPERIPHERAL SYMPATHOINHIBITORYEFFECTS$AMPENINGOF THE BARORECEPTORS SUPPRESSED RELEASE OF CATECHOLAMINEFROMAUTONOMICNERVElND INGS AND ESPECIALLY SUPPRESSION OF SYM PATHETIC OUTmOW FROM THE CENTRAL NERVOUS SYSTEMHAVEALLBEENREPORTED 4HE LONG TERM CONTINUOUS INFUSION OF !.0 HAS BEEN SHOWN TO BE CLINICALLY USEFULINPATIENTSWITHSEVEREACUTEHEART FAILURE (EMODYNAMIC MEASUREMENTS EVALUATEDBY3WAN 'ANZCATHETERSIGNIl CANTLY IMPROVED WITH!.0 )N A RECENT STUDY HEMODYNAMIC INDICES CHARACTER IZED BY DECREASES IN RIGHT ATRIAL PRES SURE MEAN PULMONARY ARTERIAL PRESSURE AND 0#70 AND AN INCREASE IN CARDIAC INDEX WERE OBSERVED AFTER !.0 INFU SION ,EFT VENTRICULAR PERFORMANCE WAS ENHANCED WITHOUT THE DEVELOPMENT OF TOLERANCE 4HE ACTIVATION OF THE 2!!3 PROMOTES STRUCTURAL REMODELING OF THE HEART AND PROGRESSION OF HEART FAILURE !.0 THEREBY IMPROVED LEFT VENTRICULAR

ˆÛi˜Ê̅iˆÀʈ˜>LˆˆÌÞÊÌœÊ >vviVÌʜÕÌVœ“iÊ>˜`Ê ˆ˜VÀi>Ãi`ʈ˜Vˆ`i˜ViÊ œvÊ>`ÛiÀÃiÊivviVÌÃ]Ê ˆ˜œÌÀœ«ˆVÊÃÕ««œÀÌÊÊ Ã…œÕ`ÊLiÊÀiÃiÀÛi`ÊÊ vœÀÊ«>̈i˜ÌÃÊ܈̅ÊÛiÀÞÊ œÜÊV>À`ˆ>VʜÕÌ«ÕÌ°



%MERGENCY$IAGNOSISAND4REATMENTOF !CUTE$ECOMPENSATED(EART&AILURE!$(&

FUNCTIONPOSSIBLYBYBLUNTINGMYOCARDIAL REMODELING 7HILEAVAILABLEIN!SIA AND%UROPE !.0ISNOTAPPROVEDFORUSE INTHE5NITED3TATES

*>̈i˜ÌÃÊÌÀi>̓i˜ÌÊ i>ÀÞʜ˜ÊÌi˜`Ê̜ʅ>ÛiÊ Ã…œÀÌiÀʅœÃ«ˆÌ>ÊÊ ÃÌ>ÞÃÊ>˜`ÊLiÌÌiÀÊ œÕÌVœ“iÃÊ̅>˜Ê̅œÃiÊ Ü…œÃiʈ˜ÌiÀÛi˜Ìˆœ˜ÊÊ Ü>ÃÊ`i>Þi`°

".0 IS AN ENDOGENOUS NEUROHORMONE PRODUCEDINTHEVENTRICLESINRESPONSETO INCREASEDWALLSTRESSTHATOCCURSFROMVOL UMEOVERLOADIN!$(&PATIENTS.ESIRIT IDEISTHElRSTNATRIURETICPEPTIDEIDENTI CALTOENDOGENOUS".0 TOBEAVAILABLE INTHE5NITED3TATESFORTHETREATMENTOF !$(& 7ITHIN MINUTES OF ADMINISTRA TIONNESIRITIDEPRODUCESSIGNIlCANTREDUC TIONSIN0#70 RIGHTATRIALPRESSUREAND SYSTEMIC VASCULAR RESISTANCE AS WELL AS CONCOMITANT INCREASES IN STROKE VOLUME ANDCARDIACOUTPUT.ESIRITIDEHASADDI TIONALADVANTAGESOVEROTHERVASODILATORS SUCHASNITROGLYCERIN INCLUDINGDIURESIS NATRIURESISANDLUSITROPY4HEBENElCIAL CORONARY ARTERY EFFECTS OF NITROGLYCERIN AREALSOPRESENTINNESIRITIDE!DDITION ALLY NESIRITIDE LACKS THE PROARRHYTHMIC ANDTACHYCARDIASEENWITHINOTROPESAND MANYVASODILATORS 4HE6ASODILATION IN THE -ANAGEMENT OF !CUTE#ONGESTIVE(EAR&AILURE6-!# TRIAL COMPARED THE USE OF NESIRITIDE NI TROGLYCERINORPLACEBOINADDITIONTOSTAN DARDTHERAPYINPATIENTSWITH!$(& 4HIS SAFETY AND EFlCACY TRIAL FOUND THAT NESIRITIDE REDUCED 0#70 MORE THAN EI THER NITROGLYCERIN OR PLACEBO AT  HOURS ANDHOURS)MPROVEMENTSINDYSPNEA AND GLOBAL CLINICAL STATUS IN THE NESIRIT IDE TREATED PATIENTS WERE GREATER THAN THOSEINTHEPLACEBORECIPIENTSANDSIMI LAR TO THOSE IN THE NITROGLYCERIN GROUP



.ESIRITIDESHEMODYNAMICEFFECTERSWERE LONG LASTINGWITHOUTTHENEEDFORUPWARD TITRATION WHEREASTITRATIONWASNECESSARY IN ORDER TO MAINTAIN NITROGLYCERINS EF FECT4HISWASMOSTSTRIKINGINTHESUBSET OF PATIENTS WITH RIGHT HEART CATHETERS ON A CONSTANT DOSE OF NITROGLYCERIN WHERE RAPIDATTENUATIONOFTHEDESIREDEFFECTAND RISEIN0#70WASSEENATHOURS ".0 DOESNT INCREASE HEART RATE OR PRO VOKE ARRHYTHMIAS AND HAS NO INOTROPIC EFFECTS 4HIS LACK OF ARRHYTHMOGENICITY IS ESPECIALLY IMPORTANT IN HEART FAILURE PATIENTSWITHATRIALlBRILLATIONANDTHOSE PREDISPOSED TO VENTRICULAR TACHYCARDIA 4HE 02%#%$%.4 STUDY COMPARED THE PROARRHYTHMICEFFECTSOFDOBUTAMINEVER SUSDOSESOFNESIRITIDEINPATIENTS $OBUTAMINESIGNIlCANTLYINCREASEDVEN TRICULAR TACHYCARDIA EVENTS .ESIRITIDE DIDNOTINCREASEHEARTRATEDESPITEGREATER REDUCTIONINBLOODPRESSURE"OTHAGENTS WEREEQUALLYEFFECTIVEINIMPROVINGSIGNS ANDSYMPTOMSOFHEARTFAILURE#OMPARED TODOBUTAMINE NESIRITIDEREDUCED DAY HOSPITALREADMISSIONSFORHEARTFAILUREAND HADLOWER MONTHMORTALITY )NTHE0ROSPECTIVE2ANDOMIZED/UTCOMES 3TUDY OF !CUTELY $ECOMPENSATED #ON GESTIVE (EART &AILURE 4REATED )NITIALLY IN /UTPATIENTS WITH .ATRECOR 02/!# 4)/. STUDY PATIENTSWERERANDOM IZEDTOSTANDARDCAREORATLEASTHOURS OF NESIRITIDE INFUSION IN AN %$ OBSERVA TIONSETTING)MPORTANTLY NONEOFTHESEPA TIENTSWASSUBJECTTOINVASIVEOR)#5LEVEL MONITORINGINTHE%$ YETDIDWELL-OR TALITYRATESANDCOMPLICATIONSWERESIMILAR

/, / /Ê"Ê 1/ Ê "* -/ Ê ,/Ê 1, Ê Ê/ Ê  , 9Ê *,/ /

BETWEEN THE TWO GROUPS .ESIRITIDE WAS ASSOCIATEDWITHAREDUCTIONINHOSPI TALREADMISSIONWITHINDAYSCOMPARED WITH STANDARD THERAPY AND A SUBSTANTIAL DECREASE IN TOTAL LENGTH OF STAY OVER THE ENSUINGMONTHSAFTERTHEINDEXVISIT )N A POOLED ANALYSIS FROM THE 02/!# 4)/.  6-!#  AND .3'%4 TRIALS THESHORTTERMRISKOFDEATHFROMNESIRIT IDE WAS INVESTIGATED !S NONE OF THE STUDIES INCLUDED IN THE POOLED ANALYSIS WEREPOWEREDTODETERMINEMORTALITYDIF FERENCES THEREISNOCONCLUSIVEEVIDENCE OFHARM4HEMANUSCRIPTCONCLUDEDTHAT WHEN COMPARED TO NONIONOTROPIC BASED THERAPY NESIRITIDEMAYBEASSOCIATEDWITH ANINCREASEDRISKOFDEATH&URTHERSTUDY WITH MORTALITY OUTCOMES OF NESIRITIDE COMPARED TO CONVENTIONAL THERAPY HAVE YET TO OCCUR !S WITH ANY NEW THERAPY THEFAVORABLEATTRIBUTESMUSTBEWEIGHED AGAINSTTHEPOTENTIALRISKS %ARLY'OAL$IRECTED4HERAPY %ARLYGOALDIRECTEDTHERAPY%'$4 AP PROACH EMPHASIZES AGGRESSIVE UPFRONT TREATMENT BECAUSE PRELIMINARY EVALU ATIONS HAVE SHOWN THAT PATIENTS TREATED EARLY OUT TEND TO HAVE SHORTER HOSPITAL STAYS AND BETTER OUTCOMES THAN THOSE WHOSE INTERVENTION IS DELAYED )T AIMS TO ACHIEVE  HEMODYNAMIC AND RESPI RATORY IMPROVEMENT  PROMPT RELIEF OF SYMPTOMS  ENHANCEDDECISION MAKING IN THE %$ WITH AN EMPHASIS ON TIMELY TRANSITIONTOINPATIENTCAREIFINDICATED  EARLYINITIATIONOFTHERAPYALSOFACILITATES HOSPITAL DISCHARGE AND  AVOIDANCE OF HIGHRESOURCEUTILIZATION #ARENEEDS

TO FOCUS ON RAPID INITIATION OF PROVEN THERAPIES THAT IMPROVE PATIENT SYMPTOM AND CARDIORESPIRATORY STATUS WITHOUT PLACINGTHEPATIENTATRISKFORIMMEDIATE ARRHYTHMIA HYPOTENSION ISCHEMIA AND DELAYED WORSENING RENAL INSUFlCIENCY TOXICITY ADVERSEEVENTS4HEREISGROW INGEVIDENCETHAT%'$4HASBOTHCLINICAL ANDECONOMICADVANTAGESOVERMORECON SERVATIVETREATMENTAPPROACHES 4HERE IS A SUBPOPULATION OF PATIENTS MODERATELY SICK REQUIRING MORE THAN A FEWHOURSOFCARE WHODONTNECESSARILY NEEDHOSPITALADMISSION4HEAVAILABILITY OF AN %$ OBSERVATION UNIT MAKES GOOD CLINICALANDECONOMICSENSE%'$4CAN BE INITIATED AND PATIENTS MONITORED FOR IMPROVEMENT 0ATIENT SELECTION IS CRITI CALLYIMPORTANTINDETERMININGWHOWILL MOST BENElT FROM AN OBSERVATION UNIT STAYMATCHINGACUITYWITHAVAILABLESER VICES 'ENERALSELECTIONCRITERIAINCLUDE THEFOLLOWING  ADEQUATESYSTEMICPERFUSIONNORMAL MENTALSTATUS  EVIDENCEOFREASONABLE HEMODYNAMICSTABILITY(2AND BEATSMIN SYSTOLIC"0 ANDMM(G OXYGENSATURATION   NOEVIDENCEOFACUTECARDIAC ISCHEMIABY%#'ORBIOMARKERS  CHESTX RAYlNDINGSCOMPATIBLEWITH THEDIAGNOSISOFHEARTFAILURE  DIAGNOSISOF(&".0PG M, WITHOUTOTHERCONFOUNDING MORBIDITIES

6>Ü`ˆ>̜ÀÃÊÀi`ÕViÊ «Àiœ>`Ê>˜`Ê>vÌiÀœ>`]Ê i˜…>˜Vˆ˜}ÊÛi˜ÌÀˆVՏ>ÀÊ v՘V̈œ˜Ê>˜`ÊV>À`ˆ>VÊ œÕÌ«ÕÌÊLÞʈ“«ÀœÛˆ˜}Ê ÀiÃ̈˜}ʅi“œ`ޘ>“ˆVð



%MERGENCY$IAGNOSISAND4REATMENTOF !CUTE$ECOMPENSATED(EART&AILURE!$(&

)NITIAL TREATMENT OF !$(& IS GENERALLY BASEDONTHEPRESENCEORABSENCEOFPUL MONARY CONGESTION VOLUME OVERLOAD ANDANASSESSMENTOFPERFUSIONCARDIAC OUTPUT Qˆ}ÕÀiÊ ÎR7HILETREATMENTAL GORITHMS FOCUS ON PARENTAL THERAPY DUR ING THE EARLY PHASE CONTINUATION OF THE PATIENTS CHRONIC HEART FAILURE MEDICA TION INCLUDING ” BLOCKERS AND !#% IN HIBITORSAREIMPORTANT-ILDCONGESTION IMPROVES WITH INTRAVENOUS DIURETICS -ONITORINGOFURINEOUTPUTISCRITICAL&OR THOSEWITHNORMALRENALFUNCTIONAGOALOF MLHRISACCEPTABLE0ATIENTSWITHIN ADEQUATERESPONSETOFUROSEMIDESHOULD BEASSESSEDFORTHEPRESENCEOFMODERATE TOSEVEREVOLUMEOVERLOAD ANDVASODILA TOR THERAPY SHOULD BE CONSIDERED )NTRA VENOUSNITROGLYCERINORNESIRITIDESHOULD BESTARTEDINPATIENTSWITHADEQUATEBLOOD PRESSURE TO SPEED RELIEF OF CONGESTION )FNITROGLYCERINISUSEDITWILLBENECES SARYTOUPTITRATETHEINFUSIONFREQUENTLY 0ATIENTSWITHEVIDENCEOFPOORPERFUSION

ˆ}ÕÀiÊÎ°Ê *Àˆ“>ÀÞÊ/>À}iÌÃʜvÊ/Ài>̓i˜Ìʈ˜Êi>ÀÌÊ>ˆÕÀi°ÊÊ ,i«Àœ`ÕVi`Ê>˜`ÊÀi«Àˆ˜Ìi`Ê܈̅ʫiÀ“ˆÃȜ˜ÊvÀœ“ÊiÃÃÕ«Ê ]Ê Àœâi“>Ê-°Ê Ê ˜}ÊÊi`ÊÓääÎÆÎ{n\ÓääLJÓä£n°Ê

œ«ÞÀˆ}…ÌÊ^ÊÓääÎÊ>ÃÃ>V…ÕÃiÌÌÃÊi`ˆV>Ê-œVˆiÌÞ°

%HWDEORFNHUV

+($57

'LJR[LQ LQRWURSHV

&DUGLDF UHV\QFKURQL]DWLRQ WKHUDS\ $&(LQKLELWRUV DQJLRWHQVLQUHFHSWRUEORFNHUV DOGRVWHURQHDQWDJRQLVWV 'LXUHWLFV DOGRVWHURQH DQWDJRQLVWV QHVLULWLGH .LGQH\

$&(LQKLELWRUV

3HULSKHUDO

DQJLRWHQVLQUHFHSWRUEORFNHUV 4REATMENTOPTIONSFORPATIENTSWITHHEARTFAILUREAFFECT DUWHULHV YDVRGLODWRUVDOSKDEORFNDGH THEPATHOPHYSIOLOGICALMECHANISMSTHATARESTIMULATED QHVLULWLGHH[HUFLVH IN HEART FAILURE !NGIOTENSIN CONVERTINGnENZYME !#% INHIBITORS AND ANGIOTENSIN RECEPTOR BLOCKERS DECREASE AFTERLOADBYINTERFERINGWITHTHERENINnANGIOTENSINnALDOSTERONESYSTEM RESULTINGINPERIPHERALVASODILATATION4HEYALSO AFFECTLEFTVENTRICULARHYPERTROPHY REMODELING ANDRENALBLOODmOW!LDOSTERONEPRODUCTIONBYTHEADRENALGLANDSIS INCREASEDINHEARTFAILURE)TSTIMULATESRENALSODIUMRETENTIONANDPOTASSIUMEXCRETIONANDPROMOTESVENTRICULARAND VASCULARHYPERTROPHY!LDOSTERONEANTAGONISTSCOUNTERACTTHEMANYEFFECTSOFALDOSTERONE$IURETICSDECREASEPRELOAD BYSTIMULATINGNATRIURESISINTHEKIDNEYS$IGOXINAFFECTSTHE.A + n!40ASEPUMPINTHEMYOCARDIALCELL INCREASING CONTRACTILITY )NOTROPES SUCH AS DOBUTAMINE AND MILRINONE INCREASE MYOCARDIAL CONTRACTILITY "ETA BLOCKERS INHIBIT THE SYMPATHETICNERVOUSSYSTEMANDADRENERGICRECEPTORS4HEYSLOWTHEHEARTRATE DECREASEBLOODPRESSURE ANDHAVE ADIRECTBENElCIALEFFECTONTHEMYOCARDIUM ENHANCINGREVERSEREMODELING3ELECTEDAGENTSTHATALSOBLOCKTHEALPHA ADRENERGICRECEPTORSCANCAUSEVASODILATATION6ASODILATORTHERAPYSUCHASCOMBINATIONTHERAPYWITHHYDRALAZINEAND ISOSORBIDEDINITRATEDECREASESAFTERLOADBYCOUNTERACTINGPERIPHERALVASOCONSTRICTION#ARDIACRESYNCHRONIZATIONTHERAPY WITHBIVENTRICULARPACINGIMPROVESLEFTVENTRICULARFUNCTIONANDFAVORSREVERSEREMODELING.ESIRITIDEBRAINNATRIURETIC PEPTIDE DECREASESPRELOADBYSTIMULATINGDIURESISANDDECREASESAFTERLOADBYVASODILATATION%XERCISEIMPROVESPERIPH ERALBLOODmOWBYEVENTUALLYCOUNTERACTINGPERIPHERALVASOCONSTRICTION)TALSOIMPROVESSKELETAL MUSCLEPHYSIOLOGY



/, / /Ê"Ê 1/ Ê "* -/ Ê ,/Ê 1, Ê Ê/ Ê  , 9Ê *,/ /

SHOULDBECONSIDEREDFORINOTROPICSUPPORT$OBUTA MINE SHOULD BE STARTED IN PATIENTS WITH LOW CARDIAC OUTPUTANDSYSTOLICBLOODPRESSUREMM(G4HEY MAY REQUIRE VASOPRESSOR SUPPORT IF HYPOTENSION DE VELOPS0ATIENTSWITHLOWCARDIACOUTPUTBUTADEQUATE BLOODPRESSUREMAYBENElTFROMMILRINONE ESPECIAL LYIFTHEYAREALREADYTAKINGBETA BLOCKERS4HOSERE QUIRINGINOTROPICSUPPORTWILLREQUIREADMISSIONTOAN INTENSIVECAREUNIT4HOSERECEIVINGVASODILATORSCAN OFTENBEMANAGEDINALESSACUTESETTINGTELEMETRYOR %$OBSERVATIONUNIT 0RELIMINARYANALYSISFROMTHE !$(%2% REGISTRY INDICATED THAT LENGTH OF STAY WAS REDUCED BY UP TO A THIRD IN PATIENTS RECEIVING VASO ACTIVEAGENTSVASODILATORS NESIRITIDEORINOTROPES IN THE %$ OR OBSERVATION UNIT COMPARED WITH PATIENTS WHOHADVASOACTIVETHERAPYINITIATEDINTHEHOSPITAL 4HISEARLYINITIATIONOFEMERGENCYDEPARTMENTTHERAPY ISASSOCIATEDWITHLOWERHOSPITALMORTALITY DECREASED FREQUENCYOFINVASIVEPROCEDURESANDDECREASED)#5 LENGTHOFSTAY4HUS EARLYTARGETEDVASOACTIVETHERAPY INTHE!$(&PATIENTSEEMSTOBEVERYPROMISING

.EWPHARMACOLOGICALAGENTSUNDERINVESTIGATION AT TEMPT TO ENHANCE OUR UNDERSTANDING OF ABNORMAL NEUROENDOCRINEFUNCTIONINHEARTFAILURE"YSPECIl CALLYTARGETINGKEYPOINTSSUCHASTHEACTIVATIONAND FEEDBACKPROCESS THEYMAYPREVENTDISEASEPROGRES SION AND ACUTE DECOMPENSATION 7HILE WE AWAIT NEW TREATMENT MODALITIES CURRENT %$ EFFORTS MUST FOCUSONTHEEARLYIMPLEMENTATIONOFEFFECTIVESTRATE GIESTOIMPROVESYMPTOMSANDCORRECTTHEUNDERLYING PHYSIOLOGY

-1,9 )NTHEMAJORITYOFPATIENTSWHOPRESENTTOTHE%$WITH !$(& INITIALTHERAPYWITHOXYGENANDDIURETICSWILL NOT ADEQUATELY REDUCE lLLING PRESSURES OR IMPROVE CARDIACOUTPUTENOUGHTOIMPROVESYMPTOMS)NOTRO PESIMPROVESYMPTOMSINTHESHORT TERMBUTAREDEL ETERIOUS IN THE LONG RUN6ASODILATORS ARE FREQUENTLY NECESSARY AS THEY ADDRESS THE PRIMARY UNDERLYING PATHOPHYSIOLOGYOFHEARTFAILURE.ITROGLYCERINAND NITROPRUSSIDEAREEFFECTIVEBUTTHEIRUSEISHAMPERED BY ADVERSE EFFECTS AND LIMITATIONS .ATRIURETIC PEP TIDES SUCH AS NESIRITIDE WITH THEIR NEUROHORMONAL ANTAGONISM MAYOFFERSEVERALBENElTSOVERCONVEN TIONALVASODILATORSANDINOTROPESFORTHETREATMENTOF !$(&)THASBEENSHOWNTHATNESIRITIDECANBEUSED SAFELYINTHE%$ANDUPFRONTUSECANREDUCEHOSPITAL LENGTHOFSTAY



%MERGENCY$IAGNOSISAND4REATMENTOF !CUTE$ECOMPENSATED(EART&AILURE!$(&

,  ,

-

 +IVIKKO- ,EHTONEN, #OLUCCI733USTAINEDHEMODYNAMIC EFFECTSOFINTRAVENOUSLEVOSIMENDAN #IRCULATION 



!GHABABIAN26 !CUTELYDECOMPENSATEDHEARTFAILURE OPPORTUNITIESTOIMPROVECAREANDOUTCOMESINTHEEMERGENCY DEPARTMENT 2EV#ARDIOVASC-EDSUPPL 3 



-AGNER** 2OYSTON$(EART&AILURE "R*!NESTH 

 .ANAS*. 0APAZOGLOU00 4ERROVITIS*6 ETAL (EMODYNAMIC EFFECTSFLEVOSIMENDANADDEDTODOBUTAMINEINPATIENTSWITH DECOMPENSATEDADVANCEDHEARTFAILUREREFRACTORYTODOBUTAMINE ALONE !M*#ARDIOL 



&ONAROW'#4HETREATMENTTARGETSINACUTEDECOMPENSATEDHEART FAILURE 2EV#ARDIOVASC-ED3 



.OHRIA! ,EWIS% 3TEVENSON,7 -EDICALMANAGEMENTOF ADVANCEDHEARTFAILURE*!-! 



6ANDERHEYDEN- "ARTUNEK* 'OETHALS-"RAINANDOTHER NATRIURETICPEPTIDESMOLECULARASPECTS %UR*(EART&AIL  



3TRAIN7$4HEUSEOFRECOMBINANTHUMAN" TYPENATRIURETIC PEPTIDEINTHEMANAGEMENTOFACUTEDECOMPENSATEDHEARTFAILURE )NT*#LIN0RACT 



(OLLANDER* 0HARMACOLOGICMANAGEMENTOPTIONSINTHEEMERGENCY DEPARTMENT!DVIN(EART&AIL 



6ANDER7AL-( *AARSMA4 VAN6ELDHUISEN$* .ON COMPLIANCE INPATIENTSWITHHEARTFAILUREHOWCANWEMANAGEIT%UR*(EART &AIL 



7ELSCH*D (EISER2- 3CHOOLER-0ETAL #HARACTERISTICS ANDTREATMENTOFPATIENTSWITHHEARTFAILUREINTHEEMERGENCY DEPARTMENT*%MERG.URS 

 3HARMA- 4EERLINK*2!RATIONALAPPROACHFORTHETREATMENTOF ACUTEHEARTFAILURECURRENTSTRATEGIESANDFUTUREOPTIONS#URR/PIN #ARDIOL 

 -OAZEMI+ #HANA* 7ILLARD!- +OCHERIL!' )NTRAVENOUS VASODILATORTHERAPYINCONGESTIVEHEARTFAILURE$RUGS!GING    4ORRE !MIONE' 9OUNG*" #OLUCCI73 ETAL (EMODYNAMIC ANDCLINICALEFFECTSOFTEZOSENTAN ANINTRAVENOUSDUALENDOTHELIN RECEPTORANTAGONIST INPATIENTSHOSPTIALIZEDFORACUTE DECOMPENSATEDHEARTFAILURE *!M#OLLL#ARDIOL   #OTTER' +ALUSKI% 3TANGL+ ETAL 4HEHEMODYNAMICAND NEUROHORMONALEFFECTSOFLOWDOSETEZOSENTANANENDOTHELIN!" RECEPTORANTAGONIST INPATIENTSWITHACUTEHEARTFAILURE%UR*(EART &AIL   DE$ENUS3 0(ARAND# 7ILLIAMSON$2"RAIN.ATRIURETICPEPTIDE INTHEMANAGEMENTOFHEARTFAILURE #HEST   +ASAMA3 4OYAMA4 +UMAKURA( ETAL%FFECTSOFINTRAVENOUS ATRIALNATRIURETICPEPTIDEONCARDIACSYMPATHETICNERVEACTIVITYIN PATIENTSWITHDECOMPENSATEDCONGESTIVEHEARTFAILURE *.UCL-ED    #OHN*. &ERRARI2 3HARPE.#ARDIACREMODELINGCONCEPTSAND CLINICALIMPLICATIONSnACONSENSUSPAPERFROMANINTERNATIONAL FORUMONCARDIACREMODELING*!M#OLL#ARDIOL 

 $I$OMENICO2* 0ARK(9 3OUTHWORTH-2 ETAL 'UIDELINESFOR ACUTEDECOMPENSATEDHEARTFAILURETREATMENT !NN0HARMACOTHER  

 6-!#INVESTIGATORS )NTRAVENOUSNESIRITIDEVSNITROGLYCERINFOR TREATMENTOFDECOMPENSATEDCONGESTIVEHEARTFAILUREARANDOMIZED CONTROLLEDTRIAL*!-! 

 #ODY2 #LINICALTRAILSOFDIURETICTHERAPYINHEARTFAILURE RESEARCHDIRECTIONSANDCLINICALCONSIDERATIONS*!M#OLL #ARDIOL! !

 3ILVER-! (ORTON$0 #HALI*+ %LKAYAM5 %FFECTOFNESIRITIDE VERSUSDOBUTAMINEONSHORT TERMOUTCOMESINTHETREATMENTOF PATIENTSWITHACTUELYDECOMPENSATEDHEARTFAILURE!M*#OLL #ARDIOL 

 +UBO3( #LARK- ,ARAGH*( ETAL )DENTIlCATIONOFNORMAL NEUROHORMONALACTIVITYINMILDCONGESTIVEHEARTFAILUREAND STIMULATINGEFFECTOFUPRIGHTPOSTUREANDDIURETICS!M*#ARDIOL    #OTTER' -ETZKOR% +ALUSKI% ETAL 2ANDOMIZEDTRIALOF HIGH DOSEISOSORBIDEDINITRATEPLUSLOW DOSEFUROSEMIDEVERSUS HIGH DOSEFUROSEMIDEPLUSLOW DOSEISOSORBIDEDINITRATEINSEVERE PULMONARYEDEMA,ANCET   3ALVADOR$2+ 2EY.2 2AMOS'#0UNZALAN&%2#ONTINUOUS INFUSIONVERSUSBOLUSINJECTIONOFLOOPDIURETICSINCONGESTIVEHEART FAILURE#OCHRANE$ATABASE3YSTEMATIC2EVIEWS#$  'HEORGHIADE- .IAZI) /UYANG* ETAL6ASOPRESSIN6 RECEPTOR BLOCKADEWITHTOLVAPTANINPATIENTSWITHCHRONICHEARTFAILURE RESULTSFROMADOUBLE BLIND RANDOMIZEDTRIAL#IRCULATION    3TEVENSON,7#LINICALUSEOFINOTROPICTHERAPYFORHEARTFAILURE LOOKINGBACKWARDORFORWARD#IRCULATION   "URGER!* (ORTON$0 ,E*EMETEL4 ETAL %FFECTOFNESIRITIDE ANDDOBUTAMINEONVENTRICULARARRHYTHMIASINTHETREATMENTOF PATIENTSWITHACUTELYDECOMPENSATEDCONGESTIVEHEARTFAILURETHE 02%#%$%.4STUDY!M(EART*   #UFFE-3 #ALIFF2- !DAMS+& ETAL3HORT TERMINTRAVENOUS MILRINONEFORACUTEEXACERBATIONOFCHRONICHEARTFAILURE*!-!  

 0EACOCK7& %MERMAN#, THE02/!#4)/.STUDYGROUP3AFETY ANDEFlCACYOFNESIRITIDEINTHETREATMENTOFDECOMPENSATEDHEART FAILUREINOBSERVATIONPATIENTS*!M#OLL#ARDIOL!  #OLUCCI73 %LKAYAM5 (ORTON$ ETAL)NTRAVENOUSNESIRITIDE A NATRIURETICPEPTIDE INTHETREATMENTOFDECOMPENSATEDCONGESTIVEHEART FAILURE.ESIRITIDE3TUDY'ROUP.%NGL*-ED   3ACKNER "ERNSTEIN*$ +OWALSKI- &OX- ETAL3HORT TERM2ISK OF$EATH!FTER4REATMENT7ITH.ESIRITIDEFOR$ECOMPENSATED (EART&AILURE!0OOLED!NALYSISOF2ANDOMIZED#ONTROLLED4RIALS *!-!   3ALTZBERG-4 "ENElCIALEFFECTSOFEARLYINITIATIONOFVASOACTIVE AGENTSINPATIENTSWITHACUTEDECOMPENSATEDHEARTFAILURE 2EV #ARDIOVASC-EDSUPPL    0EACOCK 7&(EART&AILURE-ANAGEMENTINTHEEMERGENCY DEPARTMENTOBSERVATIONUNIT0ROGIN#ARDIOVAS$IS   %MERMAN#, 0EACOCK7& THE!$(%2%INVESTIGATORS%VOLVING PATETERSOFCAREFORDECOMPENSATEDHEARTFAILUREIMPLICATIONSFROM THE!$(%2%REGISTRYDATABASE!CAD%MERG-ED  9OUNG*".EWTHERAPEUTICCHOICESINTHEMANAGEMENTOFACUTE CONGESTIVEHEARTFAILURE 2EV#ARDIOVASC-ED3 

#OPYRIGHT%-#2%' )NTERNATIONAL 



/ Ê 6"6 Ê," Ê"Ê *Ê Ê/ Ê  "--Ê Ê/, / /Ê "Ê \ÊÊÊ-1,9Ê"Ê/ Ê *Ê " - -1-Ê* Ê, *",/

7&RANK0EACOCK -$ $EPARTMENTOF%MERGENCY-EDICINE 4HE#LEVELAND#LINIC&OUNDATION #LEVELAND /(

"  /6 -\  $ISCUSSTHEAPPLICATIONANDLIMITATIONSOF".0TESTINGINTHEEMERGENCYSETTING  $ESCRIBETHEAPPROPRIATECANDIDATEFOR".0THERAPY

 /," 1 /" !".0EXPERTCONSENSUSPANEL CONSISTINGOFINDIVIDUALSWITHBASIC METHODOLOGIC AND CLINICALEXPERTISE WASCONVENEDINTOCREATEASUMMARYDOCUMENTTOHELPGUIDE THECLINICIANONTHERECENTEXPLOSIONOFNATRIURETICPEPTIDE.0 DATA4HISDOCUMENT CONTAINS THE DATA FROM THEIR RECOMMENDATIONS MOST APPLICABLE TO THE EMERGENCY PHYSICIAN .ATRIURETIC0EPTIDE0HYSIOLOGY -ORETHANAPUMP THEHEARTISACRITICAL ENDOCRINE ORGAN FUNCTIONING WITH OTHER PHYSIOLOGICAL SYSTEMS TO CONTROL mUID VOLUME -YOCYTES MANUFACTURE A FAM ILYOFPEPTIDEHORMONES TERMEDTHE.0S REPRESENTED BY ATRIAL NATRIURETIC PEPTIDE !.0 AND " TYPE NATRIURETIC PEPTIDE ".0 2ELEASEOFTHE.0SISSTIMULATED BY VOLUME OVERLOAD  AND PHYSIOLOGI CALLY THEY HAVE POWERFUL DIURETIC NATRI URETIC ANDVASCULARSMOOTHMUSCLERELAX ING ACTIONS )MPORTANTLY THEY ALSO SERVE ASANTAGONISTSTOTHESYMPATHETICNERVOUS SYSTEM AND THE RENIN ANGIOTENSIN ALDO STERONE AXIS 2!!3   2ELEASE OF .0S RESULTSFROMCARDIACWALLSTRETCH VENTRIC ULARDILATION ORINCREASEDPRESSURESFROM CIRCULATORYVOLUMEOVERLOAD4HEEFFECTS OF.0SRESULTINLOWERINGBLOODVOLUME ANDPRESSURE ".0 IS DERIVED FROM A PRECURSOR PRE PRO".0 WHICHUNDERGOESSEVERALCLEAV

AGES 4HE ASSAY RELEVANT PRODUCTS ARE THE INERT . TERMINAL PRO ".0 FRAGMENT AND PHYSIOLOGICALLY ACTIVE ".0 ".0S AREPREFERENTIALLYPRODUCEDANDSECRETED BYTHECARDIACVENTRICLES ALTHOUGHmUID OVERLOADMAYCAUSERAPID".0MANUFAC TUREINBOTHHEARTCHAMBERS4HEPRIMARY FUNCTIONOF.0SISTODEFENDAGAINSTVOL UMEOVERLOAD!FTERRELEASEINTOCIRCULA TION ".0ACTIONSAREMODULATEDATTARGET SITES BY SPECIlC CELL MEMBRANE RECEP TORS TERMED! " AND# WHICHMEDIATE PHYSIOLOGICAL ACTIONS BY CYCLIC '-0 #YCLIC'-0HASPOTENTVASODILATORYAC TIONS ".0 ALSO CAUSES AN INTRAVASCULAR mUIDSHIFT FROMTHECAPILLARYBEDINTOTHE INTERSTITIUM WHICH CONTRACTS INTRAVASCU LARVOLUMEANDDECREASES"0 )NADDI TION ".0ISA2!!3ANTAGONIST WHEREIT COUNTERACTS SODIUM CONSERVATION VASO CONSTRICTION ANDVOLUMERETENTION".0 ALSO INHIBITS THE RELEASE OF RENIN FROM KIDNEY CELLS AND ALDOSTERONE FROM ADRE

/…iÊivviVÌÃʜvÊ *½ÃÊÊ ÀiÃՏÌʈ˜ÊœÜiÀˆ˜}ÊÊ Lœœ`ÊۜÕ“iÊÊ >˜`Ê«ÀiÃÃÕÀi°



%MERGENCY$IAGNOSISAND4REATMENTOF !CUTE$ECOMPENSATED(EART&AILURE!$(&

NALCELLS".0ISPRIMARILYMETABOLIZEDBYTHE.02 # RECEPTOR ALTHOUGHSOMEADDITIONALDEGRADATIONMAY OCCURBYNEUTRALENDOPEPTIDASE .EUTRALENDOPEP TIDASE HAS A WIDE TISSUE DISTRIBUTION INCLUDING ADI POSE KIDNEYS LUNG ANDBRAIN­ˆ}ÕÀiÊ£®

ˆ}ÕÀiÊ£°Ê

*Ê  /-

, 6 5z 6 'z z z z 6 z 0 6 z z . * z z 5 z* / z + z * z z 5 ) z z& z & 6 z 5 6 z /z . 9z z zz * z 3 . 0 6 zz 6 z zz 9 4 *z zz

&DUGLDF Ɣ /XVLWURSLF  Ɣ $QWLILEURWLF  Ɣ $QWLUHPRGHOLQJ  0DUFXV/6HWDO&LUFXODWLRQ =HOOQHU&HWDO$P-3K\VLRO SW ++ $EUDKDP:7HWDO-&DUG)DLO &ODUNVRQ3%0HWDO&LUFXODWLRQ 7DPXUD1HWDO3URF1DWO$FDG6FL86$

+HPRG\QDPLF %DODQFHGYDVRGLODWLRQ Ɣ 9HLQV  Ɣ $UWHULHV  Ɣ &RURQDU\DUWHULHV  1HXURKXPRUDO  $OGRVWHURQH   (QGRWKHOLQ   1RUHSLQHSKULQH  5HQDO   'LXUHVLV  1DWULXUHVLV

"IOLOGIC$ETERMINANTSON".0-EASUREMENTS "LOODLEVELSOF.0SAREAFFECTEDBYAVARIETYOFFACTORS INCLUDING CIRCADIAN RHYTHM AGE EXERCISE AND BODY POSTURE-ANYDRUGSINCLUDINGDIURETICS ANGIOTENSIN CONVERTINGENZYMEINHIBITORS ADRENERGICAGONISTS SEX ANDTHYROIDHORMONES GLUCOCORTICOIDS SODIUMINTAKE ANDOTHERCONDITIONSIMPACTLEVELS".0INCREASESWITH AGE AND GENDER "ASELINE AND PATHOLOGIC LEVELS ARE HIGHER IN WOMEN 4HE AGE INDUCED ".0 INCREASE MAYBEDUETOTHEDECLINEINMYOCARDIALFUNCTIONOR TODECREASEDCLEARANCE ".0!SSAY )TSHOULDBEMADECLEARTHATTHE".0ASSAYISNOTA STAND ALONETEST)TSGREATESTVALUEISWHENITISUSED WITHTHEPHYSICIANSCLINICALJUDGMENT ANDWITHOTHER APPROPRIATETESTING4HE4RIAGE".0ASSAYSYSTEMIS THE ONLY &$! APPROVED POINT OF CARE ASSAY )T RE



QUIRES MINUTESTOPERFORM ANDREPORTS".0LEVELS FROM  TO  PGM,4HIS ASSAY IS RATED AS MOD ERATELY COMPLEX ASSAY PER #LINICAL ,ABORATORY )M PROVEMENT!MENDMENTS#,)! REGULATIONS ".0FOR$IAGNOSISOF(EART &AILURE $ESPITE ADVANCES IN OUR UNDER STANDING OF HEART FAILURE (& PATHOPHYSIOLOGY DIAGNOSIS IS STILL DIFlCULT 7HILE EMERGEN CY DEPARTMENT %$ DIAGNOSIS NEEDSTOBERAPIDANDACCURATE  THE SIGNS AND SYMPTOMS OF (& ARE NONSPECIlC 2ESPIRATORY DISTRESS CAN PRECLUDE OBTAINING THEHISTORY ANDDYSPNEAISNON SPECIlCINTHEELDERLYOROBESE 2OUTINE LABS %#' AND X RAYS ARE ALSO NOT ACCURATE ENOUGH TO ALWAYSMAKETHECORRECTDIAGNO SIS 

#/.3%.35334!4%-%.43 '%.%2!,#/--%.43 4HELABORATORYSHOULDPERFORM".0TESTING ONACONTINUOUS HOURBASISWITHA TURN AROUND TIME4!4 OFMINUTESOR LESS4HE4!4ISDElNEDASTHETIMEFROM BLOODCOLLECTIONTONOTIlCATIONOFRESULT TOPHYSICIANORCAREGIVER%ITHERCENTRAL LABORATORYINSTRUMENTATIONORPOINTOFCARE TESTINGSYSTEMSAREACCEPTABLE % )NCONSIDERING.0MEASUREMENTS ONE NEEDSTOCAREFULLYCONSIDERLABORATORY ANDBIOLOGICVARIATION INCLUDINGGENDER SEX OBESITY ANDRENALFUNCTION % 4HERESULTSOFNATRIURETICTESTINGIS DEPENDENTONTHETYPEOFTESTYOUARE OBTAINING.TERMINALPRO".0AND BIOACTIVE".0ARE./4INTERCHANGEABLE

/ Ê 6"6 Ê," Ê"Ê *Ê Ê/ Ê  "--Ê Ê/, / /Ê "Ê \ÊÊÊ-1,9Ê"Ê/ Ê *Ê " - -1-Ê* Ê, *",/

4HE"REATHING.OT0ROPERLYSTUDYWASALARGE MUL TINATIONAL PROSPECTIVE STUDY USING ".0 TO EVALUATE DYSPNEA IN  DYSPNEIC %$ PATIENTS ".0 LEVELS WERE MEASURED ON ARRIVAL AND PHYSICIANS ASSESSED THEPROBABILITYOFTHEPATIENTHAVING(&4WOCARDI OLOGISTS BLINDEDTOTHE".0LEVEL REVIEWEDALLDATA AFTER HOSPITALIZATION TO PRODUCE A hGOLD STANDARDv CLINICALDIAGNOSIS".0LEVELSALONEMOREACCURATELY PREDICTEDTHEPRESENCEORABSENCEOF(&THANANYOTH ERlNDING4HEPGM,CUTPOINTHADASEN SITIVITY AND  SPECIlCITY FOR A (& DIAGNOSIS )N MULTIVARIATEANALYSIS ".0LEVELSALWAYSCONTRIBUTED TOTHEDIAGNOSIS EVENAFTERCONSIDERINGFEATURESOFTHE HISTORYANDPHYSICALEXAMINATION ".0 LEVELS MAY ALSO HELP IN DISPOSITION DECISIONS 4HE2APID%MERGENCY$EPARTMENT(EART&AILURE/UT PATIENT2%$(/4 4RIALDEMONSTRATEDAhSTRONGDIS CONNECTv BETWEEN THE PERCEIVED SEVERITY OF (& AND ILLNESS SEVERITY AS DETERMINED BY ".0 /N AVERAGE PATIENTS DISCHARGED FROM THE %$ HAD A HIGHER ".0 THANTHOSEADMITTED PGM, VERSUSPGM, RESPECTIVELY".0ALSOPREDICTEDOUTCOMESOFPATIENTS DISCHARGED HADA".0PGM, HOWEVER THEREWASNOMORTALITYATDAYSIFTHE".0WASLESS THANPGM, 4HE3WISS"!3%,3TUDYEXAMINED COST EFFECTIVE NESSOFUSING".0THROUGHTHEDIAGNOSISANDHOSPITAL IZATIONINACUTEDECOMPENSATEDHEARTFAILURE!$(&  )NPATIENTS %$MEASUREMENTOF".0WASASSO CIATED WITH A  DECREASE IN HOSPITAL ADMISSIONS A DAYDECLINEINLENGTHOFSTAY ANDANSAV INGS WITHNOEFFECTSONMORTALITYORRE HOSPITALIZATION RATES ".0AND2ENAL&AILURE #HRONIC KIDNEY DISEASE #+$ INmUENCES THE CUT POINTFOR".0)NGENERAL AS#+$ADVANCES AHIGHER ".0 CUT POINT IS IMPLIED ! CUT POINT OF APPROXI MATELY  PGM, IS REASONABLE FOR THOSE WITH AN

#/.3%.35334!4%-%.453).'".04/ (%,042)!'%%$0!4)%.437)4($930.%! ".0ISOFDIAGNOSTICUTILITYINTHEEVALUATION OFPATIENTSWITHACUTEDYSPNEA4HUS IN NEWPATIENTSPRESENTINGWITHDYSPNEATO ANEMERGENCYSETTING AHISTORY PHYSICAL EXAMINATION CHESTX RAYAND%#'SHOULD BEUNDERTAKENTOGETHERWITHLABORATORY MEASUREMENTSTHATINCLUDE".0#URRENT DATASUGGESTTHEFOLLOWINGGUIDELINES % !S".0RISESWITHAGEANDISAFFECTED BYGENDER COMORBIDITY ANDDRUGUSE IT SHOULDNOTBEUSEDINISOLATIONFROMTHE CLINICALCONTEXT % )FTHE".0ISPGM, THEN(&IS HIGHLYUNLIKELY.06  % )FTHE".0ISPGM, THEN(&IS HIGHLYLIKELY006  % )FTHE".0ISnPGM, CONSIDER ABASELINE".0ELEVATEDDUETOSTABLE UNDERLYINGDYSFUNCTION RIGHTVENTRICULAR FAILUREFROMCORPULMONALE ACUTE PULMONARYEMBOLISM ORRENALFAILURE % 0ATIENTSMAYPRESENTWITH(&ANDA NORMAL".0 ORWITHLEVELSBELOWWHAT ISEXPECTEDINTHEFOLLOWINGSITUATIONS mASHPULMONARYEDEMAnHOURS (& UP STREAMFROMTHELEFTVENTRICLESUCH ASWITHACUTEMITRALREGURGITATIONFROM PAPILLARYMUSCLERUPTUREANDOBESE PATIENTSBODYMASSINDEX;"-)= 

ESTIMATED GLOMERULAR lLTRATION RATE '&2  M, MINM5SINGTHISAPPROACH ".0MAINTAINSA HIGHLEVELOFDIAGNOSTICUTILITY WITHANAREAUNDERTHE 2/#CURVEOFACROSSALL#+$GROUPS



%MERGENCY$IAGNOSISAND4REATMENTOF !CUTE$ECOMPENSATED(EART&AILURE!$(&

#/.3%.35334!4%-%.43#/-/2")$)4)%3 !.$30%#)!,)335%34(!4).&,5%.#%4(% ).4%202%4!4)/./&".0,%6%,3 % ".0ISALTEREDWITHCHRONICRENAL INSUFlCIENCYESTIMATED'&2M, MIN WITHARECALIBRATIONOFTHECUTOFF VALUETOPGM, % ".0ISHELPFULINTHEEVALUATIONOF DYSPNEAWHENITISVERYLOWORHIGH.4 PRO".0HASGREATERCORRELATIONWITH E'&2THAN".0 HENCELEVELSCANBE ELEVATEDEVENWITHTHENORMALAGERELATED DECLINEOFRENALFUNCTIONINTHEE'&2 M,MINRANGE % 7HENTHEE'&2ISBELOWM,MIN . TERMINALPRO".0CANBECONSIDERABLY ELEVATEDANDINTHISSETTINGITSUTILITYIN THEEVALUATIONOF(&ISUNKNOWN % "ASELINE".0LEVELSMIGHTTHEREFOREBE IMPORTANTINDIALYSISPATIENTS ASCHANGES MOSTLIKELYREmECTVOLUMESTATUS4HUS APRE DIALYSIS".0MAYHELPDETERMINE THEAMOUNTOFVOLUMEWHICHSHOULDBE REMOVED

#ARDIOPULMONARY$ISEASE 3OME NON (& CARDIOPULMONARY DISEASE MAY CAUSE ".0 ELEVATIONS 4HESE INCLUDE COR PULMONALE LUNG CANCER PULMONARY EMBOLISM 0% AND PRIMARY PUL MONARYHYPERTENSION)NTHESE ".0MAYBEELEVATED BUTNOTTOTHEEXTENTFOUNDIN!$(&)N0% ".0MAY BEPROGNOSTICSINCEPATIENTSWITHA".0INTHEUPPER NORMALRANGEORPGM,HAVEAHIGHERMORTAL ITYRATE!LTHOUGH".0ISNOTANADEQUATESCREENING TESTFOR0% INTHESETTINGOFASUSPECTEDORCONlRMED EMBOLICEVENT A".0ELEVATIONIMPLIES26PRESSURE OVERLOADANDINCREASEDMORTALITYRISK&INALLY INPRI MARY PULMONARY HYPERTENSION ".0 ELEVATIONS PAR ALLELTHEEXTENTOFPULMONARYHEMODYNAMICCHANGES ANDRIGHT(&



#/.3%.35334!4%-%.4".0). 05,-/.!29!.$!33/#)!4%$#!2$)!# $)3%!3% % )NAPPROXIMATELYOFPATIENTSWITH PULMONARYDISEASE ".0ISELEVATED IMPLYINGCOMBINED(&ANDLUNGDISEASE CORPULMONALE ORAMISDIAGNOSISWHEN THETRUEETIOLOGYOFDYSPNEAIS(& % )NTHESETTINGOF0% ".0ISELEVATEDIN OFCASESANDISASSOCIATEDWITH26 PRESSUREOVERLOADANDAHIGHERMORTALITY ".0ISNOTDIAGNOSTICFORACUTE0% % 0ULMONARYDISEASEWHICHRESULTS INPULMONARYHYPERTENSIONAND26 PRESSUREORVOLUMEOVERLOADCANLEADTO ELEVATED".0LEVELS USUALLYINTHERANGE OF PGM,

0RESERVED3YSTOLIC&UNCTION03& (EART&AILURE $IASTOLICMYOCARDIALDYSFUNCTION ALSOKNOWNAS03& ISTHECAUSEOF(&INASMANYOFOFCASESAND ISALSOASSOCIATEDWITHHIGH".0 ".0HASBEEN FOUNDTOBEAPPROXIMATELYHALFASHIGHIN03&ASIN CASESOFSYSTOLICDYSFUNCTION #/.3%.35334!4%-%.4".0). $)!34/,)#$93&5.#4)/. % ".0MIGHTBEUSEDTODETECTPATIENTS WITHDIASTOLICDYSFUNCTION % ".0CONCENTRATIONSABOVEAGE ADJUSTED CUT POINTSMAYIDENTIFYELDERLYPATIENTS WITHDIASTOLICDYSFUNCTION

/ Ê 6"6 Ê," Ê"Ê *Ê Ê/ Ê  "--Ê Ê/, / /Ê "Ê \ÊÊÊ-1,9Ê"Ê/ Ê *Ê " - -1-Ê* Ê, *",/

/BESITY /BESITY IS AN IMPORTANT RISK FACTOR FOR CORONARY AR TERYDISEASEAND(& 0HYSIOLOGICALLY ADIPOSETIS SUEISRELATEDTOTHENATRIURETICCLEARANCERECEPTOR  AND OBESITY CAN INTERFERE WITH THE USUAL DIAGNOSTIC APPROACHTO(&-EHRADOCUMENTEDANINVERSERE LATIONSHIPBETWEEN"ASAL-ETABOLIC)NDEX"-) AND ".0,OWERLEVELSOF".0INTHEOBESE"-)+G - WERENOTED DESPITESIMILARSEVERITYOF(&COM PAREDTOALEANCOHORT ANDNEARLYOFOBESEPA TIENTSHAD".0PGM,

GROUPEDINTO".0QUARTILESHOURSAFTER!#3ONSET AN INCREASING ".0 WAS ASSOCIATED WITH HIGHER  MONTHMORTALITY ANDTHISRELATIONSHIPPERSISTEDEVEN WITHOUTEVIDENCEOF(&ORMYOCARDIALNECROSIS #/.3%.35334!4%-%.4".0).35$$%. $%!4( !#3 !.$#!$

7HEN USED TOGETHER ".0 AND CARDIAC TROPONIN PROVIDE A MORE EFFECTIVE TOOL FOR IDENTIFYING PATIENTS AT INCREASED RISK FORCLINICALLYIMPORTANTCARDIACEVENTSRE LATEDTO(&AND!#3-ULTIMARKERPANELS WITH".0ANDTROPONINARENOWAVAILABLE WHERE EACH OF THESE MARKERS PROVIDE UNIQUEANDINDEPENDENTOUTCOMEDATA

#/.3%.35334!4%-%.4".0)./"%3)49 % 3INCEOBESEPATIENTSBODYMASS INDEX;"-)=KGM EXPRESSLOWER LEVELSOF".0FORANYGIVENSEVERITY OF(& CAUTIONSSHOULDBEEXERCISEDIN INTERPRETING".0LEVELSINSUCHPATIENTS

".0AND!CUTE#ORONARY3YNDROMES!#3 ,ARGESTUDIESREPORT.0ELEVATIONSINUNSTABLEANGINA WITHOUTMYOCARDIALNECROSIS !SISCHEMIAMAYRE SULTINONLYSMALL.0ELEVATIONS THEIRSENSITIVITYAND SPECIlCITYAREINADEQUATEASAhRULEOUTvTOOL(OW EVERIFPRESENT ANELEVATIONOF.0IN!#3ISAPOW ERFULPREDICTOROFADVERSEEVENTS)N PATIENTS

".0AND0ROGNOSIS ".0ELEVATIONISAPOWERFULMARKEROF(&PROGNOSIS )N  PATIENTS FOLLOWED FOR  MONTHS AFTER AN %$ VISITFORDYSPNEA THERELATIVERISKOF MONTH(&AD MISSIONORDEATH WASTIMESHIGHERIFTHE".0WAS PGM,­ˆ}ÕÀiÊÓ®4HISWASCONlRMEDBYTHE 6AL (E&4TRIAL WHERETHELOWESTQUARTILEOF".0 PGM, HADTHELOWESTALL CAUSEMORTALITYANDTHE HIGHESTQUARTILEPGM, HADTHEHIGHESTMOR TALITY ATMONTHS­ˆ}ÕÀiÊÓ®

ˆ}ÕÀiÊÓ°Ê



,i>̈œ˜Ã…ˆ«Ê œvÊ *Ê `iÌiÀ“ˆ˜i`Ê ˆ˜Ê i“iÀ}i˜VÞÊ `i«>À̓i˜ÌÊ V>ÀiÊ ÌœÊ `i>̅ʜÀʅi>ÀÌÊv>ˆÕÀiʅœÃ«ˆÌ>ˆâ>̈œ˜°Ê ,i«Àˆ˜Ìi`Ê܈̅ʫiÀ“ˆÃȜ˜ÊvÀœ“ʘ˜Ê

“iÀ}Êi`°ÊÓääÓÆΙ\£Î£‡£În°

   ".0PGM,

   

".0 PGM,

 ".0PGM,  



















$AYS 

%MERGENCY$IAGNOSISAND4REATMENTOF !CUTE$ECOMPENSATED(EART&AILURE!$(&

ˆÛˆ˜}Ê *]ʈ˜Ê̅iÊ

".0AS4HERAPY 7HEN!$(&OCCURS THEBALANCEBETWEEN VASOCONSTRICTORSANDENDOGENOUSVASODI LATORS IS DISTURBED 4HIS FORMS THE BASIS AS TO WHY EXOGENOUS ".0 IS GIVEN AS THERAPY DESPITE HIGH ENDOGENOUS LEVELS ISANALOGOUSTOGIVINGINSULINFORINSULIN RESISTANCE)N!$(& HIGHLEVELSOF".0 OCCURASAhDISTRESSHORMONEv WHERESU PRA NORMALLEVELSARENOLONGEREFFECTIVE AT MAINTAINING THE BALANCE OF VASOCON STRICTION AND VASODILATION (ENCE GIVING ".0 INTHEFORMOFNESIRITIDE CANRESTORE NEUROHORMONALHOMEOSTASIS

vœÀ“ÊœvʘiÈÀˆÌˆ`i]ÊV>˜Ê ÀiÃ̜ÀiʘiÕÀœ…œÀ“œ˜>Ê …œ“iœÃÌ>ÈÃÊ>˜`ʈÃÊ >ÃÜVˆ>Ìi`Ê܈̅ÊÀi`ÕVi`Ê wˆ˜}Ê«ÀiÃÃÕÀiÃ]Ê `iVÀi>Ãi`ʫՏ“œ˜>ÀÞÊ Û>ÃVՏ>ÀÊÀiÈÃÌ>˜Vi]Ê œÜiÀi`ÊVi˜ÌÀ>ÊÊ Ûi˜œÕÃÊ«ÀiÃÃÕÀiÃ]ÊÊ >˜`ÊÀi`ÕV̈œ˜Êˆ˜Ê ÃÞÃÌi“ˆVÊ *°

.0 ARE MUCH CLOSER TO IDEAL DRUGS FOR !$(&THANOTHERAGENTS4HEUSEOFNE SIRITIDEISASSOCIATEDWITHREDUCEDlLLING PRESSURES DECREASED PULMONARY VASCU LAR RESISTANCE LOWERED CENTRAL VENOUS PRESSURES ANDREDUCTIONINSYSTEMIC"0 4HEREISALSOINCREASEDCARDIACOUTPUTDUE TOTHEUNLOADINGEFFECTOFVASODILATATION BUTWITHOUTREmEXTACHYCARDIA-OREOVER REDUCING PRELOAD AND AFTERLOAD WITHOUT INCREASING HEART RATE IS CONSISTENT WITH DECREASEDMYOCARDIALOXYGENCONSUMP TION AND A DECREASE IN VENTRICULAR STRESS

A STIMULUS PRESUMED TO DRIVE THE NEU ROHORMONAL ACTIVATION OF!$(& ,ASTLY TOLERANCETOTHESEEFFECTSDOESNOTOCCUR ANDTHESECHANGESINHEMODYNAMICSARE PRESENTANDPERSISTENTTHROUGHOUTTHEAD MINISTRATIONOFNESIRITIDE 4ODATE NESIRITIDEISTHEONLYNATRIURETIC PEPTIDEAVAILABLEINTHE53FOR)6THERA PY#OLUCCIETAL INTHE%FlCACY4RIAL SHOWED THAT NESIRITIDE CAUSES A DOSE RE LATED DECREASE IN 0#70 SYSTEMIC VAS CULARRESISTANCE MEANRIGHTARTERIALPRES SURE DYSPNEA FATIGUE A SIGNIlCANT IN CREASEINCARDIACINDEX ANDANIMPROVE



MENTINGLOBALSTATUS4HEMOSTCOMMON SIDE EFFECT WAS DOSE RELATED HYPOTENSION 4HE #OMPARATIVE 4RIAL EVALUATED NE SIRITIDE VERSUS MANY OTHER CARDIOVASCULAR AGENTS INCLUDING DOBUTAMINE MILRINONE NITROGLYCERIN DOPAMINE AND AMRINONE 'LOBAL CLINICAL STATUS FATIGUE AND DYS PNEAIMPROVEDINALLGROUPS WITHNOSIG NIlCANTDIFFERENCESBETWEENNESIRITIDEAND STANDARDTHERAPY4HEMOSTCOMMONSIDE EFFECTSWEREBRADYCARDIAANDDOSE RELATED HYPOTENSION )N  "URGER ET AL  CONDUCTED THE 02%#%$%.4 STUDY )TS PRIMARY OBJEC TIVE WAS TO COMPARE HEART RATE AND AR RHYTHMIAS WITH TWO DOSES OF NESIRITIDE OR§GKGMIN TODOBUTAMINE 4HEY CONCLUDED THAT ALTHOUGH INOTROPIC (&THERAPIES INCLUDINGDOBUTAMINEAND MILRINONE AREASSOCIATEDWITHFAVORABLE HEMODYNAMIC AND SYMPTOMATIC EFFECTS THEY CAUSE ARRHYTHMIAS AND TACHYCARDIA WHICH MAY INCREASE MYOCARDIAL OXYGEN DEMAND ISCHEMIA AND MORTALITY 4HEY DEMONSTRATED FEWER ARRHYTHMIAS AND NO HEART RATE INCREASE WITH NESIRITIDE &UR THERMORE THE RATES OF  DAY READMIS SIONAND MONTHMORTALITYWEREHIGHER WITHDOBUTAMINE4HEAUTHORSCONCLUDED THAT NESIRITIDE IS SAFER THAN DOBUTAMINE FORSHORT TERM!$(&MANAGEMENT 4HE6-!# TRIAL WAS A SAFETY AND EF lCACY STUDY OF INTRAVENOUS NESIRITIDE VERSUS INTRAVENOUS NITROGLYCERIN OR PLA CEBOIN!$(&PATIENTSWITHDYSPNEA AT REST 3WAN 'ANZ CATHETERIZATION WAS PERFORMEDINROUGHLYHALF ATTHEPHYSI CIANSCHOICE0ATIENTSWERERANDOMIZED INTOFOURBLINDEDGROUPS EACHRECEIVING STANDARDTHERAPYANDlXEDDOSENESIRIT IDE TITRATABLE NESIRITIDE TITRATABLE NITRO

/ Ê 6"6 Ê," Ê"Ê *Ê Ê/ Ê  "--Ê Ê/, / /Ê "Ê \ÊÊÊ-1,9Ê"Ê/ Ê *Ê " - -1-Ê* Ê, *",/

GLYCERIN OR PLACEBO .ESIRITIDE HAD A FASTER ONSET AND GREATER REDUCTION IN 0#70 THAN NITROGLYCERIN 4HEIMPROVEMENTINCLINICALSTATUSANDDYSPNEAWAS SIMILAR IN BOTH GROUPS ­ˆ}ÕÀiÊ Î®4HEY CONCLUDED THATWHENADDEDTOSTANDARDCARE NESIRITIDEIMPROVES HEMODYNAMIC FUNCTION MORE EFFECTIVELY THAN )6 NI TROGLYCERINORPLACEBO

YIELDANINTUITIVERATIONALEANDAREASONABLEEVIDENCE BASED APPROACH FOR !$(& ASSESSMENT AND MANAGE MENT/NEOFTHEMOSTVALUABLElNDINGSISTHATBEGIN NINGVASOACTIVETHERAPYINTHE%$ISASSOCIATEDWITHA  DAYREDUCTIONINHOSPITALLENGTHOFSTAYCOMPARED TO THERAPIES NOT INITIATED UNTIL AFTER ADMISSION 4HIS SUGGESTSTHATTHECHOICEOFTHERAPYINTHE%$MAYCRITI CALLYIMPACTTHECOURSEOFTHEPATIENT

)NANOTHEREVALUATION ARISKADJUSTEDCOMPARISONOF OUTCOMES FROM THE!$(%2% REGISTRY OF MORE THAN  !$(&PATIENTSFOUNDIMPROVEDSURVIVALWITH VASODILATORSCOMPAREDTOINOTROPES7HENCOMPARING VASODILATORS THEREARESIMILAROUTCOMESBETWEENNE SIRITIDEANDNITROGLYCERIN

).4%'2!4).'".0,%6%,3).4/! 2!4)/.!,53%/&.%3)2)4)$% 7HILE".0ISAPPROVEDBYTHE&$!FOR(&DIAGNOSIS ITSUSEFULNESSTOMONITORTREATMENTISSTILLUNDERSTUDY (OWEVER SOMESUGGESTIONSCANBEMADE7EBELIEVE THATONECANSTRATIFYPATIENTSTOTHEHIGH RISKCATEGORYIN PARTBYUSING".0LEVELS&ONOROWRECENTLYANALYZED THE!$(%2%DATABASEANDFOUNDTHATHIGH"5.LEVELS PROVIDEAPOORPROGNOSISFORPATIENTSIN!$(&4HUS

4HE CURRENT APPROVED USE OF NESIRITIDE IS FOR!$(& !LTHOUGHGUIDELINESTATEMENTSARELACKING THETOTALITY OFDIAGNOSTICANDTHERAPEUTICDATAREGARDINGNESIRITIDE

S

3ODFHER

0HDQ2EVHUYHGYDOXH PP+J

s

S

s



 S

S

S





1HVLULWLGH

0HDQ&KDQJH PP+J





s

1LWURJO\FHULQ

S

ss s







S

s



S

s





S

s

S S

S

S

 

s s







s



KU

KU



s

  %/ P P

 KU

KU

KU

%/ P P

KU

SYVSODFHER

SYV17*

ˆ}ÕÀiÊΰ 6>Ü`ˆ>̈œ˜Êˆ˜Ê̅iÊ>˜>}i“i˜ÌʜvÊVÕÌiÊ Ê­6 ®ÊÌÀˆ>\Ê*Àˆ“>ÀÞÊi˜`Ê«œˆ˜ÌʈÃÊ «Õ“œ˜>ÀÞÊV>«ˆ>ÀÞÊÜi`}iÊ«ÀiÃÃÕÀiÊV…>˜}iÃʜÛiÀÊÎʅœÕÀð{È



%MERGENCY$IAGNOSISAND4REATMENTOF !CUTE$ECOMPENSATED(EART&AILURE!$(&

THECOMBINATIONOFHIGH".0ANDPOORRENALFUNCTION IDENTIlESHIGH RISKPATIENTS­ˆ}ÕÀiÊ{® )FPATIENTSAREADMITTEDWITH".0LEVELSPGM, AND"5.LEVELSARELOWERRISK ONECANOFTEN STARTTREATMENTWITHPARENTERALDIURETICS3UBSEQUENTLY THEYCANBERECLASSIlEDINTOLOW ORHIGH RISKGROUPS BASED ON THEIR RESPONSE OVER THE NEXT n HOURS 4HOSEWITHANADEQUATEDIURESIS AFALLIN".0 AND NODETERIORATIONINRENALFUNCTIONMAYBECANDIDATES FOR CONTINUED DIURETICSVASODILATORS UNTIL EUVOLEMIA IS REACHED (OPEFULLY THIS WILL LEAD TO A ".0 LEVEL PGM,INTHESEPATIENTS)NONESTUDY PATIENTS WHOSEDISCHARGE".0LEVELSWEREPGM,HADA REASONABLELIKELIHOODOFNOTBEINGREADMITTEDWITHIN THEFOLLOWINGDAYS)FTHE".0LEVELWAS PGM, THE VOLUME STATUS REQUIRED RE EVALUATION )F THEPATIENTISNOTYETEUVOLEMIC NESIRITIDEMIGHTBE CONSIDEREDFORHOURS )F PATIENTS AFTER RECEIVING n HOURS OF INTRAVENOUS DIURETICSHAVEANINADEQUATEDIURESIS NOCHANGEORAN INCREASE IN ".0 AND WORSENING RENAL FUNCTION THEY SHOULDBECONSIDEREDATHIGHRISK)FTHEIRSYSTOLIC"0 ISATLEASTMM(G THEYCANBEGIVENnDAYSOF

*,&',(),#('+*#  "!&%('"%"!%+&+!%" &

,#',)*+',#'!/#,"1+)' "1+#%0&#',#(' "+,0*1%.%

NESIRITIDEWITHIVDIURETICS".0CANTHENBECHECKED HOURSAFTERCESSATIONOFNESIRITIDEANDORALVASODILATORS ANDDIURETICSCANBEUSEDUNTILEUVOLEMIAISACHIEVED 0ATIENTSWITHSYSTOLIC"0SMM(GOFTENNEEDVA SOPRESSORSANDORINOTROPES SOMETIMESUNDER3WAN 'ANZ GUIDANCE )N OUR EXPERIENCE AT THE #LEVELAND #LINIC IFTHESEINDIVIDUALSSHOWIMPROVEMENTIN"0 ANDSYMPTOMS WEWILLTHENTRANSITIONTHEIRTHERAPY TO NESIRITIDE )F THERE IS NO IMPROVEMENT ON INOTRO PESORPRESSORS FURTHERINVASIVESTRATEGIESSHOULDBE CONSIDERED&INALLY ITISCONCEIVABLETHATINPATIENTS WHOAREADMITTEDWITHVERYHIGH".0LEVELS ORHAVE IMPAIRED RENAL FUNCTION NESIRITIDE MIGHT BE STARTED IMMEDIATELY

-1,9 )NSUMMARY THE".0#ONSENSUS0ANELOFHAS PROVIDEDCONSENSUSAPPROACHESFORTHEUSEOF".0 FORTHEDIAGNOSISANDTREATMENTOF(&)DEALLY THE USEOFTHESERECOMMENDATIONSWILLIMPROVETHECARE OFYOURPATIENTS

*,&',(),#('+ (* /#,"  (%'&#(&!&%' &#+*'%"!!+&& !#( "!%+"!&'"! "!&%! )&"'"%&+#%'!&) "!&% !!"'%"#&"%#""%#%(&"!

 )!&

  )!&

 )!&

.*1-')*(% 

%#'#%+-+)##('( (* )+,"#+,(*1( 

.*1)*(% 

)*(%  *,&',(),#('+'('*# "!&% #("!%+ "&

&'  #!( "! &#&&



*,&',(),#('+ (%'&&%$(%

"!&%!&%'#( "!%+"!&'"! "%"%"%%! "+! !&''+ %'!!  %    !

  

*,&',(),#('+ (* /#," (*+"($ (%'&!"'%"#&)&"'"%& !"%!&%''"""*

ˆ}ÕÀiÊ{°Ê *Ê œ˜Ãi˜ÃÕÃÊ }œÀˆÌ…“

/ Ê 6"6 Ê," Ê"Ê *Ê Ê/ Ê  "--Ê Ê/, / /Ê "Ê \ÊÊÊ-1,9Ê"Ê/ Ê *Ê " - -1-Ê* Ê, *",/

,  ,

-Ê 



3ILVER7 -AISEL! 9ANCY#7 -C#ULLOUGH0! "URNETT*# &RANCIS'3 -EHRA-2 0EACOCK7& &ONOROW' 'IBLER" -ORROW$! (OLLANDER*".0#ONSENSUS0ANEL!#LINICAL !PPROACHFORTHE$IAGNOSTIC 0ROGNOSTIC 3CREENING 4REATMENT -ONITORING AND4HERAPEUTIC2OLESOF.ATRIURETIC0EPTIDESIN #ARDIOVASCULAR$ISEASES#(&  3UPPL n #LERICO! )ERVASI' -ARIANI'#LINICALRELEVANCEOFTHE MEASUREMENTOFCARDIACNATRIURETICPEPTIDEHORMONESINHUMANS (ORM-ETAB2ES n

 7IECZOREK3* 7U!( #HRISTENSON2 ETAL!RAPID" TYPE NATRIURETICPEPTIDEASSAYACCURATELYDIAGNOSESLEFTVENTRICULAR DYSFUNCTIONANDHEARTFAILUREAMULTICENTEREVALUATION!M(EART * n  2EDlELD-- 2ODEHEFFER2* *ACOBSEN3* ETAL0LASMABRAIN NATRIURETICPEPTIDECONCENTRATIONIMPACTOFAGEANDGENDER*!M #OLL#ARDIOL n  &RIESINGER'# &RANCIS*0ROMISESANDPERILSOFMANAGEDCAREFOR OLDERPATIENTSWITHCARDIACDISEASE #ARDIOL#LIN n



-AISEL!" TYPENATRIURETICPEPTIDELEVELSAPOTENTIALNOVEL hWHITECOUNTvFORCONGESTIVEHEARTFAILURE*#ARD&AIL n



"OOMAMA& 6ANDER-EIRACKER!(0LASMA! AND" TYPE NATRIURETICPEPTIDESPHYSIOLOGY METHODOLOGYANDCLINICALUSE #ARDIOVASC2ES n

 4HE3/,6$)NVESTIGATORS%FFECTOFENALAPRILONMORTALITYAND THEDEVELOPMENTOFHEARTFAILUREINASYMPTOMATICPATIENTSWITH REDUCEDVENTRICULAREJECTIONFRACTIONSANDCONGESTIVEHEARTFAILURE .%NGL*-ED n



-AIR* (AMMERER ,ERCHER! 0UCHENDORF"4HEIMPACTOFCARDIAC NATRIURETICPEPTIDEDETERMINATIONONTHEDIAGNOSISANDMANAGEMENT OFHEARTFAILURE#LIN#HEM,AB-ED n

 3TEVENSON,74HELIMITEDAVAILABILITYOFPHYSICALSIGNSFOR ESTIMATINGHEMODYNAMICSINCHRONICHEARTFAILURE*!-! n



,UCHNER! 3TEVENS4, "ORGESON$$ ETAL$IFFERENTIALATRIAL ANDVENTRICULAREXPRESSIONOFMYOCARDIAL".0DURINGEVOLUTIONOF HEARTFAILURE!M*0HYSIOL (n(

 (YPERTENSIONANDGENERALPOPULATIONRESEARCH(YPERTENSION PT ))n))



3TEIN" ,EVIN2.ATRIURETICPEPTIDESPHYSIOLOGY THERAPEUTIC POTENTIAL ANDRISKSTRATIlCATIONINISCHEMICHEARTDISEASE!M (EART* n



7EIDMANN0 (ASLER, 'NADINGER-0 ETAL"LOODLEVELSANDRENAL EFFECTSOFATRIALNATRIURETICPEPTIDEINNORMALMAN*#LIN)NVEST n



#HARLES#* %SPINER%! 2ICHARDS!-#ARDIOVASCULARACTIONSOF !.&CONTRIBUTIONSOFRENAL NEUROHUMORAL ANDHEMODYNAMIC FACTORSINSHEEP!M*0HYSIOL 2n2

 (UNT0* %SPINER%! .ICHOLLS-' ETAL$IFFERINGBIOLOGICAL EFFECTSOFEQUIMOLARATRIALANDBRAINNATRIURETICPEPTIDEINFUSIONSIN NORMALMAN*#LIN%NDOCRINOL-ETAB n  -UKOYAMA- .AKAO+ (OSODA+ ETAL"RAINNATRIURETICPEPTIDE ASANOVELCARDIACHORMONEINHUMANS%VIDENCEFORANEXQUISITE DUALNATRIURETICPEPTIDESYSTEM ATRIALNATRIURETICPEPTIDEANDBRAIN NATRIURETICPEPTIDE*#LIN)NVEST n  $AVIDSON.# 3TRUTHERS!$"RAINNATRIURETICPEPTIDE* (YPERTENSION n  3AGNELLA'!-EASUREMENTANDIMPORTANCEOFPLASMABRAIN NATRIURETICPEPTIDEANDRELATEDPEPTIDES!NN#LIN"IOCHEM n  #LERICO! )ERVASI' -ARIANI'#LINICALRELEVANCEOFTHE MEASUREMENTOFCARDIACNATRIURETICPEPTIDEHORMONESINHUMANS (ORM-ETAB2ES n

 ".0TESTFORRAPIDQUANTIlCATIONOF" TYPENATRIURETICPEPTIDE ;PACKAGEINSERT=3AN$IEGO #ALIF"IOSITE$IAGNOSTICS 

 7UERZ2# -EADOR3!%FFECTSOFPREHOSPITALMEDICATIONS ONMORTALITYANDLENGTHOFSTAYIN(&!NN%MERG-ED  n  $EVERAUX2" ,IEBSON02 (ORAN-*2ECOMMENDATIONS CONCERNINGUSEOFECHOCARDIOGRAPHYINHYPERTENSIONANDGENERAL POPULATIONRESEARCH(YPERTENSION PT ))n))  $AVIE!0 &RANCIS#- ,OVE-0 ETAL6ALUEOFTHE ELECTROCARDIOGRAMINIDENTIFYINGHEARTFAILUREDUETOLEFTVENTRICULAR SYSTOLICDYSFUNCTION"-*   -AISEL! +RISHNASWAMY0 .OWAK2- ETAL2APIDMEASUREMENT OF" TYPENATRIURETICPEPTIDEINTHEEMERGENCYDIAGNOSISOFHEART FAILURE.%NGL*-ED  n  -UELLER# 3CHOLER! ,AULE +ILIAN+ ETAL5SEOF" TYPE NATRIURETICPEPTIDEINTHEEVALUATIONANDMANAGEMENTOFACUTE DYSPNEA.%NGL*-ED n  7OLDE- 4ULEVSKI)) -ULDER*7 ETAL"RAINNATRIURETICPEPTIDE ASAPREDICTOROFADVERSEOUTCOMEINPATIENTSWITHPULMONARY EMBOLISM#IRCULATION     ,EUCHTE(( (OLZAPFEL- "AUMGARTNER2! ETAL#LINICAL SIGNIlCANCEOFBRAINNATRIURETICPEPTIDEINPRIMARYPULMONARY HYPERTENSION*!##  n  ,UBIEN% $E-ARIA! +RISHNASWAMY0 ETAL5TILITYOF" NATRIURETIC0EPTIDE".0 INDIAGNOSINGDIASTOLICDYSFUNCTION #IRCULATION  n



%MERGENCY$IAGNOSISAND4REATMENTOF !CUTE$ECOMPENSATED(EART&AILURE!$(&

 +RISHNASWAMY0 ,UBIEN% #LOPTON0 ETAL5TILITYOF" NATRIURETIC PEPTIDE".0INELUCIDATINGLEFTVENTRICULARDYSFUNCTIONSYSTOLIC ANDDIASTOLIC INPATIENTSWITHANDWITHOUTSYMPTOMSOFCONGESTIVE HEARTFAILUREATAVETERANSHOSPITAL!M*-ED n  -AISEL!3 -C#ORD*- .OWAK2- ETAL"EDSIDE" TYPE NATRIURETICPEPTIDEINTHEEMERGENCYDIAGNOSISOFHEARTFAILUREWITH REDUCEDORPRESERVEDEJECTIONFRACTIONRESULTSFROMTHE"REATHING .OT0ROPERLY".0 MULTINATIONALSTUDY*!M#OLL#ARDIOL  n  (UBERT(" &EINLEIB- -C.AMARA0-AND#ASTELLI70  /BESITYASANINDEPENDENTRISKFACTORFORCARDIOVASCULAR DISEASEA YEARFOLLOW UPOFPARTICIPANTSINTHE&RAMINGHAM (EART3TUDY#IRCULATION  -%$,).%  %CKEL2( "AROUCH77 %RSHOW!'2EPORTOFTHE.ATIONAL (EART ,UNG AND"LOOD)NSTITUTE .ATIONAL)NSTITUTEOF$IABETES AND$IGESTIVEAND+IDNEY$ISEASES7ORKING'ROUPONTHE 0ATHOPHYSIOLOGYOF/BESITY !SSOCIATED#ARDIOVASCULAR$ISEASE #IRCULATION n  !LPERT-! ,AMBERT#2AND0ANAYIOTOU(ETAL 2ELATIONOFDURATIONOFMORBIDOBESITYTOLEFTVENTRICULARMASS SYSTOLICFUNCTION ANDDIASTOLIClLLING ANDEFFECTOFWEIGHTLOSS !M*#ARDIOL  -%$,).%  +ENCHAIAH3 %VANS*#AND,EVY$ETAL /BESITYAND THERISKOFHEARTFAILURE.%NGL*-ED    3ARZANI2 $ESSI &ULGHERI0 0ACI6- %SPINOSA%AND 2APPELLI!* %XPRESSIONOFNATRIURETICPEPTIDERECEPTORSIN HUMANADIPOSEANDOTHERTISSUES*%NDOCRINOL)NVEST   -%$,).%  3ENGENES# "ERLAN- $E'LISEZINSKI) ,AFONTAN-AND 'ALITZKY* .ATRIURETICPEPTIDESANEWLIPOLYTICPATHWAYIN HUMANADIPOCYTES&!3%"*  -%$,).%  -EHRA-2 5BER0! 0ARK- ETAL/BESITYANDSUPPRESSED" TYPE NATRIURETICPEPTIDELEVELSINHEARTFAILURE*!##  n   +IKUTA+ 9ASUE( 9OSHIMURA- ETAL)NCREASEDPLASMALEVELS OF" TYPENATRIURETICPEPTIDEINPATIENTSWITHUNSTABLEANGINA!M (EART* n

 4ALWAR3 3QUIRE)" $OWNIE0& ETAL0LASMA.TERMINALPRO BRAINNATRIURETICPEPTIDEANDCARDIOTROPHINARERAISEDINUNSTABLE ANGINA(EART n  DE,EMOS*! -ORROW$! "ENTLEY*( ETAL4HEPROGNOSTIC VALUEOF" TYPENATRIURETICPEPTIDEINPATIENTSWITHACUTECORONARY SYNDROMES.%NGL*-ED n  (ARRISON! -ORRISON,+ +RISHNASWAMY0 ETAL" TYPE NATRIURETICPEPTIDE".0 PREDICTSFUTURECARDIACEVENTSINPATIENTS PRESENTINGTOTHEEMERGENCYDEPARTMENTWITHDYSPNEA!NN%MERG -ED n  #OLUCCI7 %LKAYAM5 (ORTON$ ETAL)NTRAVENOUSNESIRITIDE A NATRIURETICPEPTIDE INTHETREATMENTOFDECOMPENSATEDCONGESTIVE HEARTFAILURE.%NGL*-ED n  3ILVER-! (ORTON$0 'HALI*+ ETAL%FFECTOFNESIRITIDEVERSUS DOBUTAMINEONSHORT TERMOUTCOMESINTHETREATMENTOFPATIENTS WITHACUTELYDECOMPENSATEDHEARTFAILURE*!M#OLL#ARDIOL  n  "URGER! (ORTON$ ,E*EMTEL4%FFECTSOFNESIRITIDE" TYPE NATRIURETICPEPTIDE ANDDOBUTAMINEONVENTRICULARARRHYTHMIAS INTHETREATMENTOFPATIENTSWITHACUTELYDECOMPENSATED CONGESTIVEHEARTFAILURETHE02%#%$%.4STUDY!M(EART*  n  0UBLICATION#OMMITTEEFORTHE6-!#)NVESTIGATORS6ASODILATORS INTHE-ANAGEMENTOF!CUTE(& )NTRAVENOUSNESIRITIDEVS NITROGLYCERINFORTREATMENTOFDECOMPENSATEDCONGESTIVEHEART FAILUREARANDOMIZEDCONTROLLEDTRIAL*!-! n   !$(%2%3CIENTIlC!DVISORY#OMMITTEE4HE!CUTE $ECOMPENSATED(EART&AILURE.ATIONAL2EGISTRY!$(%2%  OPPORTUNITIESTOIMPROVECAREOFPATIENTSHOSPITALIZEDWITHACUTE DECOMPENSATEDHEARTFAILURE2EV#ARDIOVASC-ED SUPPL  3n3  -EHRA-2 5BER0! 0OTLURI3 6ENTURA(/ 3COTT2, 0ARK-( 5SEFULNESSOFANELEVATEDB TYPENATRIURETICPEPTIDETOPREDICT ALLOGRAFT  #HENG6, +RISHNASWAMY0 +AZANEGRA2 ETAL!RAPIDBEDSIDE TESTFOR" TYPENATRIURETICPEPTIDEPREDICTSTREATMENTOUTCOMESIN PATIENTSADMITTEDWITHDECOMPENSATEDHEARTFAILURE*!M#OLL #ARDIOL n

#OPYRIGHT%-#2%' )NTERNATIONAL 



 ,"1 Ê Ê  -Ê,"ÊÊ / Ê  , Ê /" Ê, -/,9 7ILLIAM4!BRAHAM -$ #HIEF $IVISIONOF#ARDIOVASCULAR-EDICINE 4HE/HIO3TATE5NIVERSITY#OLLEGEOF-EDICINE #OLUMBUS /(

"  /6 -\ £°Ê iÃVÀˆLiÊ̅iʓi̅œ`ÃÊ>˜`Ê«ÀœViÃÃʜvÊ̅iÊ  , ÊÀi}ˆÃÌÀÞ Ó°Ê iÃVÀˆLiʅœÜÊw˜`ˆ˜}ÃʜvÊ̅iÊ  , ÊÀi}ˆÃÌÀÞÊV>˜ÊLiÊÕÃi`Ê̜Ê`ˆÀiVÌÊ>˜`ʈ“«ÀœÛiÊV>ÀiÊ vœÀÊ Ê«>̈i˜ÌÃ

 /," 1 /" !CUTEDECOMPENSATEDHEARTFAILURE!$(& REPRESENTSAMAJORPUBLICHEALTHPROBLEM )NTHE5NITED3TATES THEREAREAPPROXIMATELYMILLIONHOSPITALIZATIONSANNUALLYWITH APRIMARYDISCHARGEDIAGNOSISOF!$(&.EARLYTWICEASMANYHOSPITALIZATIONSAREAS SOCIATEDWITHHEARTFAILURE ASASECONDARYDIAGNOSIS4HESENUMBERSAREEXPECTEDTO INCREASEOVERTHENEXTTWODECADES (EARTFAILURETAKESAPARTICULARLYHIGHTOLLONTHE ELDERLY3INCETHEEARLYS !$(&HASBEENTHELEADINGCAUSEOFHOSPITALIZATIONIN PERSONSOVERTHEAGEOFYEARS2EPORTEDDEATHRATESAPPEAREXCESSIVEBOTHDURING ANDAFTERHOSPITALIZATIONANDHIGHREADMISSIONRATESSUGGESTTHATINPATIENTCAREDOESNOT RESULTINEFFECTIVELONG TERMMANAGEMENT 4HEENORMOUSDIRECTCOSTSASSOCIATEDWITH TREATINGTHEMILLION!MERICANSWITHCHRONICHEARTFAILUREAREMOSTLYATTRIBUTABLETO THEINPATIENTMANAGEMENTOFEPISODESOFDECOMPENSATION)THASBEENPROPOSEDTHAT THESEDISMALSTATISTICSEXIST INPART DUETOAPOORUNDERSTANDINGOFTHECHARACTERISTICS OFPATIENTSADMITTEDWITH!$(&ANDHOWTOTREATTHEM)NTHISREGARD MOSTINFORMA TIONABOUT!$(&ISDERIVEDFROMCLINICALTRIALSTHATARESMALLHUNDREDSOFPATIENTS ANDPOORLYREPRESENTATIVEOFPATIENTSHOSPITALIZEDFOR!$(& DUETOTHEMANYINCLUSION ANDEXCLUSIONOFSUCHTRIALS !FEWREGISTRIESHAVEBEENDEVELOPEDTOEVALUATECHRONICHEARTFAILUREINTHEOUTPA TIENTCOMMUNITYSETTING 4HE!CUTE$ECOMPENSATED(EART&AILURE.ATIONAL2EGISTRY !$(%2% WASDEVELOPEDTOPROVIDEALARGE NATIONALDATABASEDESCRIBINGTHECLINICAL CHARACTERISTICS PHYSICIAN PRACTICE AND TREATMENT PATTERNS AND OUTCOMES OF PATIENTS HOSPITALIZEDWITH!$(& -ETHODOLOGYOF!$(%2% !$(%2% IS A LARGE MULTICENTER REG ISTRY DESIGNED TO AMASS A LARGE CLINICAL DATABASE ON THE CLINICAL CHARACTERISTICS MANAGEMENT AND OUTCOMES OF PATIENTS HOSPITALIZEDFOR!$(&ACROSSTHE5NITED

3TATES$ATAARECOLLECTEDONTHEEPISODE OF HOSPITALIZATION BEGINNING WITH THE POINTOFINITIALCAREANDENDINGWITHTHE PATIENTS DISCHARGE TRANSFER OUT OF THE HOSPITAL OR IN HOSPITAL DEATH!$(%2% IS SPONSORED BY 3CIOS )NC &REMONT

/…iÊVÕÌiÊ iVœ“«i˜Ã>Ìi`Ê i>ÀÌÊ>ˆÕÀiÊ >̈œ˜>Ê ,i}ˆÃÌÀÞÊ­  , ®Ê Ü>ÃÊ`iÛiœ«i`ÊÌœÊ «ÀœÛˆ`iÊ>ʏ>À}i]ʘ>̈œ˜>Ê `>Ì>L>ÃiÊ`iÃVÀˆLˆ˜}Ê̅iÊ Vˆ˜ˆV>ÊV…>À>VÌiÀˆÃ̈VÃ]Ê «…ÞÈVˆ>˜Ê«À>V̈ViÊ>˜`Ê ÌÀi>̓i˜ÌÊ«>ÌÌiÀ˜Ã]Ê >˜`ʜÕÌVœ“iÃʜvÊ «>̈i˜ÌÃʅœÃ«ˆÌ>ˆâi`Ê ÜˆÌ…Ê °



%MERGENCY$IAGNOSISAND4REATMENTOF !CUTE$ECOMPENSATED(EART&AILURE!$(&

#ALIFORNIA 4HESPECIlCOBJECTIVESOF!$(%2%ARE  TODESCRIBETHEDEMOGRAPHICANDCLINICALCHARAC TERISTICSOFPATIENTSWHOAREHOSPITALIZEDWITH!$(& INCLUDINGSPECIlCSUBGROUPSOFINTEREST TOCHAR ACTERIZETHEINITIALEMERGENCYDEPARTMENTEVALUATION AND SUBSEQUENT INPATIENT MANAGEMENT OF PATIENTS HOSPITALIZEDWITH!$(& TOIDENTIFYPATIENTCHAR ACTERISTICSANDMEDICALCAREPRACTICESASSOCIATEDWITH IMPROVED HEALTH OUTCOMES IN PATIENTS HOSPITALIZED WITH!$(&  TO CHARACTERIZE TRENDS OVER TIME IN THEMANAGEMENTOF!$(&AND TOASSISTHOSPITALS IN EVALUATING AND IMPROVING QUALITY OF CARE FOR PA TIENTSHOSPITALIZEDWITHHEARTFAILURE!DDITIONALGOALS OF!$(%2%INCLUDEDEVELOPMENTOFPREDICTIVEMOD ELS FOR MORTALITY COMPLICATIONS AND LENGTH OF HOS PITALSTAYANDTOLINKWITHDE IDENTIlEDDATAONLON GITUDINALTRENDSINTHECLINICALCAREANDOUTCOMESOF REGISTRYPATIENTS!GGREGATEDATAFROMTHE!$(%2% DATABASE IS ALSO USED FOR THE OBSERVATIONAL STUDY OF TREATMENTEFFECTS 3ITES WERE SELECTED TO REPRESENT THE hREAL WORLDv OF !$(& 3ITES INCLUDED BOTH ACADEMIC  HOSPITALS ANDNONACADEMICHOSPITALS HOSPITALSANDWERE GEOGRAPHICALLY DIVERSE INCLUDING  HOSPITALS IN THE .ORTHEASTERN5NITED3TATES HOSPITALSINTHE3OUTH HOSPITALSINTHE-IDWEST HOSPITALSINTHE7EST ANDHOSPITALSINTHE-ID !TLANTICREGION3OMEOF THE LARGEST ACUTE CARE HOSPITALS IN THE 5NITED 3TATES AREPARTICIPATINGBUTSITESAREDIVERSEINSIZE RANGING FROMTOBEDS3ITESAREREIMBURSEDANOMINAL FEEFOREACHCOMPLETEDCASEREPORTFORM &ORTHEPURPOSEOFTHISREGISTRY !$(&ISDElNEDAS EITHER NEW ONSET HEART FAILURE OR DECOMPENSATION OF CHRONIC ESTABLISHEDHEARTFAILUREWITHSYMPTOMSSUF lCIENT TO WARRANT HOSPITALIZATION 0ATIENTS ARE IDEN TIlED FOR INCLUSION IN THE REGISTRY FROM ADMISSIONS GIVENADISCHARGEDIAGNOSISOFHEARTFAILUREBASEDON )NTERNATIONAL#LASSIlCATIONOF$ISEASES .INTH2EVI



SION)#$  CODING%LIGIBILITYISNOTCONTINGENTON THEUSEOFANYPARTICULARTHERAPEUTICAGENTORREGIMEN 0ATIENTSMAYBEMALEORFEMALEANDMUSTBEATLEAST  YEARS OLD AT THE TIME OF HOSPITAL ADMISSION 4HE REGISTRYISACCUMULATINGDATAONINDIVIDUALHOSPITAL IZATIONS NOTINDIVIDUALPATIENTS ANDITISPOSSIBLETHAT SOME PATIENTS MAY BE ENROLLED IN THE REGISTRY MORE THANONCE4HEGOALOFTHEREGISTRYISTOENROLLAREPRE SENTATIVEPATIENTSAMPLE3ITESAREENCOURAGEDTOENROLL ADMISSIONSMEETINGENTRYCRITERIAASCONSECUTIVELYAS POSSIBLE(OSPITALSWITHMORETHANELIGIBLEPATIENTS INAMONTHAREALLOWEDTOENROLLARANDOMSAMPLEOF THESECONSECUTIVEADMISSIONSUSINGA*OINT#OMMIS SION FOR !CCREDITATION OF (EALTHCARE /RGANIZATIONS *#!(/ nAPPROVEDSAMPLINGMETHOD3PECIlCATIONS -ANUALFOR.ATIONAL)MPLEMENTATIONOF(OSPITAL#ORE -EASURES *#!(/  SECTION  $ATAARECOLLECTEDBYCHARTREVIEWANDENTEREDUSING A WEB BASED ELECTRONIC DATA CAPTURE %$# SYSTEM DESIGNEDBY0HASE&ORWARD7ALTHAM -ASS ANDLI CENSED BY THE STUDY CONTRACT RESEARCH ORGANIZATION 0HARMA,INK&()2ESEARCH4RIANGLE .# $ATAARE RECORDED CONCERNING DEMOGRAPHICS MEDICAL HIS TORY NON INTRAVENOUS AND INTRAVENOUS CARDIOVASCU LAR MEDICATIONS INITIAL EVALUATION AT SITE HOSPITAL CHRONICINFUSIONTHERAPY HOSPITALCOURSE DISPOSITION AND PROCEDURES )NFORMATION RELATED TO FOUR SPECIlC ASPECTSOFTHE*#!(/QUALITYIMPROVEMENTINITIATIVE FORHEARTFAILUREAREALSOCAPTURED PATIENTINSTRUC TIONONDIET WEIGHT ANDMEDICATIONMANAGEMENTAT DISCHARGE ASSESSMENTOFLEFTVENTRICULARSYSTOLIC FUNCTION DOCUMENTED OR SCHEDULED  ANGIOTENSIN CONVERTINGENZYME!#% INHIBITORUSEATDISCHARGE IN PATIENTS CONSIDERED CANDIDATES FOR THIS THERAPY BASEDONACCEPTEDCLINICALCRITERIAAND COUNSEL INGONSMOKINGCESSATIONINCURRENTSMOKERS(UMAN SUBJECTS CONSIDERATIONS PATIENT CONlDENTIALITY SITE MONITORING ANDOTHERSPECIlCMETHODOLOGICALISSUES HAVEBEENPREVIOUSLYOUTLINEDINDETAIL ELSEWHERE

 ,"1 Ê Ê  -Ê,"ÊÊ / Ê  , Ê /" Ê, -/,9

)NSIGHTSFROM!$(%2% &ROM/CTOBERTHROUGH$ECEMBER   HEART FAILURE DISCHARGES WERE ENROLLED IN!$(%2% 4HE MEAN AGE OF PATIENTS WAS  YEARS AND  WEREWOMEN-OSTPATIENTSWEREWHITE ORBLACK  AND WERE COVERED BY -EDICARE OR -EDICAID  3EVENTY SIXPERCENTOFPATIENTSENROLLEDHADA PRIORHISTORYOFHEARTFAILUREANDONE THIRDHADAHISTO RYOFADMISSIONFOR!$(&WITHINTHEPRIORMONTHS !HISTORYOFHYPERTENSIONWASCOMMON ASWAS CORONARY ARTERY DISEASE  AND DIABETES   /THER IMPORTANT OR COMMON CO MORBID CONDITIONS INCLUDED HISTORY OF ATRIAL lBRILLATION  CHRONIC OBSTRUCTIVE PULMONARY DISEASE OR ASTHMA  ANDCHRONICRENALINSUFlCIENCY -OSTPATIENTS  PRESENTEDWITHDYSPNEA2ALESANDPERIPHERAL EDEMA WERE PRESENT IN  AND  OF THE CASES RESPECTIVELY /F PATIENTS WITH DOCUMENTED LEFT VEN TRICULAREJECTIONFRACTIONPRIORTOADMISSION HAD PRESERVEDORONLYMILDLYDEPRESSEDSYSTOLICFUNCTION 4HECHARACTERISTICSOFPATIENTSENROLLEDIN!$(%2% AREVERYDIFFERENTFROMTHOSEOFPATIENTSINCLUDEDIN CLINICALTRIALSQ/>LiÊ£R

/>LiÊ£°ÊÊ

œ“«>ÀˆÃœ˜ÊœvÊ*>̈i˜ÌÃÊ ˜Àœi`ʈ˜Ê,>˜`œ“ˆâi`Ê

œ˜ÌÀœi`Ê/Àˆ>ÃʜvÊ Ê6iÀÃÕÃÊ  , °

4HEMEDIANLENGTHOFSTAYFORALLHOSPITALIZEDPATIENTS WASDAYSMEANDAYS4HEIN HOSPITALMORTAL ITY RATE WAS   FOR PATIENTS WHO RECEIVED TREATMENT IN AN INTENSIVE CARE UNIT )#5  2EGISTRY DATAONTHE*#!(/QUALITYOFCAREINDICATORSSHOWED THAT ONLY  OF PATIENTS WERE GIVEN INSTRUCTION ON DIET WEIGHT MONITORING ACTIVITY LEVEL WORSENING SYMPTOMS FOLLOW UP APPOINTMENTS AND MEDICATION MANAGEMENT AT DISCHARGE !SSESSMENT OF LEFT VEN TRICULAR SYSTOLIC FUNCTION WAS EITHER DOCUMENTED OR SCHEDULEDINOFPATIENTS!TOTALOFOFTHE PATIENTS JUDGED ELIGIBLE TO RECEIVE AN!#% INHIBITOR BYSTANDARDCLINICALCRITERIAWEREDISCHARGEDONTHIS MEDICATION#OUNSELINGONSMOKINGCESSATIONFORCUR RENTSMOKERSWASGIVENTOOFELIGIBLEPATIENTS !$(%2%-ORTALITY!NALYSES 4ODATE TWOPRIMARYANALYSESOFMORTALITYHAVEBEEN PERFORMEDON!$(%2%4HESEINCLUDEACLASSIlCATION ANDREGRESSIONTREE#!24 ANALYSISINALLPATIENTSTO DElNECOVARIATEADJUSTEDODDSRATIOSOFDEATH AND AMULTIVARIABLEREGRESSIONANDPROPENSITYANALYSISIN PATIENTS RECEIVING )6 VASOACTIVE MEDICATIONS TO DE lNECOVARIATEADJUSTEDPROBABILITYOFTREATMENT  4HEFORMERANALYSISALLOWSTHEDEVELOPMENTANDVALI DATIONOFAPREDICTIVEMODELFORIN HOSPITALMORTALITY BASEDONPATIENTCHARACTERISTICSDISCERNEDATTHETIME



#HARACTERISTIC

#LINICAL4RIALS

!$(%2%



!VERAGE!GEYEARS

 





'ENDER7OMEN

 





)SCHEMIC%TIOLOGY







2ENAL)NSUFlCIENCY

5SUALLYEXCLUDED



0RESERVED,63YSTOLIC&UNCTION

5SUALLYEXCLUDED





!TRIAL&IBRILLATION







$IABETES

 





%MERGENCY$IAGNOSISAND4REATMENTOF !CUTE$ECOMPENSATED(EART&AILURE!$(&

OFPRESENTATION4HATIS THE#!24ANALYSISPROVIDES nFORTHElRSTTIMEnAWAYTOSTRATIFYPATIENTSFORRISK OF IN HOSPITAL MORTALITY 4HE LATTER ANALYSIS PERMITS THECOMPARISONOFTREATMENTCHOICEONOUTCOME3PE CIlCALLY THECOVARIATEANDPROPENSITYSCOREADJUSTED RISKOFIN PATIENTMORTALITYWASEVALUATEDBYTREATMENT STATUSCOMPARINGINTRAVENOUSDOBUTAMINE MILRINONE NESIRITIDE ANDNITROGLYCERINE )NORDERTODEVELOPAPRACTICALUSER FRIENDLYBEDSIDE TOOL FOR RISK STRATIlCATION FOR PATIENTS HOSPITALIZED WITH!$(& #!24 ANALYSIS OF THE!$(%2% DATA BASEWASPERFORMEDUSINGTHElRST DISCHARGES ENROLLED 4HE lRST   HOSPITALIZATIONS FROM /CTOBERTHROUGH&EBRUARY SERVEDASTHE DERIVATION COHORT AND WERE ANALYZED TO DEVELOP THE RISKPREDICTIONMODEL4HEN THEVALIDITYOFTHEMODEL WASPROSPECTIVELYTESTEDUSINGDATAFROM SUB SEQUENT HOSPITALIZATIONS VALIDATION COHORT ENROLLED IN!$(%2%FROM-ARCHTHROUGH*ULY)N HOSPITALMORTALITYWASSIMILARINTHEDERIVATION ANDVALIDATION COHORTS2ECURSIVEPARTITIONING OFTHEDERIVATIONCOHORTFORVARIABLESINDICATEDTHAT THE BEST SINGLE PREDICTOR FOR MORTALITY WAS HIGH AD MISSIONLEVELSOFBLOODUREANITROGEN*MGD,

ˆ}ÕÀiÊ£°ÊÊ   , Ê,ˆÃŽÊ ÃÃiÃÓi˜ÌÊ/ÀiiÊvÀœ“Ê

,/ʘ>ÞÈðÊÊ`>«Ìi`Ê vÀœ“Êœ˜>ÀœÜÊiÌÊ>]Ê °ÊÓääxÆәÎ\xÇӇ xnäÊ܈̅ʫiÀ“ˆÃȜ˜Ê vÀœ“Ê̅iÊ“iÀˆV>˜Ê i`ˆV>ÊÃÜVˆ>̈œ˜°

FOLLOWED BY LOW ADMISSION SYSTOLIC BLOOD PRESSURE   MM (G AND THEN BY HIGH LEVELS OF SERUM CREATININE*MGD, !SIMPLERISKTREEIDENTI lEDPATIENTGROUPSWITHMORTALITYRANGINGFROM TO  ­ˆ}ÕÀiÊ £® 4HE ODDS RATIO FOR MORTALITY BETWEENPATIENTSIDENTIlEDASHIGHANDLOWRISKWAS CONlDENCEINTERVAL   ANDSIMI LARRESULTSWERESEENWHENTHISRISKSTRATIlCATIONWAS APPLIEDPROSPECTIVELYTOTHEVALIDATIONCOHORT4HESE RESULTS SUGGEST THAT!$(& PATIENTS AT LOW INTERME DIATE AND HIGH RISK FOR IN HOSPITAL MORTALITY CAN BE EASILYIDENTIlEDUSINGVITALSIGNANDLABORATORYDATA OBTAINED ON HOSPITAL ADMISSION 4HE!$(%2% RISK ASSESSMENTTOOLPROVIDESCLINICIANSWITHAVALIDATED PRACTICALBEDSIDEINSTRUMENTFORMORTALITYRISKSTRATI lCATION3IMILARTOTHECONTEMPORARYAPPROACHTOTHE TRIAGEANDMANAGEMENTOFCHESTPAINPATIENTSBASEDON RISKASSESSMENTATPRESENTATION THE!$(%2%#!24 ANALYSISMAYULTIMATELYHELPDIRECTTHEPLACEMENTAND THERAPYOFPATIENTSPRESENTINGWITH!$(& 4O COMPARE IN HOSPITAL MORTALITY OF!$(& PATIENTS RECEIVINGPARENTERALTREATMENTWITHONEOFFOURINTRA VENOUSVASOACTIVEMEDICATIONS ARETROSPECTIVEANAL YSIS OF DATA FROM !$(%2% WAS PERFORMED $ATA

  

  

  

  

   

   

 

 



   

  

   

 

  



   

 ,"1 Ê Ê  -Ê,"ÊÊ / Ê  , Ê /" Ê, -/,9

WITH MILRINONE AND DOBUTAMINE RESPECTIVELY 4HE CORRESPONDING VALUES FOR NESIRITIDE COMPARED WITH MILRINONE AND DOBUTAMINE WERE  n P ) ANDn P) RESPECTIVELY 4HEADJUSTED/2FORNESIRITIDECOMPAREDWITHNITRO GLYCERINWASn P 4HUS THERA PYWITHEITHERANATRIURETICPEPTIDEORVASODILATORWAS ASSOCIATED WITH SIGNIlCANTLY LOWER IN HOSPITAL MOR TALITY THAN POSITIVE INOTROPIC THERAPY IN HOSPITALIZED !$(&PATIENTSIN!$(%2%4HERISKOFIN HOSPITAL MORTALITYWASSIMILARFORNESIRITIDEANDNITROGLYCERIN ­/>LiÊ Ó® 4HESE OBSERVATIONS ARE CONSISTENT WITH lNDINGS FROM RANDOMIZED CONTROLLED TRIALS AND SUP PORT THE USE OF VASODILATORS NESIRITIDE OR NITROGLYC ERIN ASlRST LINEINTRAVENOUSAGENTSFORTHETREATMENT OF!$(&4HESELECTIONOFASPECIlCINTRAVENOUSVA SODILATORMAYBEGUIDEDBYTHERESULTSOFRANDOMIZED CONTROLLEDTRIALS/FCOURSE INOTROPESMAYSTILLPLAY AROLEFORTHOSEWHOPRESENTINORINIMPENDINGCAR DIOGENICSHOCK

FROMTHElRST PATIENTEPISODESFROM/CTOBER THROUGH*ULY WEREINCLUDEDINTHISANALY SIS #ASES IN WHICH PATIENTS RECEIVED NITROGLYCERIN NESIRITIDE MILRINONE OR DOBUTAMINE WERE IDENTIlED ANDREVIEWEDN  TODETERMINEIFTHECHOICE OFINTRAVENOUSVASOACTIVETHERAPYAFFECTEDIN HOSPITAL MORTALITY3INCETHECHOICEOFTHERAPYWASNOTDIRECT EDBYAPROTOCOLBUTBYCLINICIANJUDGMENTORPREFER ENCE PROPERADJUSTMENTBASEDONFACTORSINmUENCING TREATMENT DECISION USING ADJUSTMENT FOR COVARIATES ANDPROPENSITYSCORING WEREMADE2ISKFACTORAND PROPENSITY SCORE ADJUSTED ODDS RATIOS /2S FOR IN HOSPITALMORTALITYWERECALCULATED 0ATIENTS WHO RECEIVED INTRAVENOUS NITROGLYCERIN OR NESIRITIDEHADLOWERIN HOSPITALMORTALITYTHANTHOSE TREATEDWITHDOBUTAMINEORMILRINONE4HERISKFACTOR ANDPROPENSITYSCORE ADJUSTED/2SFORNITROGLYCERIN WERECONlDENCEINTERVAL;#)=n P) ANDn P) COMPARED

/>LiÊÓ°Ê œÀÌ>ˆÌÞÊ"``ÃÊ,>̈œÃʈ˜Ê*>ˆÀ‡7ˆÃiÊ/Ài>̓i˜ÌÊ œ“«>ÀˆÃœ˜Ãʈ˜Ê̅iÊ  , Ê,i}ˆÃÌÀÞ°ÊÊ ,i«Àˆ˜Ìi`Ê܈̅ʫiÀ“ˆÃȜ˜ÊvÀœ“ÊLÀ>…>“ÊiÌÊ>]Ê

ÊÓääxÊ­˜Ê*ÀiÃî° !NALYSIS

.4'N VS -),N

.4'N VS $/"N

.%3N VS -),N

.%3N VS $/"N

.%3N VS .4'N

$/"N VS -),N

5NADJUSTED

  o

  o

  o

  o

  o

  o

!DJUSTEDFORCOVARIATES\\

  o

  o

  o

  o

  p

  e

!DJUSTEDFORCOVARIATES ANDPROPENSITYSCOREr

  o

  o

  o

  o

  p

  e

XCLUDEFROMAHPI TNSKGBW 0

WISEANLY

ATION DYSPE123MUR 6%& 5. ," 3"0 -), .4'VS

o

P   p P  e P    OR F AR ITE V CO ADJUSTMEN AND   OR F AR ITE V CO AND SCORE ADJUSTMEN SODIUM5.CREATN" \ $"0 X 3"0ASERITNCLUDGV#O AND YSP E  r YTREAMNCOPISLUDHBV# 6%& EIGHT ,WA5.CRNSODUM" 3"0 $/ .%VS EIGHT DYSPNAW 6%& ,AGE 3"0 -), .%VS AT SYMPODUR 6%& 5. HEARSODIUM",T 3"0 $/ .4'VS

PROENSITY HEAR T ISONARE ED MA ION

ASCULRIZTONVEP ED NOITARUMPYS &%6 , ENITARC.5" 0"3 '4. SV3% 123MS  64& HEMOGLBINARDYSPT 3"0 -), $/VS .OTE W(OSMER ,H GDNFlT ES NOT SIGlCA T ELV MODELS ADJUSTE ORF RISK ACTOF ANDOR PROENSITYXC F $/"COMPAR!EISNUDWHT.4V' U L T I" PE C A S RO F W M N     H G ERONICTSDGlAU"FW 5."  LODB UREA NITOG$"0  DIASTOLC B PRESU$/" -),  MILRNOE .%3  NESIRTD .4'  NITROGLYCE /2  OD YCARDIlBLTENUH64&V LODPRSYTICB

MS RP AM &( OI S ORF THE ARITE DJUSVCO ATORPECUV AL U E S     Y P V  UTAMINE DOB DS ATIO R 3"0  ION



%MERGENCY$IAGNOSISAND4REATMENTOF !CUTE$ECOMPENSATED(EART&AILURE!$(&

-1,9

,  ,

-

2EGISTRIES SUCH AS !$(%2% MAY PROVIDE INSIGHTS THATCANNOTBEDISCERNEDFROMRANDOMIZEDCONTROLLED TRIALS(EARTFAILUREPATIENTSENROLLEDINCLINICALTRIALS ARE VERY DIFFERENT THAN HEART FAILURE PATIENTS IN THE COMMUNITY AS DEMONSTRATED BY THE CHARACTERISTICS OF MORE THAN   DISCHARGES FOR!$(& IN!$ (%2% 4HE !$(%2% REGISTRY PROVIDES IMPORTANT INSIGHTSINTO!$(&TREATMENTANDOUTCOMESTHATMAY FAVORABLYIMPACTFUTURECARE3PECIlCALLY ITPROVIDES USWITHAVALUABLERISK ASSESSMENTTOOLANDWITHIN SIGHTSINTOTHEEFFECTSOFTREATMENTSELECTIONONOUT COMESIN!$(&PATIENTS



"ONNEUX, "ARENDREGT** -EETER+ ETAL%STIMATINGCLINICAL MORBIDITYDUETOISCHEMICHEARTDISEASEANDCONGESTIVEHEART FAILURETHEFUTURERISEOFHEARTFAILURE!M*0UBLIC(EALTH  



'HALI*+ #OOPER2 &ORD%4RENDSINHOSPITALIZATIONRATES FORHEARTFAILUREINTHE5NITED3TATES  EVIDENCEFOR INCREASINGPOPULATIONPREVALENCE!RCH)NTERN-ED 



!MERICAN(EART!SSOCIATIONHEARTANDSTROKESTATISTICAL UPDATE$ALLAS4EX !MERICAN(EART!SSOCIATION



#UFFE-3 #ALIFF2- !DAMS+& ETAL3HORT TERMINTRAVENOUS MILRINONEFORACUTEEXACERBATIONOFCHRONICHEARTFAILUREA RANDOMIZEDCONTROLLEDTRIAL*!-! 



+RUMHOLZ(- 0ARENT%- 4U. ETAL2EADMISSIONAFTER HOSPITALIZATIONFORCONGESTIVEHEARTFAILUREAMONG-EDICARE BENElCIARIES!RCH)NTERN-ED 



/#ONNELL*"4HEECONOMICBURDENOFHEARTFAILURE#LIN#ARDIOL 3UPPL )))  



4HE3/,6$)NVESTIGATORS3TUDIESOFLEFTVENTRICULARDYSFUNCTION 3/,6$ ˆRATIONALE DESIGNANDMETHODSTWOTRIALSTHATEVALUATE THEEFFECTOFENALAPRILINPATIENTSWITHREDUCEDEJECTIONFRACTION !M*#ARDIOL 



&RANCIOSA*! !BRAHAM74 &OWLER- ETAL2ATIONALE DESIGNAND METHODSFORACOREGCARVEDILOL HEARTFAILUREREGISTRY#/(%2%  *#ARD&AIL 



!DAMS+& /#ONNOR#- /REN2- ETAL$EVELOPMENTOFA MULTICENTERHEARTFAILUREDATABASEINITIALREPORTFROMTHEUNITED INVESTIGATORSTOEVALUATEHEARTFAILURE*#ARD&AIL 

!CKNOWLEDGMENTS 4HE!$(%2%3CIENTIlC!DVISORY#OMMITTEE !$(%2% )NVESTIGATORSAND#OORDINATORS AND3CIOS)NC-EMBERSOF THE!$(%2%3CIENTIlC!DVISORY#OMMITTEEARE7ILLIAM 4!BRAHAM -$ &!#0 &!## 4HE/HIO3TATE5NIVERSITY (EART#ENTER #OLUMBUS /( +IRKWOOD&!DAMS *R -$ 5NIVERSITYOF.ORTH#AROLINA #HAPEL(ILL .# 2OBERT, "ERKOWITZ -$ 0H$ (ACKENSACK 5NIVERSITY (OSPITAL (ACKENSACK .* -ARIA2OSA#OSTANZO -$ -IDWEST(EART 3PECIALISTS .APERVILLE ), 4ERESA$E-ARCO -$ 5NIVER SITYOF#ALIFORNIA 3AN&RANCISCO #! #HARLES,%MERMAN -$ #LEVELAND#LINIC #LEVELAND /( 'REGG#&ONAROW -$ !HMANSON 5#,!#ARDIOMYOPATHY#ENTER ,OS!N GELES #! -ARIE'ALVAO -3. !.0 # -ONTElORE-EDI CAL#ENTER "RONX .9 *4HOMAS(EYWOOD -$ &!## ,OMA,INDA5NIVERSITY-EDICAL#ENTER ,OMA,INDA #! 4HIERRY(,E*EMTEL -$ !LBERT%INSTEIN(OSPITAL "RONX .9 ,YNNE7ARNER3TEVENSON -$ "RIGHAMAND7OMENS (OSPITAL "OSTON -! AND#LYDE79ANCY -$ &!## 5NIVERSITYOF4EXAS3OUTHWESTERN-EDICAL#ENTER-EDICAL #ENTER $ALLAS 48

 !DAMS+& &ONAROW'# %MERMAN#, ETALFORTHE!$(%2% 3CIENTIlC!DVISORY#OMMITTEEAND)NVESTIGATORS#HARACTERISTICS ANDOUTCOMESOFPATIENTSHOSPITALIZEDFORHEARTFAILUREINTHE 5NITED3TATESRATIONALE DESIGN ANDPRELIMINARYOBSERVATIONS FROMTHElRST CASESINTHE!CUTE$ECOMPENSATED(EART &AILURE.ATIONAL2EGISTRY!$(%2% !M(EART*   &ONAROW'# !DAMS+& !BRAHAM74 9ANCY#7 FORTHE !$(%2%3CIENTIlC!DVISORY#OMMITTEEAND3TUDY'ROUP2ISK STRATIlCATIONFORIN HOSPITALMORTALITYINACUTELYDECOMPENSATED HEARTFAILURECLASSIlCATIONANDREGRESSIONTREE#!24 ANALYSISOF THE!$(%2%2EGISTRY*!-!   !BRAHAM74 !DAMS+& &ONAROW'# ETAL FORTHE!$(%2% 3CIENTIlC!DVISORY#OMMITTEEAND)NVESTIGATORSANDTHE!$(%2% 3TUDY'ROUP)N HOSPITALMORTALITYINPATIENTSWITHACUTE DECOMPENSATEDHEARTFAILURETREATEDWITHINTRAVENOUSVASOACTIVE MEDICATIONSANANALYSISFROMTHE!$(%2%2EGISTRY*!M#OLL #ARDIOLINPRESS   0UBLICATION#OMMITTEEFORTHE6-!#)NVESTIGATORS)NTRAVENOUS NESIRITIDEVSNITROGLYCERINFORTREATMENTOFDECOMPENSATED CONGESTIVEHEARTFAILUREARANDOMIZEDCONTROLLEDTRIAL*!-!  

#OPYRIGHT%-#2%' )NTERNATIONAL 



- - Ê   /Ê"Ê 1/ Ê "* -/ Ê ,/Ê 1, \Ê/ Ê  , Ê  , 9Ê   Ê" 1 2ICHARD,3UMMERS -$ $EPARTMENTOF%MERGENCY-EDICINE 5NIVERSITYOF-ISSISSIPPI-EDICAL#ENTER *ACKSON -3

"  /6 -\ £°Ê ,iۈiÜÊ̅iʘiViÃÃ>ÀÞÊii“i˜ÌÃÊ>˜`Ê«ÀœViÃÃÊÀiµÕˆÀi`ÊvœÀÊ>ÊÜi‡œÀV…iÃÌÀ>Ìi`Ê`ˆÃi>ÃiÊ “>˜>}i“i˜ÌÊ«Àœ}À>“ Ó°Ê ˆÃVÕÃÃÊ̅iʜLiV̈ÛiÃ]Ê`iÈ}˜Ê>˜`ʏœ}ˆÃ̈VÃʜvÊ̅iÊ  , Ê “iÀ}i˜VÞÊi`ˆVˆ˜iÊœ`Տi

 /," 1 /" !MAJORFACTORLIMITINGTHELONG TERMEFlCACYOFCURRENTCONGESTIVEHEARTFAILURE#(& TREATMENT STRATEGIES IS A LACK OF COMPELLING DATA CONlRMING WHICH APPROACHES AND THERAPIESWORKBESTINMOSTCLINICALSITUATIONS3TUDIESHAVESHOWNTHATTHECAREGIVEN TO#(&PATIENTSVARIESWIDELY BASEDONTHELOCATIONWHEREPATIENTSRECEIVETREATMENT ANDTHESPECIALTYOFTHEPHYSICIANWHOTREATSTHEM)NTHEABSENCEOFANYESTABLISHED STANDARDSORBEST PRACTICEGUIDELINES PHYSICIANSHAVELITTLEEVIDENCEONWHICHTOBASE TREATMENTDECISIONS"ECAUSEOFTHISLACKOFCONSENSUSSTANDARDS MANY#(&PATIENTS RECEIVE LESS THAN OPTIMAL CARE4HE .ATIONAL 2EGISTRY!$(%2% IS THE lRST NATIONAL REGISTRYTHATPROSPECTIVELYCOLLECTSOBSERVATIONALDATAFROMACROSSTHE5NITED3TATESIN ORDERTOTRACKANDSTUDYTHEMEDICALMANAGEMENTOFPATIENTSHOSPITALIZEDWITHACUTE DECOMPENSATEDHEARTFAILURE!$(& !$(%2%ISSPONSOREDBY3CIOSANDOVERSEEN BYANINDEPENDENTSCIENTIlCADVISORYCOMMITTEEOFNATIONALLYRECOGNIZEDHEARTFAILURE EXPERTS4ODATE MORETHANHOSPITALSANDMORETHAN PATIENTCASESHAVE BEENENTEREDINTOTHE!$(%2%REGISTRY MAKINGITTHELARGEST MOSTEXTENSIVEREGISTRY OFITSKIND

/…iÊ >̈œ˜>Ê,i}ˆÃÌÀÞÊ   , ʈÃÊ̅iÊwÀÃÌÊ ˜>̈œ˜>ÊÀi}ˆÃÌÀÞÊ̅>ÌÊ «ÀœÃ«iV̈ÛiÞÊVœiVÌÃÊ

4HEORIGINALREGISTRYISREFERREDTOASTHE #ORE 2EGISTRY !S INTEREST IN THE LONG TERMOUTCOMESOFTHESEPATIENTSEMERGED THE,ONGITUDINAL-ODULEWASDEVELOPED TO FOLLOW THE COURSE OF THESE PATIENTS BEYOND THE IMMEDIATE HOSPITALIZATION AND INTO THE OUTPATIENT SETTING -ORE RECENTLY THE!$(%2%$ISEASE-ANAGE MENT 1UALITY )NITIATIVE FOR #ARE "EGIN NINGINTHE%MERGENCY$EPARTMENT-OD ULE!$(%2%%$$- WASINITIATEDTO GIVE INSIGHT INTO THE TREATMENT PATTERNS AND OVERALL QUALITY OF DISEASE MANAGE MENT $- OF!$(& IN THE EMERGENCY SETTING

$ISEASE-ANAGEMENT 4RADITIONAL APPROACHES TO THE TREATMENT OFDISEASEHAVEBEENAhCOMPONENT BASED MANAGEMENT MODELv WHEREBY SELECTED PORTIONS OF THE DISEASE ARE MANAGED BY CERTAIN SPECIALISTS THAT ADDRESS SPECIlC ASPECTS OF THE PATIENTS ILLNESS )N THIS SYSTEM THE INTERNIST OR CARDIOLOGIST FO CUSES ON THE LONG TERM MANAGEMENT OF #(&WHEREASTHEEMERGENCYPHYSICIANIS CONCERNEDWITHTHEACUTESTABILIZATIONOF ADECOMPENSATEDSTATE4HENEWERCON CEPTSOFDISEASEMANAGEMENTINCORPORATE THE ENTIRE SPECTRUM OF PATIENT CARE AND INCLUDE THE FULL USE OF ANCILLARY HEALTH

œLÃiÀÛ>̈œ˜>Ê`>Ì>Ê vÀœ“Ê>VÀœÃÃÊ̅iÊ1˜ˆÌi`Ê -Ì>ÌiÃʈ˜ÊœÀ`iÀÊÌœÊ ÌÀ>VŽÊ>˜`ÊÃÌÕ`ÞÊ̅iÊ “i`ˆV>Ê“>˜>}i“i˜ÌÊ œvÊ«>̈i˜ÌÃÊ …œÃ«ˆÌ>ˆâi`Ê܈̅Ê>VÕÌiÊ `iVœ“«i˜Ã>Ìi`ʅi>ÀÌÊ v>ˆÕÀiÊ­ ®°



%MERGENCY$IAGNOSISAND4REATMENTOF !CUTE$ECOMPENSATED(EART&AILURE!$(&

CAREANDSOCIALSERVICES"ECAUSE!$(&PATIENTSHAVE ACOMBINATIONOFBOTHANACUTEANDCHRONICCONDITIONIT ISIMPORTANTTOBEGINTOCONSIDERTHELONGITUDINALCOURSE OFTHEIRMANAGEMENTEVENASWEBEGINTHESTABILIZATION PROCESSINTHEEMERGENCYDEPARTMENT%$ 4HISCON SIDERATIONHASBECOMEMOREIMPORTANTINRECENTYEARS ASTHE%$HASBECOMETHESAFETY NETANDPRIMARYCARE PROVIDERFORMANYOFTHESEPATIENTS)TISNOTUNCOM MONFOR!$(&PATIENTSTOBECOMEFREQUENTPATIENTS INOUREMERGENCYDEPARTMENTS"YDEFAULT THEEMER GENCY PHYSICIAN THEN BECOMES RESPONSIBLE FOR THEIR OVERALLCAREANDMUSTCONSIDERISSUESSUCHASACCESSTO OUTPATIENTMEDICATIONS THERAMIlCATIONSOFTHEIRINPA TIENTMANAGEMENTANDTHELONGITUDINALIMPACTOFEARLY TREATMENT DECISIONS WITHIN THE EMERGENCY SETTING  4HEREISCONSIDERABLEEVIDENCETOSUGGESTTHATTHETREAT MENTPLANINITIATEDBYTHEEMERGENCYPHYSICIANHASA SIGNIlCANTIMPACTONTHELONG TERMOUTCOMESOFOTHER COMMON DISEASE PROCESSES SUCH AS PNEUMONIA AND ACUTE CORONARY SYNDROMES )T IS REASONABLE TO EXPECT THATTHESAMEWOULDBETRUEINTHETREATMENTOF!$(&  4HERE ARE TYPICALLY THREE COMMON ELEMENTS TO ANY WELL ORCHESTRATEDDISEASEMANAGEMENTPROGRAM  )DENTIFYPATIENTSATELEVATEDRISKOFADVERSE OUTCOMES  )NTERVENTIONTOREDUCETHOSERISKS  3YSTEMATICEVALUATIONTOASSESSTHEIMPACTOFTHE INTERVENTION

ˆ}ÕÀiÊ£°Ê /…iÊVœ˜}iÃ̈œ˜Ê>˜`ÊyՈ`ÊÀiÌi˜Ìˆœ˜Ê œvÊ̅iʅi>ÀÌÊv>ˆÕÀiÊÃÌ>ÌiʈÃÊ>Ê ˜>ÌÕÀ>Ê«…ÞȜœ}ˆVÊ>`ÕÃ̓i˜ÌÊÌœÊ >Ê`ÞÃv՘V̈œ˜>Ê-Ì>Àˆ˜}‡6i˜œÕÃÊ ,iÌÕÀ˜ÊÀi>̈œ˜Ã…ˆ«°Ê "ÊrÊV>À`ˆ>VÊ œÕÌ«ÕÌ°Ê6,ÊrÊÛi˜œÕÃÊÀiÌÕÀ˜



'OODDISEASEMANAGEMENTPRACTICEALSOREQUIRESTHE PHYSICIANTOTHINKABOUTTHEPATIENTSPATHOLOGYFROM BOTHTHESHORT TERMANDLONG TERMMANAGEMENTPER SPECTIVES4HIS IS PARTICULARLY IMPORTANT WHEN TREAT ING CHRONIC DISEASES SUCH AS #(& DUE TO THE DIFFER ENCES IN THE PATHOPHYSIOLOGIC MECHANISMS INVOLVED IN THE ACUTE AND CHRONIC PRESENTATIONS #(& IN ITS ACUTELY DECOMPENSATED FORM IS PRIMARILY A PROBLEM OFPLUMBING7ITHINTHEVASCULARCONDUITSINVOLVED IN!$(& THEREISAMISMATCHINTHEPRESSURES RESIS TANCESANDmUIDVOLUMESREQUIREDTOMAINTAINBLOOD mOWORCARDIACOUTPUTWHICHFURTHERRESULTSINACON GESTIVE STATE THAT LIMITS OXYGENATION BY THE LUNGS 4HISCONDITIONHASTHEPOTENTIALFORPOSITIVEFEEDBACK ANDCANRAPIDLYSPIRALTOANUNSTABLESTATE4RADITIONAL THERAPIESSUCHASNITROGLYCERIN MORPHINEANDDIURET ICS CAN AMELIORATE THE CONGESTION BY MANIPULATION OFTHEACUTEPLUMBINGDERANGEMENT4HERESULTISA DRAMATIC CHANGE IN THE IMMEDIATE CLINICAL SITUATION ANDTHEPATIENTOFTENAPPEARSALMOSTBACKTONORMAL INTERMSOFSYMPTOMS(OWEVER DESPITETHISILLUSION OFSTABILITY THECHRONICPATHOPHYSIOLOGYOF#(&AND THE UNDERLYING CAUSE OF THE DECOMPENSATION IS STILL PRESENT 4HECONGESTIONANDmUIDRETENTIONOFTHE HEARTFAILURESTATEISANATURALPHYSIOLOGICADJUSTMENT TO A DYSFUNCTIONAL 3TARLING 6ENOUS 2ETURN RELATION SHIPANDISNECESSARYTOBRINGCARDIACOUTPUTBACKTO NORMAL­ˆ}ÕÀiÊ£®  4HECOSTOFTHISADJUSTMENTIS

- - Ê   /Ê"Ê 1/ Ê "* -/ Ê ,/Ê 1, \Ê/ Ê  , Ê  , 9Ê   Ê" 1

HIGHER ATRIAL PRESSURES THAT CAN LEAD TO PULMONARY EDEMA AND DYSPNEA WHICH BRINGS THE PATIENT ACUTELY TO THE %$ )F THISMECHANISMISNOTTAKENINTOCONSID ERATION IN THE DISPOSITION OF STABILIZED !$(& PATIENT THEN THERE IS TREMENDOUS POTENTIAL FOR OVERALL TREATMENT FAILURE 0ROPERDISEASEMANAGEMENTALSOREQUIRES AGLOBALPERSPECTIVEOFALLASPECTSOFTHE PATIENTSPATHOPHYSIOLOGYTOBESUCCESS FUL )N THE PAST FEW DECADES WE SAW AN EM PHASISONANEVIDENCE BASEDAPPROACHTO $-WITHAFOCUSONUTILIZINGRESULTSFROM CLINICALTRIALSTODICTATETHEBESTTREATMENT OPTIONSFORPATIENTSWITHSPECIlCDISEASE STATES OR PRESENTATIONS -ORE RECENTLY WEHAVEBEGUNTOREALIZETHENECESSITYOF BALANCING THIS POPULATION BASED PROBA BILISTIC VIEW OF TREATMENT WITH A SCIEN TIlC ORIENTEDANALYSISOFTHEPHYSIOLOGIC NUANCES OF THE INDIVIDUAL PATIENT IN A GOALDIRECTEDAPPROACHTOMANAGEMENT !$(&$-ISESPECIALLYAMENABLETOTHIS NOTIONSINCETHEREISLITTLECURRENTTRIALS BASED INFORMATION AND THE PATHOPHYSI OLOGIC SPECTRUM OF DISEASE PRESENTATION IS VARIED (OWEVER AS WE DEVELOP AN EMERGENCYMEDICINE!$(&$-STRATEGY ITISIMPORTANTTHATWELOOKATTHEPROCESS AS A WHOLE AND THE IMPACT OF TREATMENT PLANSONOUTCOMES &ORALLTHESEREASONSAREGISTRYTHATTRACKS THE COURSE OF PATIENTS WITH!$(& FROM THEEMERGENCYMEDICINEPERSPECTIVECAN BEINSTRUMENTALINDElNINGTHEBESTPRAC TICESFORFUTURE$-

!$(%2%%MERGENCY-EDICINE -ODULE 4HE !$(%2% %MERGENCY -EDICINE -ODULE IS EXPECTED TO BE THE VEHICLE THROUGH WHICH A COMPREHENSIVE DISEASE MANAGEMENT PROCESS IS DEVELOPED FROM THE UNIQUE PERSPECTIVE OF EMERGENCY MEDICINEASASPECIALTY"UILDINGONPRIOR !$(%2%PROGRAMS THISMODULEWASDE SIGNEDBYEMERGENCYPHYSICIANSWITHTHE INTENTIONOFANSWERINGSPECIlCQUESTIONS OFINTERESTTOTHOSEMANAGING!$(&PA TIENTSTHATPRESENTTOTHE%$ANDFOLLOWS THEIRHOSPITALCOURSEANDOUTCOMES 0ROGRAM/BJECTIVES 4HEMAINOBJECTIVESOF!(%2%%$$- ARE  $EVELOPALARGECLINICAL!$(& DATABASEFROMACUTECAREHOSPITALS ACROSSTHE5NITED3TATES  %XAMINETHECURRENTNATIONALSTATE OFMEDICALMANAGEMENTOFPATIENTS PRESENTINGTOTHE%$FOR!$(&  #OMPAREPREPOSTOUTCOMESOF IMPLEMENTATIONOFA$ISEASE -ANAGEMENTPROGRAMFOR%$ PRESENTATIONSOF!$(&

ÃÊÜiÊ`iÛiœ«Ê>˜Ê i“iÀ}i˜VÞʓi`ˆVˆ˜iÊ  Ê ÊÃÌÀ>Ìi}ÞʈÌʈÃÊ ˆ“«œÀÌ>˜ÌÊ̅>ÌÊÜiʏœœŽÊ >ÌÊ̅iÊ«ÀœViÃÃÊ>ÃÊ>Ê Ü…œiÊ>˜`Ê̅iÊÊ ˆ“«>VÌʜvÊÌÀi>̓i˜ÌÊ «>˜Ãʜ˜ÊœÕÌVœ“ið

3OMEOFTHESECONDARYOBJECTIVESINCLUDE  !SSISTHOSPITALSINEVALUATINGAND IMPROVINGQUALITYOFCAREBY A TRACKINGQUALITYINDICATORS B PROVIDINGMONTHLYANDQUARTERLY SITESPECIlCAND5NITED3TATES BENCHMARKDATA  #HARACTERIZETRENDSOVERTIMEINTHE MANAGEMENTOF!$(&



%MERGENCY$IAGNOSISAND4REATMENTOF !CUTE$ECOMPENSATED(EART&AILURE!$(&

 &ORTHE!$(&PATIENTINAN%$ SETTING A $ESCRIBEDEMOGRAPHICANDCLINI CALCHARACTERISTICSOF!$(& B #HARACTERIZETHEINITIAL%$ EVALUATIONSUBSEQUENTMAN AGEMENT C )DENTIFYCHARACTERISTICSAND MEDICALCAREASSOCIATEDWITH IMPROVEDOUTCOMES

œ“«œ˜i˜ÌÃʜvÊ̅iÊ Ê Ê«Àœ}À>“ʈ˜VÕ`i\ £°Ê /Ài>̓i˜ÌÊ>}œÀˆÌ…“ÃÊ Ó°Ê "À`iÀÊ-iÌÃ Î°Ê *…ÞÈVˆ>˜É, Ê i`ÕV>̈œ˜ {°Ê *>̈i˜ÌÊ `ÕV>̈œ˜ x°Ê ˆÃV…>À}iʘÃÌÀÕV̈œ˜Ã È°Ê ii`L>VŽÊœœ«Ê­`>Ì>Ê “œ˜ˆÌœÀˆ˜}Ê̜œÃ®

0ROGRAM$ESIGN /VERVIEW4HE STUDY DESIGN IS THAT OF A MULTI CENTER CONTINUOUS OBSERVATIONAL QUALITY IMPROVEMENT INITIATIVE FOCUSING ON THE MANAGEMENT OF PATIENTS TREATED IN THE HOSPITAL FOR!$(& IN THE 5NITED 3TATES WITH AN EMPHASIS ON EMERGENCY MEDICAL CARE )T IS EXPECTED THAT THERE WILLAPPROXIMATELYHOSPITALSPARTICI PATING CONTINUOUSLY ENROLLING PATIENTS FORABOUTMONTHSORUPTO PA TIENTEPISODES3ITESAREELIGIBLETOPAR TICIPATE IF THEY ARE A CURRENT !$(%2% SITEORIFTHEYAREINTHETOP LARGEST 5NITED3TATESACUTECAREHOSPITALSWITHA MEDIANNUMBEROFANNUAL(&DISCHARGES OF^PATIENTS3ELECTEDACADEMICAND COMMUNITYHOSPITALSWILLBEEQUALLYDIS TRIBUTEDALONGTHESPECTRUMOF(&PATIENT VOLUMEANDGEOGRAPHY#OMPONENTSOF THE%$$-PROGRAMINCLUDE      



4REATMENTALGORITHMS /RDER3ETS 0HYSICIAN2.EDUCATION 0ATIENT%DUCATION $ISCHARGE)NSTRUCTIONS &EEDBACKLOOPDATAMONITORING TOOLS

0ATIENTPOPULATION0ATIENTELIGIBILITYIS NOTLINKEDTOASPECIlCTHERAPEUTICAGENT OR REGIMEN 0ATIENTS ELIGIBLE FOR ENTRY INTOTHE!$(%2%2EGISTRYINCLUDETHOSE OVER THE AGE OF  ADMITTED TO AN ACUTE CARE HOSPITAL AND TREATED ACTIVELY FOR !$(& EITHERASANEWONSETWITHDECOM PENSATIONORASCHRONICHEARTFAILUREWITH DECOMPENSATION4HISWOULDINCLUDETHOSE PATIENTS WHO RECEIVE A PRINCIPAL %$ OR HOSPITALDISCHARGEDIAGNOSISOF!$(&OR ISDIAGNOSEDCLINICALLYANDISDOCUMENTED INTHE$2'CODES0ATIENTSAREEXCLUDED IF!$(&ISACOnMORBIDCONDITION BUTIS NOTAPRINCIPALFOCUSOFDIAGNOSISORTREAT MENTDURINGTHE%$ORHOSPITALEPISODE 3TAFFAND)NSTITUTIONALREQUIREMENTS  3ITESMUSTCOMMITTOUTILIZINGA $-STRATEGYANDWILLBEREQUIRED TOIMPLEMENTATLEASTTHREEOFlVE COMPONENTSLISTEDBELOW  %ACHSITEMUSTHAVE s /NE%$0HYSICIANASTHE0RINCIPAL OR#O PRINCIPALINVESTIGATOR s /NEDEDICATED2EGISTRY #OORDINATOR A 2EQUIRESACCESSTOALL%$AND HOSPITALCHARTDATA B #ANPERFORMELECTRONICDATA CAPTURE%$# ENTRY s )NPATIENTPHYSICIANSSUCHAS CARDIOLOGISTS A %NCOURAGEDTOPARTICIPATEAS A#O PRINCIPALINVESTIGATOR TOFACILITATEAFULLYINTEGRATED $-1UALITY)MPROVEMENT PROGRAM s %$(&ALGORITHM s (&ADMISSIONORDERS

- - Ê   /Ê"Ê 1/ Ê "* -/ Ê ,/Ê 1, \Ê/ Ê  , Ê  , 9Ê   Ê" 1

s 0ATIENTDISCHARGEINSTRUCTIONS s 0HYSICIAN(&EDUCATION s 0ATIENT(&EDUCATION $ATA#OLLECTION4HE!$(%2%2EGISTRYISALARGE

DATABASEOFPRIMARYCLINICALINFORMATIONCOLLECT EDFROMHOSPITALRECORDSOFPATIENTSATSELECTIN STITUTIONSNATIONWIDE.OPRIORREGISTRYHASCON DUCTEDRESEARCHATTHISLEVELONTHECLINICALCARE OF PATIENTS WITH!$(& 5SING MEDICAL RECORDS DATA ARE COLLECTED FROM THE POINT OF INITIAL CARE THROUGHPATIENTDISCHARGEFROMTHEHOSPITAL4HE REGISTRY IS COMPLETELY CONlDENTIAL AND ALL PA TIENTDATAAREKEPTANONYMOUSTHROUGHENCRYPTED TREATMENT$ATAINCLUDE % % % % % % % %

$EMOGRAPHICS %-3DATA -EDICALHISTORY )NITIALMEDICALEVALUATION (OSPITALCOURSE -EDICATIONS 0ROCEDURES

% %$#SYSTEMACCESSISCONTROLLEDBYTHEDATA COORDINATIONCENTERANDSYSTEMENTRYISLIMITED BYUSERNAMEPASSWORDnPROTECTEDLOGON PROCEDURES % (OSPITALSWILLBEPREVENTEDFROMACCESSING ELECTRONICCASEREPORTFORMSORAGGREGATEDATA FROMANYHOSPITALOTHERTHANTHEIROWN 4OFOLLOWTHEPATIENTACROSSRECURRINGVISITSTHE,ON GITUDINAL 5NIQUE )DENTIlER ,5)$ SYSTEM WILL BE UTILIZEDFORCONlDENTIALITY s

s

s

$ISPOSITION

4HEPROGRAMISDESIGNEDTOCOLLECTDATASURROUNDING THEEPISODEOFHOSPITALCARETHATBEGINSINTHE%$AS THEPOINTOFINITIALCAREANDENDSWITH%$ORHOSPITAL DISCHARGE TRANSFERORDEATH)FTHEINSTITUTIONISALSO APARTOFTHE!$(%2%CORETHEPATIENTMAYTRACKED UP TO  DAYS AFTER ADMISSION $ATA ARE COLLECTED THROUGHAN)NTERNET BASED%$#SYSTEM0ARTICIPATING INSTITUTIONSENTERDATAUSINGASTANDARDWEBBROWSER CONNECTEDTOAN%$#SYSTEMCUSTOMIZEDFORTHE!$ (%2%REGISTRY4HESYSTEMHASBEENFULLYTESTEDAND ISCOMPLIANTWITHFEDERALREGULATIONS % #&2 'UIDANCEON#OMPUTERIZED3YSTEMS USEDIN#LINICAL4RIALS AND)#('#0GUIDELINES % !LLSITESTAFFWILLBETRAINEDONTHESEREGULATIONS

s

#OMPUTERGENERATEDUNIQUEIDENTIlER A ,5)$ENCRYPTIONUSESTHE53&EDERAL 3TANDARD3(!  B 4HE,5)$ALGORITHMWILLBEINDEPENDENTLY VALIDATEDBY"OOZ!LLEN (OMELAND3ECURITY

)NFORMATION!SSURANCE #IVIL"USINESS 3EGMENT 7ITHAGIVENSETOFVARIABLES A,5)$IS GENERATEDTHATCANNOTBERELATEDBACKTOAN INDIVIDUAL 0ATIENTLEVELVARIABLESUSEDTOCONSTRUCTTHE ,5)$ARENOTSTOREDINTHESYSTEM ANDTHIS INFORMATIONCANNOTBEDE ENCRYPTEDFROMTHE ,5)$STOREDINTHEDATABASE 4HE,5)$ISSTOREDINTHEDATABASEALONGWITH PATIENTDATAANDALLOWSFORLONGITUDINALTRACKING OFHOSPITALREADMISSIONSANDPATIENTOUTCOMES

%NDPOINTS )N ORDER TO MEET THE OVERALL OBJECTIVES OF THE 0ROGRAM A NUMBER OF SPECIlC ENDPOINTS ARE TARGETEDFROMWITHINTHEDATACOLLECTIONPROCESS4HE MOSTIMPORTANTOFTHESEAREASOFFOCUSINCLUDE )MPACTOF$ISEASE-ANAGEMENT4OOLSON/UTCOMES s ,ENGTHOFSTAY SYMPTOMATOLOGY s 2ECIDIVISM TIMETOTREATMENT $ISPOSITIONOF0ATIENT s BASEDONPRESENTATIONPARAMETERSIE #R



%MERGENCY$IAGNOSISAND4REATMENTOF !CUTE$ECOMPENSATED(EART&AILURE!$(&

)MPACTOFDIURETICSRELATIVETOOUTCOMES s $OSEANDTIMING s $ElNINGWHICHPATIENTSARERESPONDERS "I0!0#0!0 s )MPACTONDRUGTHERAPY s )MPACTONSYMPTOMSOUTCOMES s /XYGEN3ATURATIONS 2ESOURCEUTILIZATION s "ENElTOFOBSERVATIONUNITS 4REATING0HYSICIANS s 0RIMARY#ARE 3PECIALISTSAND#ONSULTANTS 1UALITY )NITIATIVE 4HE!$(%2% 2EGISTRY ISSUES A "ENCHMARK2EPORTEACHQUARTERTOPARTICIPATINGCLIN ICS AND HOSPITALS 4HESE REPORTS SUMMARIZE REGISTRY DATACOLLECTEDONACUTEHEARTFAILURETREATMENTDURING THE PREVIOUS YEAR 4HE REPORTS ALSO MAKE AVAILABLE INSTITUTION SPECIlC REGIONAL AND NATIONAL STATISTICS SUCHASQUALITYINDICATORS TOPARTICIPATINGHOSPITALS INORDERTOHELPTHEMEVALUATEANDIMPROVETHECARE THEYPROVIDETOPATIENTS4HEGOALISFORTHEINDIVIDUAL HOSPITALTOUTILIZETHISINFORMATIONTOEFFECTCHANGEIN ORDERTOOPTIMIZEOVERALLDISEASEMANAGEMENT

,  ,



&ONAROW'#!$(%2%3CIENTIlC!DVISORY#OMMITTEE4HE!CUTE $ECOMPENSATED(EART&AILURE.ATIONAL2EGISTRY!$(%2%  OPPORTUNITIESTOIMPROVECAREOFPATIENTSHOSPITALIZEDWITHACUTE DECOMPENSATEDHEARTFAILURE2EV#ARDIOVASC-ED 3UPPL3 



0EACOCK7&2APIDOPTIMIZATIONSTRATEGIESFOROPTIMALCAREOF DECOMPENSATEDCONGESTIVEHEART FAILUREPATIENTSINTHEEMERGENCY DEPARTMENT2EV#ARDIOVASC-ED3UPPL3 



%MERMAN#, #OSTANZO-2 "ERKOWITZ2, #HENG- !$(%2% 3CIENTIlC!DVISORY#OMMITTEE%ARLYINITIATIONOF)6VASOACTIVE THERAPYIMPROVESHEARTFAILUREOUTCOMESANANALYSISFROMTHE !$(%2%2EGISTRYDATABASE!NN%MERG-ED 



0EACOCK7&(EARTFAILUREMANAGEMENTINTHEEMERGENCY DEPARTMENTOBSERVATIONUNIT0ROG#ARDIOVASC$IS  



'UYTON!#0HYSIOLOGYOFHEARTFAILURE4RANS!M#OLL#ARDIOL  



(ALL*% 'UYTON!# -IZELLE(,2OLEOFTHERENIN ANGIOTENSIN SYSTEMINCONTROLOFSODIUMEXCRETIONANDARTERIALPRESSURE!CTA 0HYSIOL3CAND3UPPL 



3UMMERS2, %VIDENCED BASEDMEDICINEVSSCIENTIlCREASONING !CAD%MERG-ED   



0EACOCK7& !LLEGRA* !NDER$ #OLLINS3 $IERCKS$ %MERMAN # +IRK*$ 3TARLING2 3ILVER- 3UMMERS2,-ANAGEMENT OF!CUTE$ECOMPENSATED(EART&AILUREINTHE%MERGENCY $EPARTMENT#ONG(EART&AILSUPPL  

-1,9\ !$(& IS EXPECTED TO BECOME ON THE MOST DIFlCULT MEDICALANDlNANCIALPROBLEMSFACINGOURHEALTHCARE SYSTEMS 0RELIMINARY EVIDENCE FROM THE !$(%2% #ORE 2EGISTRY AND A NUMBER OF OTHER CLINICAL TRIALS INDICATETHATTHEEMERGENCYDEPARTMENTSHOULDBETHE FOCAL POINT FOR THE DISEASE MANAGEMENT PROCESS OF !$(&4HE!$(%2%%$$-PROGRAMPRESENTSA REALOPPORTUNITYFORTHEEMERGENCYMEDICINECOMMU NITYTOBETTERUNDERSTANDTHEISSUESSURROUNDINGTHIS DISEASESTATEANDTOOBJECTIVELYOUTLINETHEBESTCOURSE FOROVERALLDISEASEMANAGEMENT

#OPYRIGHT%-#2%' )NTERNATIONAL 



 1/ Ê "* -/ Ê ,/Ê1, ÊÊ - - Ê   /Ê/""3EAN0#OLLINS -$ $EPARTMENTOF%MERGENCY-EDICINE 5NIVERSITYOF#INCINNATI#OLLEGEOF-EDICINE #INCINNATI /(

"  /6 -\ £°Ê ˆÃVÕÃÃÊVœ“«œ˜i˜ÌÃʜvÊi“iÀ}i˜VÞÊ`i«>À̓i˜Ìʅi>ÀÌÊv>ˆÕÀiÊ`ˆÃi>Ãiʓ>˜>}i“i˜ÌÊ̜œÃ

Ó°Ê /œÊ՘`iÀÃÌ>˜`ʅœÜÊ`ˆÃi>Ãiʓ>˜>}i“i˜ÌÊ̜œÃÊVœÕ`ʈ“«ÀœÛiÊ̅iÊV>ÀiʜvÊi“iÀ}i˜VÞÊ `i«>À̓i˜ÌÊ«>̈i˜ÌÃÊ܈̅ʅi>ÀÌÊv>ˆÕÀi

 /," 1 /" 4HERISINGPREVALENCEANDCOSTOFCAREFORHEARTFAILUREISSTAGGERING!LMOSTMILLION !MERICANSHAVEHEARTFAILURE WITH NEWCASESDIAGNOSEDEACHYEARATATOTAL COSTOFBILLION4HEINCIDENCEISEXPECTEDTOCONTINUETOINCREASEDRAMATICALLY DUETOOURAGINGPOPULATIONPREVALENCEOFHEARTFAILUREININDIVIDUALSOVERAGE  IMPROVEDSURVIVALFROMACUTECORONARYSYNDROMES!#3 ANDMANAGEMENTAD VANCES IN CARDIOVASCULAR DISEASES  (OSPITALIZATION ACCOUNTS FOR OVER  OF HEART FAILURECOSTS /VERHALFOFPATIENTSOLDERTHANYEARSWITHCONGESTIVEHEARTFAILURE #(& AREREADMITTEDWITHINMONTHSOFHOSPITALDISCHARGE 7HILEMEDICALRISKFACTORSAREWELLKNOWTOBEASSOCIATEDWITHHOSPITALREADMISSIONAGE INCREASEDLENGTH OF STAYANDNUMBEROFCOMORBIDITIES  OFTENOVERLOOKEDSOCIALFACTORS SUCHASSINGLEMARITALSTATUS READINESSFORDISCHARGE MEDICATIONANDDIETARYNONCOM PLIANCE ALSOINmUENCETHECHANCEOF#(&READMISSION (EARTFAILUREDISEASEMAN AGEMENT$- PROGRAMSAREDESIGNEDTOTARGETSOCIALRISKFACTORSRESULTINGINDECREASED RECIDIVISM (EART&AILURE$ISEASE-ANAGEMENT (EARTFAILURE$-PROGRAMSHAVEPROVEN TO BE EFFECTIVE AT REDUCING SUBSEQUENT READMISSIONSINTHOSEDISCHARGEDAFTERA #(&ADMISSION  )THASBEENSUGGEST EDTHAT$-PROGRAMSARENEARLYASEFFEC TIVE AS THAT SEEN WITH ANGIOTENSIN CON VERTINGENZYMEINHIBITORS BETA BLOCKERS OR DIGOXIN $- PROGRAMS STRESS THE NEED FOR COORDINATED COMPREHENSIVE CARE BOTH DURING HOSPITALIZATION AND AF TERDISCHARGE4HEYGENERALLYCONSISTOFA MULTI FACETEDAPPROACHINCLUDINGPATIENT EDUCATION AND TEACHING DIETARY ASSESS

MENT MEDICATIONANALYSISANDSOCIALSER VICESCONSULTATION4HESEPROCESSESHAVE TRADITIONALLYOCCURREDONCETHEPATIENTIS HOSPITALIZED

i>ÀÌÊv>ˆÕÀiÊ Ê «Àœ}À>“Ãʅ>ÛiÊ«ÀœÛi˜Ê ̜ÊLiÊivviV̈ÛiÊ>ÌÊ Ài`ÕVˆ˜}ÊÃÕLÃiµÕi˜ÌÊ Ài>`“ˆÃȜ˜Ãʈ˜Ê̅œÃiÊ `ˆÃV…>À}i`Ê>vÌiÀÊ>ÊÊ

Ê>`“ˆÃȜ˜°

7HY$ISEASE-ANAGEMENTINTHE%$ "ECAUSETHEEMERGENCYDEPARTMENT%$ ISTHEPORTALFOROFHOSPITALADMIS SIONS FOR HEART FAILURE IT REPRESENTS AN IDEALPLACETOBEGINA$-PROGRAM#(& PATIENTS DISCHARGED DIRECTLY FROM THE %$ HAVE A HIGH RATE OF RECIDIVISM AND DISEASE MANAGEMENT MAY HELP AVOID UNNECESSARY READMISSIONS  4HOSE PA 

%MERGENCY$IAGNOSISAND4REATMENTOF !CUTE$ECOMPENSATED(EART&AILURE!$(&

TIENTS MANAGED IN AN OBSERVATION UNIT /5 RECEIVE DElNITIVE CARE INCLUDING MEDICATIONADJUSTMENTANDFOLLOW UPAR RANGEMENTS AND$-HASBEENSUGGESTED TOIMPACTRECIDIVISMINTHESEPATIENTS  7HETHERITISINITIATIONOF#(&STANDARD IZEDORDERSFORANINPATIENTADMISSION OR COMPREHENSIVEEDUCATION ANDTEACHINGIN THEPATIENTDISCHARGEDFROMTHE%$OR/5 DISEASE MANAGEMENT CAN BE POTENTIALLY INITIATEDONEVERY%$PATIENTWITH#(&

HOURSOFHOSPITALADMISSIONHAVEADECREASEDLIKELIHOODOFIN HOSPITAL MORBIDITYANDMORTALITYCOMPAREDWITHTHOSEPATIENTSTHATRECEIVETREAT MENTAFTERHOURSP ­/>LiÊ £® 0ATIENTSWITHPNEUMONIA THATRECEIVEANTIBIOTICSWITHINHOURSOFHOSPITALARRIVALHAVEAREDUCED HOSPITAL LENGTH OF STAY ,/3 AND IN HOSPITAL MORTALITY ­/>LiÊ Ó® ! SEPARATEANALYSISFOUNDTHATAFTERADJUSTMENTFORCLINICALANDDEMOGRAPHIC VARIABLES INITIAL ANTIBIOTIC ADMINISTRATION IN THE %$ AND DOOR TO NEEDLE TIMEWASASSOCIATEDWITHREDUCED,/3

4HEIMPACTOFEARLY%$INTERVENTIONAND TREATMENTHASBEENSEENINOTHERDISEASE PROCESSES SUCH AS PNEUMONIA AND!#3 4HE#253!$%INITIATIVEHASSUGGESTED THAT THOSEPATIENTSWITHNON34 SEGMENT ELEVATION MYOCARDIAL INFARCTION .34% -) THAT RECEIVE TREATMENT WITH GLYCO PROTEIN '0 ))B)))A INHIBITORS WITHIN

,QKRVSLWDORXWFRPHVVWUDWLILHGE\WLPHWR,,E,,,DLQKLELWRUWUHDWPHQW

/>LiÊ£°



*3,,%,,,$K

1R*3,,E,,,DK



Q  

Q  

3

'HDWK  





5H ,QIDUFWLRQ  







&DUGLRJHQLF6KRFN  







&+)   5%&WUDQVIXVLRQ  















/>LiÊÓ° $QWLELRWLFDGPLQLVWUDWLRQZLWKLQKRXUVRIDUULYDODQGSDWLHQWRXWFRPHV VWUDWLILHGE\ULVNFODVVHV $GMXVWHGÁ $QWLELRWLF:LWKLQ K &,

$QWLELRWLF$IWHU K &,

$25 &,

39DOXH

GPRUWDOLW\ ,QKRVSLWDOPRUWDOLW\ /HQJWKRIVWD\aG GUHDGPLVVLRQ 36,ULVNFODVVHV,,DQG,,,

       

       

       

   

GPRUWDOLW\ ,QKRVSLWDOPRUWDOLW\ /HQJWKRIVWD\aG GUHDGPLVVLRQ

       

       

       

   

       

       

       

   

2XWFRPH0HDVXUHV $OOSDWLHQWV

36,ULVNFODVVHV,9DQG9 GPRUWDOLW\ ,QKRVSLWDOPRUWDOLW\ /HQJWKRIVWD\aG GUHDGPLVVLRQ



!BBREVIATIONS!/2 ADJUSTEDODDSRA TIO #) CONlDENCE INTERVAL /2 ODDS RATIO03) 0NEUMONIA3EVERITY)NDEX

0ATIENTS WITHOUT PREHOSPITAL ANTIBI OTICTREATMENT o5NIVARIATE ANALYSIS COMPARING THE ANTIBIOTICTIMINGSUBGROUPShWITHIN HvVShAFTERHv p-ULTIVARIATE ANALYSIS COMPARING THE ANTIBIOTICTIMINGSUBGROUPShWITHIN HvVShAFTERHvUSINGLOGISTICREGRES SION 4HE LOGISTIC REGRESSION MODEL INCLUDEDTHETIMINGOFINITIALANTIBIOTIC 03) ADMISSION TO THE INTENSIVE CARE UNIT CENSUSREGIONSOFHOSPITALIZATION RACEETHNICITY ANDOTHERPROCESSESOF CAREOXYGENATIONASSESSMENT BLOOD CULTUREWITHINHOURS ANDINITIALAN TIBIOTICCONSISTENTWITHCURRENTGUIDE LINES  !DAPTED AND REPRINTED WITH PERMISSION FROM (OUCK ET AL !RCH )NTERN-ED 

 1/ Ê "* -/ Ê ,/Ê1, ÊÊ - - Ê   /Ê/""-

%$(EART&AILURE$ISEASE-ANAGEMENT4OOLS 4HEREARESEVERALASPECTSTO%$DISEASEMANAGEMENT4HElRSTCOMPONENTISIMPLE MENTINGAN%$HEARTFAILURETREATMENTALGORITHM­ˆ}ÕÀiÊ £®#ATEGORIZINGAPATIENT BASED ON THEIR PERFUSION STATUS WARM VERSUS COLD mUID STATUS HYPERVOLEMIC EU VOLEMIC HYPOVOLEMIC ANDLEVELOFDISEASESEVERITYWILLHELPDICTATEINITIALTHERAPY 4HEMAJORITYOFPATIENTSWILLBEHYPERVOLEMICANDWELL PERFUSEDANDWILLRESPONDTO DIURETICSANDVASODILATORS 4HESECONDCOMPONENTOF$-ISTHEINTRODUCTIONOF%$#(&ADMISSIONORDERS!D MISSIONORDERSENSURECONTINUITYOFCAREFROMTHE%$TOTHEINPATIENTWARDWITHREGARD TOMEDICATIONS LABS ANDANCILLARYTESTS)TALSOENSURESTHATTHEPATIENTTHATSPENDSSEV ERALHOURSINTHE%$WAITINGFORANINPATIENTBEDISAPPROPRIATELYMANAGEDWHILECARE 6WDW('+)&RQVHQVXV3DQHO

(PHUJHQF\'HSDUWPHQW3DWLHQWZLWK6XVSHFWHG $FXWHRU'HFRPSHQVDWHG+HDUW)DLOXUH

,PPLQHQW5HVSLUDWRU\)DLOXUH$QWLFLSDWHG

<(6 2SWLRQV ",QRWURSHV "&RQVLGHU+HPRG\QDPLF 0RQLWRULQJ ",&8$GPLVVLRQ

iV>ÕÃiÊ̅iÊi“iÀ}i˜VÞÊ

<(6

&DUGLRJHQLF6KRFNRU 6\PSWRPDWLF+\SRWHQVLRQ"

3HUIRUP+LVWRU\DQG3K\VLFDO([DP

`i«>À̓i˜ÌʈÃÊ̅iÊ

2SWLRQV

<(6

"%L3$3&3$37ULDO "(QGRWUDFKHDO ,QWXEDWLRQ ",I%3HOHYDWHG &RQVLGHU5DSLG 9DVRGLODWLRQ ZLWK1LWURJO\FHULQ RU1LWURSUXVVLGH ",&8$GPLVVLRQ

«œÀÌ>ÊvœÀÊnä¯ÊÊ œvʅœÃ«ˆÌ>Ê>`“ˆÃȜ˜ÃÊ vœÀʅi>ÀÌÊv>ˆÕÀi]ʈÌÊ

+\SRSHUIXVLRQ FRROH[WUHPLWLHV RU$OWHUHG0HQWDO6WDWXV

12 &RQVLGHU2WKHU'LDJQRLVLV DQG7UHDWPHQW

12

'HFRPSHQVDWHG+HDUW)DLOXUH /LNHO\"

<(6 7KH(VWLPDWHRI6HYHULW\ ,V,QFUHDVHGE\ "$EGRPLQDO6LJQVRI2[LPHWU\ "+LVWRU\RI0XOWLSOH+)$GPLWV "%81!PJG/ "6%3PP+J "&UHDWLQLQH!PJG/ ":HLJKW$ERYH1RUPDO'U\:HLJKW "(&*ZLWK/9+(OHYDWHG%3 "l%81+\SRQDWUHPLD ".QRZQ/RZ(MHFWLRQ)UDFWLRQ "3RRU5HVSRQVHWR7KHUDS\

&ULWLFDO6HYHULW\ aRIDOO+)SDWLHQWV "2[\JHQ "/RRS'LXUHWLF "1HVLULWLGH1LWURJO\FHULQ RU1LWURSUXVVLGH

Ài«ÀiÃi˜ÌÃÊ>˜Êˆ`i>Ê

3HUIRUP:RUNXS "%13 "(&* "&;5 "26$7  "&DUGLDF0DUNHUV "&%& "(OHFWURO\WHV

«>ViÊ̜ʈ˜ˆÌˆ>ÌiÊ>ÊÊ Ê«Àœ}À>“°Ê

&RQFXUUHQW ZLWK:RUNXS ,QLWLDWH(DUO\(' 7KHUDS\%DVHGRQ &OLQLFDO(VWLPDWH RI6HYHULW\

0RGHUDWH6HYHULW\ aRIDOO+)SDWLHQWV

/RZ6HYHULW\ aRIDOO+)SDWLHQWV

"2[\JHQ "/RRS'LXUHWLF "1HVLULWLGH "1LWURSDVWHRU6/ 1LWURJO\FHULQSUQ "3DWLHQW(GXFDWLRQ

"2[\JHQ "1LWURSDVWHRU6/ 1LWURJO\FHULQSUQ "/RRS'LXUHWLFV7ULDO "3DWLHQW(GXFDWLRQ

,&8

ˆ}ÕÀiÊ£°Ê  Ê/Ài>̓i˜Ìʏ}œÀˆÌ…“°ÊՈ`iˆ˜iÃÊ vœÀÊ̅iÊi>ÀÞÊÃÌ>Lˆˆâ>̈œ˜Ê>˜`Ê`ˆÃ«œÃˆÌˆœ˜Ê œvÊ>VÕÌiÊ`iVœ“«i˜Ã>Ìi`ʅi>ÀÌÊv>ˆÕÀiÊ ˆ˜Ê̅iÊi“iÀ}i˜VÞÊ`i«>À̓i˜Ì°

7HOHPHWU\RU2EVHUYDWLRQ8QLW 2EVHUYDWLRQ8QLWRU0HGLFDO)ORRU

'LVFKDUJH+RPH



%MERGENCY$IAGNOSISAND4REATMENTOF !CUTE$ECOMPENSATED(EART&AILURE!$(&

ISTRANSITIONINGFROMTHEEMERGENCYPHYSICIANTOTHE ADMITTING TEAM4HERE ARE OTHER ADVANTAGES TO STAN DARDIZEDORDERS4HEAMOUNTOFEVOLVINGLITERATUREIS OVERWHELMING IN  THERE WERE   RANDOM IZED CONTROLLED TRIALS PUBLISHED 3TANDING ORDERS ENSUREGUIDELINECOMPLIANCEFROMTHELITERATURE YET ALLOWPHYSICIANSSOMEAUTONOMYBYALLOWINGFORIN DIVIDUALPATIENTADJUSTMENTS 4HETHIRDCOMPONENTOF$-ISTHECOMPLETIONOFAPA TIENTDISCHARGECHECKLIST4HISCHECKLISTISAMETHODOF ENSURINGTHOSEPATIENTSTHATMEETCRITERIAFORSPECIlC INTERVENTIONS MEDICATIONS SMOKING CESSATION CAR DIACREHABILITATION AREGIVENTHEAPPROPRIATEMEDICA TIONSANDINSTRUCTIONSUPONDISCHARGE4HEINSTITUTION OFADISCHARGEMEDICATIONPROGRAMATHOSPITALSIN 5TAHWASASSOCIATEDWITHDRAMATICIMPROVEMENTSIN APPROPRIATE DISCHARGE PRESCRIPTIONS AND THE RELATIVE RISKOFDEATHANDREADMISSIONAT DAYSAND YEAR AFTERHOSPITALDISCHARGE­ˆ}ÕÀiÃÊ ÓÊ >˜`Ê Î®4HIS PROGRAM FOCUSED ON NURSING INITIATED DOCUMENTA TIONOFAPPROPRIATEMEDICATIONSUPONDISCHARGEFROM THEHOSPITAL7HENANAPPROPRIATEMEDICINEWASNOT PRESCRIBEDATDISCHARGE THEDISCHARGE PLANNINGNURSE

ˆ}ÕÀiÊÓ°Ê *Àœ«œÀ̈œ˜Ê œvÊ «>̈i˜ÌÃÊ ÀiViˆÛˆ˜}Ê Ì…iÊÊ >««Àœ«Àˆ>ÌiÊ`ˆÃV…>À}iÊ«ÀiÃVÀˆ«Ìˆœ˜Ã° /…iÊ xÊ Ì>À}iÌi`Ê “i`ˆV>̈œ˜ÃÊ ÜiÀiÊ }ˆÛi˜Ê >ÃÊ ˆ˜`ˆV>Ìi`Ê ÌœÊ «>̈i˜ÌÃÊ ÜˆÌ…œÕÌÊ`œVՓi˜Ìi`ÊVœ˜ÌÀ>ˆ˜`ˆV>̈œ˜ÃÊ LivœÀiÊ >˜`Ê “œÀiÊ Ì…>˜Ê ÎÊ Þi>ÀÃÊ >vÌiÀÊ ˆ“«i“i˜Ì>̈œ˜Ê œvÊ̅iÊ `ˆÃV…>À}iÊ “i`ˆV>̈œ˜Ê «Àœ}À>“Ê ­£™™nÊ >˜`Ê ÓääÓ]Ê ÀiëiV̈ÛiÞ®°Ê >Ì>Ê vœÀÊ £™™nÊ >˜`ÊÓääÓÊÜiÀiÊVœiVÌi`Ê̅ÀœÕ}…Ê̅iÊ Ã>“iÊ «ÀœViÃÃ°Ê 

ÊrÊ>˜}ˆœÌi˜Ãˆ˜‡ Vœ˜ÛiÀ̈˜}Ê i˜âޓi°Ê Ê ,i«Àˆ˜Ìi`Ê ÜˆÌ…Ê «iÀ“ˆÃȜ˜Ê vÀœ“Ê >««iÊ iÌÊ >°Ê ˜˜Ê ˜ÌiÀ˜Êi`ÊÓää{ÆÊ£{£­È®\{{È°



CONTACTEDTHEATTENDINGPHYSICIANORRESIDENTDIRECTLY AFTERWHICHTHEMISSINGMEDICATIONCOULDBEADDEDTO THEDISCHARGELISTIFTHEREWERENOCONTRAINDICATIONS 4HE lNAL COMPONENT OF $- IS PATIENT EDUCATION 5NLIKEOTHERACUTEINPATIENTDISEASEPROCESSSUCHAS PNEUMONIA AND PYELONEPHRITIS ACUTE #(& EXACER BATIONS ARE TREATED UNTIL THE SUBJECT IS BACK TO THEIR BASELINE COMPENSATED STATE THE UNDERLYING DISEASE PROCESSISNEVERCOMPLETELYCURED!SARESULT PATIENT BEHAVIORAFTERHOSPITALIZATIONMAYHAVEATREMENDOUS INmUENCEONTHEPROGRESSIONOFTHEIRDISEASEPROCESS ANDSUBSEQUENTMORBIDITYANDMORTALITY)THASBEEN SUGGESTED THAT OVER  OF READMISSIONS ARE POSSI BLYORPROBABLYPREVENTABLE ANDTHATMEDICATIONAND DIETARY NONCOMPLIANCE INADEQUATE DISCHARGE PLAN NINGORFOLLOW UP FAILEDSOCIALSUPPORT ANDNOTREC OGNIZINGSYMPTOMRECURRENCEWEREABIGCONTRIBUTOR TOTHESEPREVENTABLEREADMISSIONS !$-PROGRAM THATEMPOWERSTHEPATIENTWITHKNOWLEDGEABOUTTHEIR DISEASEPROCESS APPROPRIATEFOLLOW UP ANDSIGNSOF DECOMPENSATION INCREASESTHELIKELIHOODOFAVOIDING READMISSIONS

 1/ Ê "* -/ Ê ,/Ê1, ÊÊ - - Ê   /Ê/""-

ˆ}ÕÀiÊΰ



DAYS

(&



#($



-)

 #!"'



(&

9EAR

 #($

 -)

 #!"'





















2ELATIVE2ISKFOR$EATH

(&

`ÕÃÌi`ÊÀi>̈ÛiÊ ÀˆÃŽÊvœÀÊ i>̅Ê>˜`Ê ,i>`“ˆÃȜ˜Ê>ÌÊÎäÊ `>ÞÃÊ>˜`Ê£ÊÞi>ÀÊvœÀÊ «>̈i˜ÌÃÊLivœÀiÊ>˜`Ê >vÌiÀʈ“«i“i˜Ì>̈œ˜Ê œvÊ̅iÊ`ˆÃV…>À}iÊ “i`ˆV>̈œ˜Ê«Àœ}À>“°Ê ,i«Àœ`ÕVi`Ê>˜`Ê Ài«Àˆ˜Ìi`ÊÜˆÌ…Ê «iÀ“ˆÃȜ˜ÊvÀœ“Ê >««iÊiÌÊ>°Ê˜˜Ê ˜ÌiÀ˜Êi`ÊÓää{ÆÊ £{£­È®\{{È°

DAYS

 #($

/…iÃiÊÀiÃՏÌÃÊÌiÃ̈vÞÊ ÌœÊ̅iÊv՘`>“i˜Ì>Ê

 -) 

Vœ˜ÌÀˆLṎœ˜Ê>Ê Ê

#!"' 

«Àœ}À>“ÊV>˜Ê“>ŽiÊ̜Ê



(&

9EAR



̅iʓ>˜>}i“i˜ÌʜvÊ̅iÊ

#($ 

-) #!"' 

…i>ÀÌÊv>ˆÕÀiÊ«>̈i˜ÌÆʈ˜Ê

 













2ELATIVE2ISKFOR2EADMISSION

̅ˆÃÊ«Àiˆ“ˆ˜>ÀÞÊÃÌÕ`Þ]Ê V…>À}iÃÊÜiÀiʅ>Ûi`ÊLÞÊ ˜œÌÊ>`“ˆÌ̈˜}Ê>Ê«>̈i˜Ì]Ê

!0RACTICAL%XAMPLE$ISEASE-ANAGEMENTINTHE/BSERVATION5NIT )N*ANUARY THE5NIVERSITYOF#INCINNATI$EPARTMENTOF%MERGENCY-EDICINEINI TIATEDANACUTEDECOMPENSATEDHEARTFAILUREOBSERVATIONUNIT/5 PROTOCOL4HEPROTO COLSELECTSNON HIGH RISKPATIENTSFORMANAGEMENTOVERA HOURPERIOD$URINGTHIS TIMEPATIENTSRECEIVEVASODILATORSANDDIURETICSASWELLASFURTHEREVALUATIONINCLUDING ECHOCARDIOGRAPHYAND!#3RISKSTRATIlCATIONEVALUATIONSERIALCARDIACMARKERSWITH THEOPTIONFORRESTISCHEMIAIMAGING ­ˆ}ÕÀiÊ{®!NEDUCATIONALVIDEOHASBEENDE VELOPEDTHATINSTRUCTSTHEPATIENTSABOUTTHEIRDISEASEPROCESS DIET MEDICATIONS AND WARNING SIGNS THAT THEIR HEART FAILURE MAY BE WORSENING $ISCHARGE PLANNING OCCURS THROUGHACOMBINATIONOFCARDIOLOGYNURSEPRACTITIONEREVALUATION ASWELLASFOLLOW UPINTHEHEARTFAILUREANDGENERALINTERNALMEDICINECLINIC

>˜`Ê>˜Ê>ÛiÀ>}iʜvʜ˜iÊ Li`‡`>ÞÊÜ>ÃÊÃ>Ûi`Ê «iÀʜLÃiÀÛ>̈œ˜>Ê ՘ˆÌÊ«>̈i˜Ì°



%MERGENCY$IAGNOSISAND4REATMENTOF !CUTE$ECOMPENSATED(EART&AILURE!$(&

ˆ}ÕÀiÊ{°Ê )NCLUSION%XCLUSION#RITERIA&ULFILLED

1˜ˆÛiÀÈÌÞʜvÊ ˆ˜Vˆ˜˜>ÌˆÊ  Ê«>̅Ü>Þ°

)6DIURETICEQUIVALENTTOHOMEDAILYDOSE 2ESTARTHOME!#%)p)6!#%) .ITRATES

%LECTROLYTES STANDING REPLACEMENT ".0LEVELS

 HOURREASSESSMENT 5/ *6$ DYSPNEA 63 ".0

.ITRATE$IURETIC!#%) 0ATHWAY

$IAGNOSTICS   HOURCARDIACENZYMES %CHOCARDIOGRAPHY 2ESTPERFUSIONSCAN

.ITRATE$IURETIC 0ATHWAY

2EASSESSEVERY HOURS (&EDUCATIONVIDEO $ISCHARGECRITERIAMET #ARDIOLOGISTCONSULT $ISCHARGEHOME &5IN DAYS

9%3

./

7EEVALUATEDTHEEFFECTIVENESSOFTHE/5PROTOCOLBY COMPARINGPATIENTSMANAGEDINTHE/5WITHASIMILAR RISK MATCHED COHORT OF INPATIENTS /VERALL  PA TIENTSWHOWEREBEINGADMITTEDTOTHEHOSPITALWITH PRESUMEDDECOMPENSATEDHEARTFAILUREWEREENROLLED INTHESTUDY!LLPATIENTSHADAHISTORYOFHEARTFAILURE ANDSATISlEDTWOMAJOR ORONEMAJORANDTWOMINOR MODIlED&RAMINGHAM#RITERIA)NCLUSIONANDEXCLU SIONCRITERIAWERESELECTEDBASEDUPONPRIORRISKSTUD IES SO AS TO IDENTIFY WHAT CURRENT PRACTICE INDICATES IS A LOW TO MODERATE RISK PATIENT 0ATIENTS CURRENTLY BELIEVEDTOBEATHIGHRISKANDPATIENTSWITHNEWONSET HEARTFAILUREWERENOTINCLUDED /NE PATIENT WAS FOUND TO HAVE NO PRIOR HISTORY OF HEARTFAILURE ANDTWOPATIENTSLEFTTHEINPATIENTSETTING AGAINST MEDICAL ADVICE )NCLUSION OF THESE SUBJECTS MAY AFFECT THE DATA BUT THIS REPRESENTS THE CLINICAL SCENARIOANDITISIMPORTANTTOINCLUDETHESESOURCES OF ERROR IN OUTCOMES ANALYSIS 4HIRTY TWO PATIENTS



!DMIT

WEREADMITTEDTOHOSPITALWHILEWEREPLACEDINTHE OBSERVATIONUNIT%IGHT /5PATIENTSREQUIRED SUBSEQUENTADMISSION /UTCOMES MEASURED IN THIS STUDY INCLUDED READ MISSIONS FOR #(& REPEAT VISITS TO THE %$ FOR HEART FAILURE AND DEATH 4HERE WERE  EVENTS AMONG AD MITTEDPATIENTS ANDEVENTSAMONG/5PA TIENTS   !NY DIFFERENCE WAS NOT SIGNIlCANT P !LLEVENTSINCLUDEDAREADMISSIONFORHEART FAILURE!LLBUTONEEVENTINCLUDEDAHEARTFAILURE RE LATED%$VISIT7EALSOCOMPAREDCRUDEESTIMATESOF BED HOURSANDCOSTSBETWEENTHETWOGROUPS5SEOF THE/5AVOIDEDADMISSIONINOFCASES-EDIAN TIME FROM TRIAGE TO DISCHARGE FOR /5 PATIENTS WAS HOURSRANGEnHOURS WHILEPATIENTS ADMITTED DIRECTLY FROM THE %$ HAD A MEDIAN LENGTH OFSTAYOFHOURSRANGEnHOURS 4HE LENGTH OF HOSPITAL STAY WAS SIGNIlCANTLY SHORTER FOR /5 PATIENTS THAN FOR ADMITTED PATIENTS P 

 1/ Ê "* -/ Ê ,/Ê1, ÊÊ - - Ê   /Ê/""-

#HARGES FOR THE TWO GROUPS OF PATIENTS WEREOBTAINED CATEGORIZEDBYTHESOURCE OFTHECHARGEˆ}ÕÀiÊxSHOWSTHESOURCE OFCHARGESFORADMITTEDAND/5PATIENTS OUTLIERSNOTSHOWN  4HE TOTAL CHARGE WAS SIGNIlCANTLY LOW ER FOR THE /5 PATIENTS -EDIAN  2ANGEn THANFORADMIT TEDPATIENTS-EDIAN RANGE n  0  )NPATIENT CHARGES AND PHARMACY CHARGES WERE DIFFERENT BETWEEN THE TWO GROUPS 0 AND 0 RESPECTIVELY  4HESE RESULTS TESTIFYTOTHEFUNDAMENTALCONTRIBUTIONA $- PROGRAM CAN MAKE TO THE MANAGE MENT OF THE HEART FAILURE PATIENT IN THIS PRELIMINARY STUDY CHARGES WERE HALVED BYNOTADMITTINGAPATIENT ANDANAVERAGE OFBED DAYWASSAVEDPER/5PATIENT ! COMBINATION OF A TREATMENT PATHWAY PATIENTEDUCATIONANDDISCHARGEPLANNING ARE INTEGRAL COMPONENTS IN MAKING /5 TREATMENTSUCCESSFUL

-1,9 $ISEASEMANAGEMENTISANINTEGRALCOM PONENTINTHECOMPREHENSIVECAREOFHEART FAILURE PATIENTS AND HAS BEEN SHOWN TO REDUCEREADMISSIONSANDTHEOVERALLCOST OFCARE4HE%$ACTSASAMAJORPORTAL FORHEARTFAILUREADMISSIONSANDBECAUSE OF THIS EMERGENCY PHYSICIANS HAVE THE POTENTIALTOSIGNIlCANTLYIMPACTTHECARE OF (& PATIENTS4HE MAJORITY OF %$ PA TIENTS WHETHERADMITTED MANAGEDINAN /5 ORDISCHARGEDHOME WILLLIKELYBEN ElTFROMONEORMOREOFTHECOMPONENTS OF$- /…iʓ>œÀˆÌÞʜvÊ Ê «>̈i˜ÌÃ]Ê܅i̅iÀÊ >`“ˆÌÌi`]ʓ>˜>}i`ʈ˜Ê >˜Ê"1]ʜÀÊ`ˆÃV…>À}i`Ê …œ“i]Ê܈ÊˆŽiÞÊLi˜iwÌÊ vÀœ“Êœ˜iʜÀʓœÀiʜvÊ



#HARGES$OLLARS

!DMITTED /5

̅iÊVœ“«œ˜i˜ÌÃʜvÊ °





ˆ}ÕÀiÊx°

 ,ABORATORY

)NPATIENT

%$

0HARMACY

œÝ«œÌÃÊŜ܈˜}Ê̅iÊÜÕÀViÊ >˜`Ê>“œÕ˜ÌʜvÊV…>À}iÃÊvœÀÊ œLÃiÀÛ>̈œ˜Ê՘ˆÌÊ>˜`Ê>`“ˆÌÌi`Ê «>̈i˜ÌðÊÊ­Iʈ˜`ˆV>ÌiÃÊ>Ê Ãˆ}˜ˆwV>˜ÌÊ`ˆvviÀi˜ViÊ® 

%MERGENCY$IAGNOSISAND4REATMENTOF !CUTE$ECOMPENSATED(EART&AILURE!$(&

,  ,



!SSOCIATION!((EARTDISEASEANDSTROKESTATISTICS UPDATE 



/#ONNELL*"4HEECONOMICBURDENOFHEARTFAILURE#LIN#ARDIOL ))) 



#ROFT*" 'ILES7( 0OLLARD2! +EENAN., #ASPER-, !NDA 2&(EARTFAILURESURVIVALAMONGOLDERADULTSINTHEUNITEDSTATES !POORPROGNOSISFORANEMERGINGEPIDEMICINTHEMEDICARE POPULATION!RCH)NTERN-ED 



-C#ULLOUGH0! 0HILBIN%& 3PERTUS*! +AATZ3 3ANDBERG+2 7EAVER7$#ONlRMATIONOFAHEARTFAILUREEPIDEMIC&INDINGS FROMTHERESOURCEUTILIZATIONAMONGCONGESTIVEHEARTFAILURE REACH STUDY*!M#OLL#ARDIOL 

 2AME*% 3HEFlELD-! $RIES$, 'ARDNER%" 4OTO+( 9ANCY#7 $RAZNER-(/UTCOMESAFTEREMERGENCYDEPARTMENT DISCHARGEWITHAPRIMARYDIAGNOSISOFHEARTFAILURE!M(EART*    0EACOCK7&T 2EMER%% !PONTE* -OFFA$! %MERMAN#% !LBERT.-%FFECTIVEOBSERVATIONUNITTREATMENTOFDECOMPENSATED HEARTFAILURE#ONGEST(EART&AIL   3TORROW!" #OLLINS30 ,INDSELL#*%MERGENCYDEPARTMENT OBSERVATIONOFHEARTFAILUREISSAFEANDCOSTEFFECTIVE!CAD%MERG -ED  (OEKSTRA* 2OE-4 0ETERSON% -6 *- 0OLLACK#6 *R -ILLER # 40 (ARRINGTON2! /HMAN%- 'IBLER7"%ARLYGLYCOPROTEIN IIBIIIAINHIBITORUSEFORNON ST SEGMENTELEVATIONACUTECORONARY SYNDROMES0ATIENTSELECTIONANDASSOCIATEDTREATMENTPATTERNS !CAD%MERG-EDINPRESS



/#ONNELL*""-%CONOMICIMPACTOFHEARTFAILUREINTHEUNITED STATES!TIMEFORADIFFERENTAPPROACH*(EART,UNG4RANS 3 3



0HILLIPS#/ 7RIGHT3- +ERN$% 3INGA2- 3HEPPERD3 2UBIN (2#OMPREHENSIVEDISCHARGEPLANNINGWITHPOSTDISCHARGESUPPORT FOROLDERPATIENTSWITHCONGESTIVEHEARTFAILURE!META ANALYSIS *AMA 

 (OEKSTRA* -6 9, 2OE-4 0ETERSON% 0OLLACK#6 *R 40 "RINDIS2' 'IBLER7" /HMAN%-%ARLYGPIIBIIIAINHIBITORUSE INNONSTELEVATIONACUTECORONARYSYNDROMESISASSOCIATEDWITH LOWERMORTALITYINTROPONINPOSITIVEPATIENTS*!M#OLL#ARDIOL 3UPPL)6 



+RUMHOLZ(- 0ARENT%- 4U. 6ACCARINO6 7ANG9 2ADFORD -* (ENNEN*2EADMISSIONAFTERHOSPITALIZATIONFORCONGESTIVE HEARTFAILUREAMONGMEDICAREBENElCIARIES!RCH)NTERN-ED  

 (OUCK0- "RATZLER$7 .SA7 -A! "ARTLETT*'4IMINGOF ANTIBIOTICADMINISTRATIONANDOUTCOMESFORMEDICAREPATIENTS HOSPITALIZEDWITHCOMMUNITY ACQUIREDPNEUMONIA!RCH)NTERN -ED 



#HIN-( 'OLDMAN,#ORRELATESOFEARLYHOSPITALREADMISSION ORDEATHINPATIENTSWITHCONGESTIVEHEARTFAILURE!M*#ARDIOL  



6INSON*- 2ICH-7 3PERRY*# 3HAH!3 -C.AMARA4%ARLY READMISSIONOFELDERLYPATIENTSWITHCONGESTIVEHEARTFAILURE*!M 'ERIATR3OC 

 "ATTLEMAN$3 #ALLAHAN- 4HALER(42APIDANTIBIOTICDELIVERY ANDAPPROPRIATEANTIBIOTICSELECTIONREDUCELENGTHOFHOSPITAL STAYOFPATIENTSWITHCOMMUNITY ACQUIREDPNEUMONIA,INK BETWEENQUALITYOFCAREANDRESOURCEUTILIZATION!RCH)NTERN-ED  

 +OSSOVSKY-0 3ARASIN&0 0ERNEGER46 #HOPARD0 3IGAUD0 'ASPOZ*5NPLANNEDREADMISSIONSOFPATIENTSWITHCONGESTIVE HEARTFAILURE$OTHEYREmECTIN HOSPITALQUALITYOFCAREORPATIENT CHARACTERISTICS!M*-ED   2ICH-7 "ECKHAM6 7ITTENBERG# ,EVEN#, &REEDLAND +% #ARNEY2-!MULTIDISCIPLINARYINTERVENTIONTOPREVENTTHE READMISSIONOFELDERLYPATIENTSWITHCONGESTIVEHEARTFAILURE. %NGL*-ED   2ICH-7 6INSON*- 3PERRY*# 3HAH!3 3PINNER,2 #HUNG -+ $AVILA 2OMAN60REVENTIONOFREADMISSIONINELDERLY PATIENTSWITHCONGESTIVEHEARTFAILURE2ESULTSOFAPROSPECTIVE RANDOMIZEDPILOTSTUDY*'EN)NTERN-ED 

 #HASSIN-2)SHEALTHCAREREADYFORSIXSIGMAQUALITY-ILBANK 1    ,APPE*- -UHLESTEIN*" ,APPE$, "ADGER23 "AIR4, "ROCKMAN2 &RENCH4+ (OFMANN,# (ORNE"$ +RALICK 'OLDBERG3 .ICPONSKI. /RTON*! 0EARSON22 2ENLUND$' 2IMMASCH( 2OBERTS# !NDERSON*,)MPROVEMENTSIN YEAR CARDIOVASCULARCLINICALOUTCOMESASSOCIATEDWITHAHOSPITAL BASED DISCHARGEMEDICATIONPROGRAM!NN)NTERN-ED   #OLLINS30 ,INDSELL#* ,YONS-3 'IBLER7" 3TORROW!" "NPLEVELSARERELATEDTO DAYEVENTSINHEARTFAILUREPATIENTS DISCHARGEDFROMANOBSEVATIONUNIT!MERICAN#OLLEGEOF %MERGENCY0HYSICIANS

 'ONSETH* 'UALLAR #ASTILLON0 "ANEGAS*2 2ODRIGUEZ !RTALEJO &4HEEFFECTIVENESSOFDISEASEMANAGEMENTPROGRAMMESIN REDUCINGHOSPITALRE ADMISSIONINOLDERPATIENTSWITHHEARTFAILURE !SYSTEMATICREVIEWANDMETA ANALYSISOFPUBLISHEDREPORTS%UR (EART* 

#OPYRIGHT%-#2%' )NTERNATIONAL 



Ê Ê œ˜Ìˆ˜Õˆ˜}Êi`ˆV>Ê `ÕV>̈œ˜Ê*œÃ̇/iÃÌ "ASEDONTHEINFORMATIONPRESENTEDINTHISMONOGRAPH PLEASECHOOSEONECORRECTRESPONSEFOREACHOFTHEFOLLOWING QUESTIONSORSTATEMENTS2ECORDYOURANSWERSONTHEANSWERSHEETONPAGE4ORECEIVE#ATEGORY)CREDIT COMPLETE THEPOST TESTANDRECORDYOURRESPONSESONTHEANSWERSHEET-AILINTHERETURNENVELOPENOLATERTHAN*UNE ! PASSINGGRADEOFISNEEDED!CERTIlCATEWILLBESENTTOYOUUPONYOURSUCCESSFULCOMPLETIONOFTHEPOST TEST ˆ>}˜œÃˆÃʜvÊVÕÌiÊ iVœ“«i˜Ã>Ìi`Êi>ÀÌÊ >ˆÕÀiʈ˜Ê̅iÊ  ! YEAR OLDMALETOBACCOSMOKERWITHAHISTORY OFASTHMAPRESENTSTOTHEEMERGENCYDEPARTMENT WITHSHORTNESSOFBREATHOFDAYSDURATION(E HASEXERTIONALDYSPNEA ORTHOPNEAANDHEARS SOMEWHEEZINGWHENHEISBREATHING0HYSICAL EXAMINATIONREVEALSSCANTCRACKLESATTHEBASES BILATERALLYWITHCMOFJUGULARVENOUSDISTENTION AN3HEARTSOUND ANDNOMURMUR7HICHOFTHE FOLLOWINGBESTSUPPORTSADIAGNOSISOFCONGESTIVE HEARTFAILURE A #ARDIOMEGALYONCHESTRADIOGRAPHY B !".0LEVELOFPGD, C .ORMALCHESTRADIOGRAPHY D !".0LEVELOFPGD,  7HICHOFTHEFOLLOWINGDISEASESCANRESULTINLOW GRADE".0ELEVATIONSPGDL  A 2IGHTVENTRICULARFAILUREFROMCORPULMONALE B !CUTEPULMONARYEMBOLISM C #(&INANOBESEPATIENT D #(&INAPATIENTWITHNORMALBODYMASSINDEX E !LLOFTHEABOVE /Ài>̓i˜ÌʜvÊVÕÌiÊ iVœ“«i˜Ã>Ìi`Êi>ÀÌÊ >ˆÕÀiʈ˜Ê̅iÊ “iÀ}i˜VÞÊ i«>À̓i˜Ì  4HEPATIENTSCLINICALSTATUSCANBEDETERMINEDBY ASSESSINGTHENFORWHICHOFTHEFOLLOWING A $EGREEOFCARDIACPERFUSIONANDPRESENCEOF CONGESTION B $EGREEOFCARDIACPERFUSIONANDBLOODPRESSURE C "LOODPRESSUREANDPRESENCEOFCONGESTION D 2ENALFUNCTIONANDVOLUMESTATUS E 2ENALFUNCTIONANDPERIPHERALEDEMA

 7HICHOFTHEFOLLOWINGISNOTTRUEABOUTTHEROLEOF VASODILATORSINACUTELYDECOMPENSATEDHEART A 4HEYREDUCEPRELOADANDAFTERLOAD B -YOCARDIALOXYGENCONSUMPTIONISOFTEN INCREASED C 4HEYINCREASESTROKEVOLUMEANDIMPROVE CARDIACOUTPUT D 4HEYMAYCAUSEHYPOTENSION E 4HEBESTHEMODYNAMICINDICATOROFVASODILATOR THERAPYRESPONSEISADROPINTHEPULMONARY CAPILLARYWEDGEPRESSURE *iÀ̈˜i˜ÌÊ *Ê œ˜Ãi˜ÃÕÃÊ*>˜iÊ ,iVœ““i˜`>̈œ˜Ã  )NANANALYSISOFMORETHAN PATIENTSENROLLED INTHE!$(%2%REGISTRY THE%$USEOFVASOACTIVE THERAPY ASCOMPAREDTODELAYEDUSAGEONTHE INPATIENTUNIT WASASSOCIATEDWITHWHICHOFTHE FOLLOWING A DECREASEDMORTALITY B LOWER)#5ADMISSIONRATE C SHORTERHOSPITALIZATIONS D FEWERINVASIVEPROCEDURES E ALLOFTHEABOVE  !NELEVATEDTROPONIN INTHESETTINGOFACUTE DECOMPENSATEDHEARTFAILUREISASSOCIATEDWITH A LONGER)#5HOSPITALIZATION B INCREASEDMORTALITY C LONGERHOSPITALIZATION D AHIGHERRATEOFINTUBATIONANDBALLOONPUMP USAGE E ALLOFTHEABOVE



Ê œ˜Ìˆ˜Õˆ˜}Êi`ˆV>Ê `ÕV>̈œ˜Ê*œÃ̇/iÃÌÊ­Vœ˜Ì°® >VŽ}ÀœÕ˜`Ê>˜`ʈ˜`ˆ˜}ÃÊvÀœ“Ê̅iÊ   , Ê >̈œ˜>Ê,i}ˆÃÌÀÞ  7HENDESCRIBINGTHEPATIENTPOPULATIONINTHE !$(%2%REGISTRYINCOMPARISONTOOTHER!$(& TRIALS ALLOFTHEFOLLOWINGARETRUE%8#%04 A 0ATIENTSIN!$(%2%TENDTOBEOLDER B !BOUTHALFTHEPATIENTSIN!$(%2%AREWOMEN C 2ENALINSUFlCIENCYPATIENTSAREEXCLUDEDFROM !$(%2% D 4HE!$(%2%POPULATIONINCLUDESACADEMICAND COMMUNITYCENTER E !LLOFTHEABOVEARETRUE  )NTHE!$(%2%INTRAVENOUSVASOACTIVEMORTALITY ANALYSIS WHICHOFTHEFOLLOWINGSTATEMENTSARETRUE A 0ATIENTSWHORECEIVEDIN HOSPITALNITROGLYCERIN HADLOWERIN HOSPITALMORTALITY B 0ATIENTSWHORECEIVEDINTRAVENOUSNESIRITIDEHAD LOWERINHOSPITALMORALITY C 0ATIENTSTREATEDWITHDOBUTAMINEORMILRINONE HADHIGHERIN HOSPITALMORTALITY D !AND#ARECORRECT E ! " AND#ARECORRECT ˆÃi>ÃiÊ>˜>}i“i˜ÌʜvÊVÕÌiÊ iVœ“«i˜Ã>Ìi`Êi>ÀÌÊ>ˆÕÀi\Ê/…iÊ   , Ê “iÀ}i˜VÞÊi`ˆVˆ˜iÊœ`Տi  7HICHOFTHEFOLLOWINGAREREQUIREDFORASUCCESSFUL POINT OF CAREPROGRAM A 1UALITYCONTROL B %DUCATIONOFPHYSICIANS C ,ABORATORYACCREDITATIONANDREGULATION D $ElNEDANDREGULATEDTESTINGPROCEDURES E !LLOFTHEABOVE



 &ACTORSTHATSHOULDBECONSIDEREDINTHECOSTANALYSIS OFAPOINT OF CARETESTINGPROGRAMINCLUDEALLOFTHE FOLLOWING%8#%04 A ,ABORATORYRESULTTURN AROUND TIME4!4 B 4IMETODISPOSITION C 0ATIENTANDPHYSICIANCONSUMER DEMAND D #OSTOFTESTINGPLATFORMANDREAGENTS E !LLOFTHEABOVEARECORRECT

VÕÌiÊ iVœ“«i˜Ã>Ìi`Êi>ÀÌÊ>ˆÕÀiÊ ˆÃi>ÃiÊ >˜>}i“i˜ÌÊ/œœÃ  4HECOMPONENTSOFDISEASEMANAGEMENTINCLUDEALL OFTHEFOLLOWINGEXCEPT A 4REATMENTALGORITHM B !DMISSIONORDERS C 0ATIENTDISCHARGECHECKLIST D 0ATIENTEDUCATION E !LLOFTHEABOVE  0ATIENTEDUCATIONANDADISCHARGECHECKLISTARETWO DISEASEMANAGEMENTTOOLSTHATAREUSEDTOIMPROVE MEDICATIONANDDIETARYCOMPLIANCEINANEFFORTTO DECREASE DAYHOSPITALREADMISSION4HECURRENT  DAYREADMISSIONRATEFORHEARTFAILUREPATIENTS DISCHARGEDFROMTHEHOSPITALISAPPROXIMATELY A  B  C  D 

%MERGENCY$IAGNOSISAND4REATMENTOF !CUTE$ECOMPENSATED(EART&AILURE!$(&

œ˜Ìˆ˜Õˆ˜}Êi`ˆV>Ê `ÕV>̈œ˜Ê *œÃ̇/iÃÌʘÃÜiÀÊœÀ“Ê>˜`Ê Û>Õ>̈œ˜ !FTERYOUHAVEREADTHEMONOGRAPH CAREFULLYRECORD YOURANSWERSBYCIRCLINGTHEAPPROPRIATELETTERFOREACH QUESTIONANDCOMPLETETHEEVALUATIONQUESTIONNAIRE

61/" Ê+1 -/"

-AILTHEANSWERSHEETTO



,

/NASCALEOFTO WITHBEINGHIGHLYSATISlEDAND BEINGHIGHLYDISSATISlED PLEASERATETHISPROGRAMWITH RESPECTTO



(IGHLYSATISlED (IGHLYDISSATISlED

/FlCEOF#ONTINUING-EDICAL%DUCATION 5NIVERSITYOF#INCINNATI#OLLEGEOF-EDICINE 0/"OX #INCINNATI/( 

/VERALLQUALITYOFMATERIAL  #ONTENTOFMONOGRAPH  /THERSIMILAR#-%PROGRAMS  (OWWELLCOURSEOBJECTIVESWEREMET

#-%EXPIRATIONDATE*UNE 

D

7HATTOPICSWOULDBEOFINTERESTTOYOUFORFUTURE#-% PROGRAMS ????????????????????????????????????????????? ?????????????????????????????????????????????

D

????????????????????????????????????????????? ?????????????????????????????????????????????







A A

B B

C C

E



A

B

C

D

E



A

B

C

D

E



A

B

C

D

E



A

B

C

D

E



A

B

C

D

E



A

B

C

D

E



A

B

C

D

E



A

B

C

D

E



A

B

C

D

E



A

B

C

D

   

   

   

   

7ASTHERECOMMERCIALORPROMOTIONALBIASINTHE PRESENTATIONQ9%3Q./)F9%3 PLEASEEXPLAIN ????????????????????????????????????????????? ????????????????????????????????????????????? ????????????????????????????????????????????? ????????????????????????????????????????????? (OWLONGDIDITTAKEFORYOUTOCOMPLETETHISMONOGRAPH ????????????????????????????????????????????? ????????????????????????????????????????????? .AME0LEASEPRINTCLEARLY ?????????????????????? ????????????????????????????????????????????? $EGREE ?????????????????????????????????????? ????????????????????????????????????????????? 3PECIALTY????????????????????????????????????? !CADEMIC!FlLIATIONIFAPPLICABLE  ??????????????? ????????????????????????????????????????????? ????????????????????????????????????????????? !DDRESS ????????????????????????????????????? ????????????????????????????????????????????? #ITY ??????????????3TATE??? :IP#ODE????????? 4ELEPHONE.UMBER ?????????????????????? 

Ê ˆÃVœÃÕÀiʜvÊ>VՏÌÞɘ`ÕÃÌÀÞÊ,i>̈œ˜Ã…ˆ«Ã )NACCORDANCEWITH#-%3TANDARDSFOR#OMMERCIAL3UPPORTOF#-% THEAUTHORSHAVEDISCLOSEDTHEFOLLOWING RELEVANTRELATIONSHIPSWITHPHARMACEUTICALORDEVICEMANUFACTURERS

*UDD%(OLLANDER -$

2ESEARCH'RANTS#ONSULTANT "IOSITE#ONSULTANT 3CIOS



$OUGLAS-#HAR -$ #ONSULTANT 3CIOS



7&RANK0EACOCK -$ 'RANT2ESEARCH#ONSULTANT 3CIOS



7ILLIAM!BRAHAM -$



2ICHARD,3UMMERS -$ #ONSULTANTANDSPEAKERSBUREAU 3CIOS



3EAN0#OLLINS -$

3PEAKERHONORARIA RESEARCHGRANTS ANDCONSULTINGFEESFOR3CIOS

.ONE

Ê "vv‡>LiÊ ˆÃVœÃÕÀià &ACULTYMEMBERSAREREQUIREDTOINFORMTHEAUDIENCEWHENTHEYAREDISCUSSINGOFF LABEL UNAPPROVEDUSES OFDEVICESANDDRUGS0HYSICIANSSHOULDCONSULTFULLPRESCRIBINGINFORMATIONBEFOREUSINGANYPRODUCT MENTIONEDINTHISMONOGRAPH

4HISEDUCATIONALMONOGRAPHWASSUPPORTEDINPARTBYANUNRESTRICTEDEDUCATIONALGRANTFROM3CIOS

#OPYRIGHT%-#2%' )NTERNATIONAL 

)NTERNATIONAL W W W  E M C R E G  O R G



0RODUCEDBY

^ÊÓääxÊ  , ‡˜ÌiÀ˜>̈œ˜> ÜÜÜ°i“VÀi}°œÀ}

/…ˆÃÊi`ÕV>̈œ˜>Ê“œ˜œ}À>«…ÊÜ>ÃÊÃÕ««œÀÌi`ʈ˜Ê«>ÀÌÊLÞÊ >˜Ê՘ÀiÃÌÀˆVÌi`Êi`ÕV>̈œ˜>Ê}À>˜ÌÊvÀœ“Ê-VˆœÃ°

0R INTE DIN TH E 5 3!

Loading...

Emergency Diagnosis and Treatment of Acute - emcreg

EMERGENCY DIAGNOSIS AND TREATMENT OF ACUTE DECOMPENSATED HEART FAILURE (ADHF) - MARCH 2005 Produced by © 2005 EMCREG-International www.emcreg.org E...

1MB Sizes 2 Downloads 11 Views

Recommend Documents

Hypertension Diagnosis and Treatment
This ICSI Health Care Guideline is designed to assist clinicians by providing an analytical framework ... Inc. If the or

Drug Treatment for Hypertensive Emergencies - emcreg
Jan 2, 2008 - emergency physicians and used to help in the care of patients with hypertension. It is our hope this EMCRE

Etiology, diagnosis and treatment of fibromyalgia - American
specificity, reflecting that diagnostic criteria have not been developed that can consistently exclude acknowledged medi

Epidemiology, Diagnosis, Treatment, and Control of Trichinellosis
Jan 1, 2009 - Early clinical diagnosis of trichinellosis is rather difficult because pathognomonic signs or symptoms are

Technology Assessment - Diagnosis and Treatment of - CMS.gov
May 28, 2010 - the same way as any medical reference and in conjunction with all other pertinent ... Peer Reviewers. We

Diagnosis and Treatment of Degenerative Lumbar Spondylolisthesis
DisclosurePolicy.pdf) and their potential conflicts have been documented ...... A Prospec- tive Study on the Outcome of

Sound management of pesticides and diagnosis and treatment of
in carbamate poisoning. 6 B 3, 7 B 3 in organophosphate poisoning. 6 B 2, 7 B 2. Avicide pesticide used for control of b

Craniosynostosis | Symptoms, Diagnosis & Treatment
Craniosynostosis, or simply synostosis, is the early growing together (or fusion) of two or more bones of the skull. A n

2014 ESC Guidelines on the diagnosis and management of acute
Aug 29, 2014 - philic defects have a low predictive value and anticoagulation manage- ment based on thrombophilia testin

Diagnosis and Management of Acute Coronary Syndrome: An
An analysis of 46,086 hospitalizations for ACS in a study conducted by Kaiser Permanente demonstrated that the percentag